Properties and Units in the Clinical Laboratory Sciences Part X

Pure Appl. Chem., Vol. 72, No. 5, pp. 747–972, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES AND UNITS (C-NPU)§

PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART X. PROPERTIES AND UNITS IN GENERAL CLINICAL CHEMISTRY

(Technical Report) (IFCC–IUPAC 1999)

Prepared for publication by HENRIK OLESEN1, INGE IBSEN1, IVAN BRUUNSHUUS1, DESMOND KENNY2, RENÉ DYBKÆR3, XAVIER FUENTES-ARDERIU4, GILBERT HILL5, PEDRO SOARES DE ARAUJO6, AND CLEM McDONALD7

1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Dublin, Ireland; 3Dept. of Standardisation in Laboratory Medicine, Kommunehospitalet, Copenhagen, Denmark; 4Dept. of Clinical Biochemistry, Ciutat Sanitària i Universitària de Bellvitge, Barcelona, Spain; 5Dept. of Clinical Chemistry, Hospital for Sick Children, Toronto, Canada; 6Dept. of Biochemistry, IQUSP, São Paolo, Brazil; 7Regenstrief Inst. for Health Care, Indiana University School of Medicine, Indianapolis, Indiana, USA

#§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994 to 1996) were as follows:

Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996). Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada; 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997).

Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected]

Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible. Publication of a translation into another language is subject to the additional condition of prior approval from the relevant IUPAC National Adhering Organization. 747 748 H. OLESEN et al.

Properties and units in the clinical laboratory sciences. Part X. Properties and units in general clinical chemistry (Technical Report)

Abstract: A coding scheme has been prepared for general clinical chemistry.

PREFACE The present document is part ten (X) of a series on properties and units in the clinical laboratory sciences initiated in 1987. The series will comprise:

I. Syntax and semantic rules [1] II. Kinds-of-property [2] III. Elements (of properties) and their code values [3] IV. Properties and their code values [4] V. Properties and units in thrombosis and haemostasis [5] VI. Properties and units in IOC-prohibited drugs [6] VII. Properties and units in inborn errors of metabolism VIII. Properties and units in clinical microbiology [7] IX. Properties and units in trace elements [8] X. Properties and units in general clinical chemistry (this report) XI. Coding systems: structure and guidelines [9] XII. Properties and units in clinical pharmacology and toxicology [10] XIII. Properties and units in reproduction and fertility [11] XVI. Properties and units in clinical allergology [12]

The size and complexity of Parts III and IV are such that their lists will be presented in electronic format. This is for ease of handling and to facilitate expression of concepts in different languages. At the end, systematic terms, elaborated according to international standards and recommendations, should be available in the different domains of clinical laboratory sciences. The core of the series is code value strings representing concepts, that in combination delineate and define each type of property regardless of linguistic expression, thus avoiding errors during translation between languages.

FOREWORD AND SCOPE Clinical laboratory sciences are characterized by the exacting nature of the work performed and the demand for an accurate presentation of the outcome. Furthermore, the domain is transnational, international or “global”. The adherent informatics system, therefore, needs to identify the findings accurately and to present them with the degree of detail required. At the same time, it has to facilitate the transfer over linguistic and cultural barriers without distortion or loss of clarity, in order to promote clear, unambiguous, mean- ingful, and fully informative communication in different terminologies. The degree to which a message (such as a laboratory report) needs to be expressed in a formal, systematic language depends on the geographical, linguistic, social, or professional distance between the communicating parties. The greater the distance, the greater the risk of misunderstanding.

Within one laboratory, local jargon terms may be used which are usually well understood between colleagues, but which would not be sufficiently widely known for communication with the out- side world. Likewise, a laboratory and its local community of users, such as hospital or community physicians, may use a “local dialect” of the language of laboratory medicine which is well understood by all concerned; but when the communication possibilities are wider, even transnational, risks of seri- ous misunderstanding arise. The purpose of this document is to apply the IFCC–IUPAC recommended syntax structures for request and report and to create a systematic terminology that can be used as the basis for encoding laboratory messages in the domain of general clinical chemistry. This is to facilitate communication of messages about such properties through computing and telecommunication between databases, messages that contain sufficient information to allow translation from and to the required “local dialect” at each end. Each entry in the list is formed following the rules given in [1] and in [9]. The systematic names recommended here are primarily for the purpose of unambiguous data exchange. Their use in routine language by clinicians or laboratory practitioners is optional but encour- aged.

ELEMENTS OF AN ENTRY The terms recommended are given in bold, e.g., the systematic term for the type of property, the unit, and the code value.

1 Name of system and parenthetic specification spelled out in full, and followed by a long dash (em dash). 2 Alphanumeric chemical prefixes to component name. 3 Recommended name of component and parenthetic specification. Shifted to the left for alphabetical sorting and searching, and followed by a semicolon. 4 Kind-of-property and parenthetic specification. 5 Unit. 6 Presently recommended calibrator. 7 Previous calibrators. 8 Other term(s). 9 Authority: Code value for the international organization recommending the name of the component or the combined elements of an entry. 10 Note(s) with any further information. 11 [NPUXXXXX] Coding scheme identifier and code value, intended for interlaboratory transmission between databases. 12 Example in abbreviated form.

The term “arbitrary”, in principle, cannot be related to a volume. In clinical chemistry, however, a less well-defined “inhouse” or regional calibrator is often referred to and is expressed in “arbitrary unit per liter” in order to enable comparison of patient data over time and regionally. In each of these instances, further information should be given in the parenthesis “procedure”. This could be information on the calibrator used, e.g., “BCR/CRM148/149R”, or it could refer to the in-laboratory document “procedure xx” that is available on request. In the examples given, a question mark, “?”, has been used to represent the value of a result for properties including quantities.

REFERENCES 1. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. I. Syntax and semantic rules. Prepared for publication by H. Olesen. Pure Appl. Chem. 67, 1563–74 (1995); Eur. J. Clin. Chem. Clin. Biochem. 33, 627– 36 (1995); Clin. Chim. Acta 245, S5–S21 (1996). 2. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. II. Kinds-of-property. Prepared for publication by D. Kenny and H. Olesen. Pure Appl. Chem. 68, 1015–42 (1997); Eur. J. Clin. Chem. Clin. Biochem. 35, 317–44 (1997). 3. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. III. Elements (of properties) and their code values. Technical report 1997. Prepared for publication by I. Bruunshuus, W. Frederiksen, H. Olesen, I. Ibsen. Pure Appl. Chem. 69, 2577–82 (1997). 4. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. IV. Properties and their code values. Technical report 1997. Prepared for publication by H. Olesen, D. Kenny, I. Bruunshuus, I. Ibsen, K. Jørgensen, R. Dybkær. Pure Appl. Chem. 69, 2583–91 (1997). 5. Scientific and Standardization Committee of the ISTH (International Society on Thrombosis and Haemostasis) and Commission/Committee on Nomenclature, Properties and Units of the IUPAC– IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. V. Properties and units in thrombosis and haemostasis. Prepared for publication by M. Blombäck, R. Dybkær, K. Jørgensen, H. Olesen, S. Thorsen. Thrombosis and Haemostasis 71-375-94 (1994); Eur. J. Clin. Chem. Clin. Biochem. 33, 637–60 (1995). Pure Appl. Chem. 69, 1043–79 (1997). 6. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. VI. Properties and units in IOC-prohibited drugs. Recommendations 1997. Prepared for publication by H. Olesen, D. Cowan, I. Bruunshuus, K. Klempel, G. Hill. Pure Appl. Chem. 69, 1081–1136 (1997); Eur. J. Clin. Chem. Clin. Biochem. 35, 805–31 (1997). 7. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. VIII. Properties and units in clinical microbiology. Technical report 1999. Prepared for publication by U. Forsum, H. Olesen, W. Frederiksen, B. Persson. Pure Appl. Chem. 72, 555–745 (2000); JIFCC, in press. 8. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. IX. Properties and units in trace elements. Technical report 1997. Prepared for publication by R. Cornelis, X. Fuentes-Arderiu, I, Bruunshuus, D. Templeton. Pure Appl. Chem. 69, 2593–2606 (1997); Eur. J. Clin. Chem. Clin. Biochem. 35, 833–843 (1997).

9. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. XI. Coding systems - structure and guidelines. Technical report 1997. Prepared for publication by R. Cornelis, H. Olesen, I. Ibsen, I. Bruunshuus, D. Kenny. Pure Appl. Chem. 69, 2607–20 (1997). 10. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. XII. Properties and units in clinical pharmacology and toxicology. Technical report 1999. Prepared for publication by H. Olesen, D. Cowan, R. de la Torre, I. Bruunshuus, M. Rohde, D. Kenny. Pure Appl. Chem. 72, 479–552 (2000); JIFCC, in press. 11. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. XIII. Properties and units in reproduction and fertility. Technical report 1997. Prepared for publication by H. Olesen, A. Giwercman, D. M. de Kretser, D. Mortimer, H. Oshima, Troen. Pure Appl. Chem. 69, 2621–28 (1997); Clin. Chem. Lab Med. 36, 57–65 (1998). 12. Commission/Committee on Nomenclature, Properties and Units of the IUPAC–IFCC (International Union of Pure and Applied Chemistry–International Federation of Clinical Chemistry). Properties and units in the clinical laboratory sciences. XVI. Properties and units in clinical allergology. Technical report 1999. Prepared for publication by I. Bruunshuus, L. K. Poulsen, H. Olesen. Pure Appl. Chem., in press. JIFCC, in press.

INDEX OF ABBREVIATIONS CAS Chemical Abstracts Service IFCC International Federation of Clinical Chemistry and Laboratory Medicine INN International Nonproprietary Names of WHO *INN Name to be approved ISO International Organization for Standardization IUPAC International Union of Pure and Applied Chemistry MSH Medical Subject Headings WHO World Health Organization

LIST OF PROPERTIES IN GENERAL CLINICAL CHEMISTRY

Blood— NPU01011 Acanthocytes; P—Acetoacetate; subst.c. = ? mmol/l arbitrary concentration(procedure) NPU17074 Secretion(Conjunctiva; specification)— B—Acanthocytes; arb.c.(proc.) = ? Acetoacetate; substance concentration Erythrocytes(Blood)— millimole/liter Acanthocytes; NPU09351 number fraction Secr(Conj; spec.)—Acetoacetate; subst.c. = ? NPU14348 mmol/l Ercs(B)—Acanthocytes; num.fr. = ? Urine— Blood— Acetoacetate; Acetaldehyde; substance concentration substance concentration millimole/liter micromole/liter NPU04166 M = 44,05 g/mol U—Acetoacetate; subst.c. = ? mmol/l NPU01005 B—Acetaldehyde; subst.c. = ? µmol/l Patient(Urine)— Acetoacetate; Urine— substance rate Acetaldehyde; micromole/day substance concentration NPU17845 micromole/liter Pt(U)—Acetoacetate; subst.rate = ? µmol/d M = 44,05 g/mol NPU01006 Patient(Urine)— U—Acetaldehyde; subst.c. = ? µmol/l N- Acetylasparaginate; Urine— substance rate Acetoacetate; micromole/day arbitrary concentration(procedure) NPU17781 NPU10504 Pt(U)—N-Acetylasparaginate; subst.rate = ? µmol/d U—Acetoacetate; arb.c.(proc.) = ? Amniotic fluid— Urine— Acetylcholinesterase; Acetoacetate; catalytic-activity concentration(20 °C; substance concentration(120 minutes after procedure) challenge; procedure) nanokatal/liter millimole/liter Other term(s): AChE; Cholinesterase; Choline NPU10316 esterase I; True cholinesterase U—Acetoacetate; subst.c.(120 min; proc.) = ? NPU14657 mmol/l Amf—Acetylcholinesterase; cat.c.(20 °C; proc.) = ? nkat/l Urine— Acetoacetate; Amniotic fluid— substance concentration(procedure) Acetylcholinesterase; millimole/liter catalytic-activity concentration(37 °C; NPU01012 procedure) U—Acetoacetate; subst.c.(proc.) = ? mmol/l microkatal/liter Other term(s): AChE; Cholinesterase; Choline Cerebrospinal fluid— esterase I; True cholinesterase Acetoacetate; NPU01034 substance concentration Amf—Acetylcholinesterase; cat.c.(37 °C; proc.) = ? millimole/liter µkat/l NPU01010 Csf—Acetoacetate; subst.c. = ? mmol/l Erythrocytes(Blood)— Acetylcholinesterase; Plasma— entitic catalytic activity(37 °C; procedure) Acetoacetate; attokatal substance concentration Other term(s): AChE; Cholinesterase; Choline millimole/liter

esterase I; True cholinesterase Urine— NPU01035 N- Ercs(B)—Acetylcholinesterase; entitic cat.act. Acetyl-L-cystine; (37 °C; proc.) = ? akat substance concentration micromole/liter Plasma— M = 282,3 g/mol Acetylcholinreceptor antibody(Immunoglobulin G); NPU01023 arbitrary substance concentration(procedure) U—N-Acetyl-L-cystine; subst.c. = ? µmol/l arbitrary unit/liter NPU01036 Urine— P—Acetylcholinreceptor antibody(IgG); N-a- arb.subst.c.(proc.) = ? arb.unit/l Acetyl-L-lysine/Creatininium; substance ratio Urine— 10-3 b- NPU14181 Acetylglucosamine/Creatininium; U—N-a-Acetyl-L-lysine/Creatininium; subst.ratio = ? substance ratio × 10-3 10-3 NPU14183 Urine— U—b-Acetylglucosamine/Creatininium; subst.ratio = N-e- ? × 10-3 Acetyl-L-lysine/Creatininium; substance ratio Urine— NPU14182 b- U—N-e-Acetyl-L-lysine/Creatininium; subst.ratio = ? Acetylglucosamine; substance concentration Urine— micromole/liter N-e- NPU01325 Acetyl-L-lysine; U—b-Acetylglucosamine; subst.c. = ? µmol/l substance concentration mole/liter Patient(Urine)— M = 188,2 g/mol b- NPU01025 Acetylglucosamine; U—N-e-Acetyl-L-lysine; subst.c.= ? prefix ? mol/l substance rate micromole/day Urine— NPU10283 N-a- Pt(U)—b-Acetylglucosamine; subst.rate = ? µmol/d Acetyl-L-lysine; substance concentration Urine— micromole/liter N- M = 188,2 g/mol Acetyl-L-cystathionine/Creatininium; NPU01024 substance ratio U—N-a-Acetyl-L-lysine; subst.c. = ? µmol/l 10-3 NPU14179 Patient(arterial Blood)— U—N-Acetyl-L-cystathionine/Creatininium; Acid base status; subst.ratio = ? × 10-3 property(list; procedure) NPU04197 Urine— Pt(aB)—Acid base status; prop.(list; proc.) N- NPU12518 P(aB)—Base excess(H+binding group); Acetyl-L-cystathionine; subst.c.(actual-norm) = ? mmol/l substance concentration NPU01348 P(aB)—Base excess(H+binding group);

micromole/liter subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? M = 264,3 g/mol mmol/l NPU01022 NPU04034 Pt(spec.)—Blood; temp. = ? °C U—N-Acetyl-L-cystathionine; subst.c. = ? µmol/l NPU08676 Pt—Body; temp. = ? °C NPU12476 P(aB)—Carbon dioxide(free); subst.c. = Urine— ? mmol/l N- NPU01470 P(aB)—Carbon dioxide(free); tension(37 Acetyl-L-cystine/Creatininium; °C) = ? kPa substance ratio NPU12526 P(aB)—Carbon dioxide(free); 10-3 tension(body temp.) = ? kPa NPU14180 NPU01471 P(aB)—Carbon dioxide(tot.); subst.c. = ? U—N-Acetyl-L-cystine/Creatininium; subst.ratio = ? mmol/l × 10-3

NPU01473 Hb(Fe; B)—Carbon monoxide NPU12494 P(cB)—Hydrogen ion; subst.c.(37 °C) = haemoglobin(Fe); subst.fr. = ? ? nmol/l NPU08753 Hb(tot.; aB)—Deoxyhaemoglobin; NPU12497 P(cB)—Hydrogen ion; subst.c.(body subst.fr. = ? temp.) = ? nmol/l NPU02319 B—Haemoglobin(Fe); subst.c. = ? NPU02725 Hb(Fe; B)—Methaemoglobin(Fe); mmol/l subst.fr. = ?

NPU02409 P(aB)—Hydrogen carbonate; NPU12514 Gas(cB)—Oxygen(O2); part.pr. = ? kPa

subst.c.(actual) = ? mmol/l NPU10197 Hb(tot.; cB)—Oxygen(O2); sat.fr. = ?

NPU02410 P—Hydrogen carbonate; subst.c.(pCO2 NPU12500 P(cB)—Oxygen(O2); tension = ? kPa

= 5,3 kPa; 37 °C) = ? mmol/l NPU03010 Hb(B)—Oxygen(O2); tension(halfsat.) = NPU12474 P(aB)—Hydrogen ion; pH(37 °C) = ? ? kPa

NPU02412 P(aB)—Hydrogen ion; pH(body temp.) = NPU12503 P(cB)—Oxygen(O2; free); subst.c. = ? ? mmol/l

NPU12475 P(aB)—Hydrogen ion; subst.c.(37 °C) = NPU12506 B(cB)—Oxygen(O2; total); subst.c. = ? ? nmol/l mmol/l NPU02413 P(aB)—Hydrogen ion; subst.c.(body NPU12510 Hb(Fe; deoxy+oxy; cB)— temp.) = ? nmol/l Oxyhaemoglobin(Fe); subst.fr. = ? NPU02725 Hb(Fe; B)—Methaemoglobin(Fe); NPU10754 Hb(Fe; tot.; cB)—Oxyhaemoglobin(Fe); subst.fr. = ? subst.fr. = ?

NPU03009 Gas(aB)—Oxygen(O2); part.pr. = ? kPa

NPU03011 Hb(tot.; aB)—Oxygen(O2); sat.fr. = ? Patient(cord Blood)—

NPU08977 P(aB)—Oxygen(O2); tension = ? kPa Acid base status;

NPU03010 Hb(B)—Oxygen(O2); tension(halfsat.) = property(list; procedure) ? kPa NPU12516

NPU03012 P(aB)—Oxygen(O2; free); subst.c. = ? Pt(cordB)—Acid base status; prop.(list; proc.) mmol/l NPU12519 P(cordB)—Base excess(H+binding

NPU03849 B(aB)—Oxygen(O2; total); subst.c. = ? group); subst.c.(actual-norm) = ? mmol/l mmol/l NPU10219 P(cordB)—Base excess(H+binding

NPU03014 Hb(Fe; deoxy+oxy; aB)— group); subst.c.(pCO2 = 5,3 kPa; 37 °C; actual- Oxyhaemoglobin(Fe); subst.fr. = ? norm) = ? mmol/l NPU03013 Hb(Fe; tot.; aB)—Oxyhaemoglobin(Fe); NPU04034 Pt(spec.)—Blood; temp. = ? °C subst.fr. = ? NPU08676 Pt—Body; temp. = ? °C NPU12483 P(cordB)—Carbon dioxide(free); subst.c. Patient(capillary Blood)— = ? mmol/l Acid base status; NPU10030 P(cordB)—Carbon dioxide(free); property(list; procedure) tension(37 °C) = ? kPa NPU12479 NPU12527 P(cordB)—Carbon dioxide(free); Pt(cB)—Acid base status; prop.(list; proc.) tension(body temp.) = ? kPa NPU12520 P(cB)—Base excess(H+binding group); NPU12517 P(cordB)—Carbon dioxide(tot.); subst.c. subst.c.(actual-norm) = ? mmol/l = ? mmol/l NPU12480 P(cB)—Base excess(H+binding group); NPU01473 Hb(Fe; B)—Carbon monoxide

subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? haemoglobin(Fe); subst.fr. = ? mmol/l NPU02319 B—Haemoglobin(Fe); subst.c. = ? NPU04034 Pt(spec.)—Blood; temp. = ? °C mmol/l NPU08676 Pt—Body; temp. = ? °C NPU14265 P(cordB)—Hydrogen carbonate; NPU12482 P(cB)—Carbon dioxide(free); subst.c. = subst.c.(actual) = ? mmol/l

? mmol/l NPU02410 P—Hydrogen carbonate; subst.c.(pCO2 NPU12481 P(cB)—Carbon dioxide(free); tension(37 = 5,3 kPa; 37 °C) = ? mmol/l °C) = ? kPa NPU10016 P(cordB)—Hydrogen ion; pH = ? NPU12528 P(cB)—Carbon dioxide(free); NPU12493 P(cordB)—Hydrogen ion; pH(body tension(body temp.) = ? kPa temp.) = ? NPU12485 P(cB)—Carbon dioxide(tot.); subst.c. = ? NPU12496 P(cordB)—Hydrogen ion; subst.c. mmol/l (37 °C) = ? nmol/l NPU01473 Hb(Fe; B)—Carbon monoxide NPU12499 P(cordB)—Hydrogen ion; subst.c.(body haemoglobin(Fe); subst.fr. = ? temp.) = ? nmol/l NPU02319 B—Haemoglobin(Fe); subst.c. = ? NPU02725 Hb(Fe; B)—Methaemoglobin(Fe); mmol/l subst.fr. = ?

NPU14264 P(cB)—Hydrogen carbonate; NPU12513 Gas(cordB)—Oxygen(O2); part.pr. = ? subst.c.(actual) = ? mmol/l kPa

NPU02410 P—Hydrogen carbonate; subst.c.(pCO2 NPU12508 Hb(tot.; cordB)—Oxygen(O2); sat.fr. = ?

= 5,3 kPa; 37 °C) = ? mmol/l NPU12502 P(cordB)—Oxygen(O2); tension = ? kPa

NPU12490 P(cB)—Hydrogen ion; pH(37 °C) = ? NPU03010 Hb(B)—Oxygen(O2); tension(halfsat.) = NPU12491 P(cB)—Hydrogen ion; pH(body temp.) = ? kPa ?

NPU12478 P(cordB)—Oxygen(O2; free); subst.c. = Patient(cord Blood; venous Blood)— ? mmol/l Acid base status;

NPU12505 B(cordB)—Oxygen(O2; total); subst.c. = property(list; procedure) ? mmol/l NPU17132 NPU12509 Hb(Fe; deoxy+oxy; cordB)— Pt(cordB; vB)—Acid base status; prop.(list; proc.) Oxyhaemoglobin(Fe); subst.fr. = ? NPU17134 P(cordB; vB)—Base excess(H+binding NPU12512 Hb(Fe; tot.; cordB)— group); subst.c.(actual-norm) = ? mmol/l Oxyhaemoglobin(Fe); subst.fr. = ? NPU17136 P(cordB; vB)—Base excess(H+binding

group); subst.c.(pCO2 = 5,3 kPa; 37 °C; actual- Patient(cord Blood; arterial Blood)— norm) = ? mmol/l Acid base status; NPU04034 Pt(spec.)—Blood; temp. = ? °C property(list; procedure) NPU08676 Pt—Body; temp. = ? °C NPU17131 NPU17138 P(cordB; vB)—Carbon dioxide(free); Pt(cordB; aB)—Acid base status; prop.(list; proc.) subst.c. = ? mmol/l NPU17133 P(cordB; aB)—Base excess(H+binding NPU17140 P(cordB; vB)—Carbon dioxide(free); group); subst.c.(actual-norm) = ? mmol/l tension(37 °C) = ? kPa NPU17135 P(cordB; aB)—Base excess(H+binding NPU17142 P(cordB; vB)—Carbon dioxide(free);

group); subst.c.(pCO2 = 5,3 kPa; 37 °C; actual- tension(body temp.) = ? kPa norm) = ? mmol/l NPU17144 P(cordB; vB)—Carbon dioxide(tot.); NPU04034 Pt(spec.)—Blood; temp. = ? °C subst.c. = ? mmol/l NPU08676 Pt—Body; temp. = ? °C NPU01473 Hb(Fe; B)—Carbon monoxide NPU17137 P(cordB; aB)—Carbon dioxide(free); haemoglobin(Fe); subst.fr. = ? subst.c. = ? mmol/l NPU02319 B—Haemoglobin(Fe); subst.c. = ? NPU17139 P(cordB; aB)—Carbon dioxide(free); mmol/l tension(37 °C) = ? kPa NPU17146 P(cordB; vB)—Hydrogen carbonate; NPU17141 P(cordB; aB)—Carbon dioxide(free); subst.c.(actual) = ? mmol/l

tension(body temp.) = ? kPa NPU02410 P—Hydrogen carbonate; subst.c.(pCO2 NPU17143 P(cordB; aB)—Carbon dioxide(tot.); = 5,3 kPa; 37 °C) = ? mmol/l subst.c. = ? mmol/l NPU17148 P(cordB; vB)—Hydrogen ion; pH = ? NPU01473 Hb(Fe; B)—Carbon monoxide NPU17150 P(cordB; vB)—Hydrogen ion; pH(body haemoglobin(Fe); subst.fr. = ? temp.) = ? NPU02319 B—Haemoglobin(Fe); subst.c. = ? NPU17152 P(cordB; vB)—Hydrogen ion; mmol/l subst.c.(37 °C) = ? nmol/l NPU17145 P(cordB; aB)—Hydrogen carbonate; NPU17154 P(cordB; vB)—Hydrogen ion; subst.c.(actual) = ? mmol/l subst.c.(body temp.) = ? nmol/l

NPU02410 P—Hydrogen carbonate; subst.c.(pCO2 NPU02725 Hb(Fe; B)—Methaemoglobin(Fe); = 5,3 kPa; 37 °C) = ? mmol/l subst.fr. = ?

NPU17147 P(cordB; aB)—Hydrogen ion; pH = ? NPU17171 Gas(cordB; vB)—Oxygen(O2); part.pr. = NPU17149 P(cordB; aB)—Hydrogen ion; pH(body ? kPa

temp.) = ? NPU12508 Hb(tot.; cordB)—Oxygen(O2); sat.fr. = ?

NPU17151 P(cordB; aB)—Hydrogen ion; NPU17156 P(cordB; vB)—Oxygen(O2); tension = ? subst.c.(37 °C) = ? nmol/l kPa

NPU17153 P(cordB; aB)—Hydrogen ion; NPU03010 Hb(B)—Oxygen(O2); tension(halfsat.) = subst.c.(body temp.) = ? nmol/l ? kPa

NPU02725 Hb(Fe; B)—Methaemoglobin(Fe); NPU17158 P(cordB; vB)—Oxygen(O2; free); subst.fr. = ? subst.c. = ? mmol/l

NPU17170 Gas(cordB; aB)—Oxygen(O2); part.pr. = NPU12505 B(cordB)—Oxygen(O2; total); subst.c. = ? kPa ? mmol/l

NPU12508 Hb(tot.; cordB)—Oxygen(O2); sat.fr. = ? NPU12509 Hb(Fe; deoxy+oxy; cordB)—

NPU17155 P(cordB; aB)—Oxygen(O2); tension = ? Oxyhaemoglobin(Fe); subst.fr. = ? kPa NPU12512 Hb(Fe; tot.; cordB)—

NPU03010 Hb(B)—Oxygen(O2); tension(halfsat.) = Oxyhaemoglobin(Fe); subst.fr. = ? ? kPa

NPU17157 P(cordB; aB)—Oxygen(O2; free); Patient(mixed Blood)— subst.c. = ? mmol/l Acid base status;

NPU12505 B(cordB)—Oxygen(O2; total); subst.c. = property(list; procedure) ? mmol/l NPU09208 NPU12509 Hb(Fe; deoxy+oxy; cordB)— Pt(mixB)—Acid base status; prop.(list; proc.) Oxyhaemoglobin(Fe); subst.fr. = ? NPU09200 P(mixB)—Base excess(H+binding NPU12512 Hb(Fe; tot.; cordB)— group); subst.c.(actual-norm) = ? mmol/l Oxyhaemoglobin(Fe); subst.fr. = ? NPU09201 P(mixB)—Base excess(H+binding

group); subst.c.(pCO2 = 5,3 kPa; 37 °C; actual- norm) = ? mmol/l

NPU04034 Pt(spec.)—Blood; temp. = ? °C haemoglobin(Fe); subst.fr. = ? NPU08676 Pt—Body; temp. = ? °C NPU02319 B—Haemoglobin(Fe); subst.c. = ? NPU09204 P(mixB)—Carbon dioxide(free); subst.c. mmol/l = ? mmol/l NPU14266 P(vB)—Hydrogen carbonate; NPU09202 P(mixB)—Carbon dioxide(free); subst.c.(actual) = ? mmol/l

tension(37 °C) = ? kPa NPU02410 P—Hydrogen carbonate; subst.c.(pCO2 NPU09203 P(mixB)—Carbon dioxide(free); = 5,3 kPa; 37 °C) = ? mmol/l tension(body temp.) = ? kPa NPU12489 P(vB)—Hydrogen ion; pH(37 °C) = ? NPU09206 P(mixB)—Carbon dioxide(tot.); subst.c. NPU12492 P(vB)—Hydrogen ion; pH(body temp.) = = ? mmol/l ? NPU01473 Hb(Fe; B)—Carbon monoxide NPU12495 P(vB)—Hydrogen ion; subst.c.(37 °C) = haemoglobin(Fe); subst.fr. = ? ? nmol/l NPU02319 B—Haemoglobin(Fe); subst.c. = ? NPU12498 P(vB)—Hydrogen ion; subst.c.(body mmol/l temp.) = ? nmol/l NPU09209 P(mixB)—Hydrogen carbonate; NPU02725 Hb(Fe; B)—Methaemoglobin(Fe); subst.c.(actual) = ? mmol/l subst.fr. = ?

NPU02410 P—Hydrogen carbonate; subst.c.(pCO2 NPU03847 Gas(vB)—Oxygen(O2); part.pr. = ? kPa

= 5,3 kPa; 37 °C) = ? mmol/l NPU10199 Hb(tot.; vB)—Oxygen(O2); sat.fr. = ?

NPU09210 P(mixB)—Hydrogen ion; pH(37 °C) = ? NPU12501 P(vB)—Oxygen(O2); tension = ? kPa

NPU09211 P(mixB)—Hydrogen ion; pH(body temp.) NPU03010 Hb(B)—Oxygen(O2); tension(halfsat.) = = ? ? kPa

NPU09212 P(mixB)—Hydrogen ion; subst.c.(37 °C) NPU12504 P(vB)—Oxygen(O2; free); subst.c. = ? = ? nmol/l mmol/l

NPU09213 P(mixB)—Hydrogen ion; subst.c.(body NPU12507 B(vB)—Oxygen(O2; total); subst.c. = ? temp.) = ? nmol/l mmol/l NPU02725 Hb(Fe; B)—Methaemoglobin(Fe); NPU12511 Hb(Fe; deoxy+oxy; vB)— subst.fr. = ? Oxyhaemoglobin(Fe); subst.fr. = ?

NPU09214 Gas(mixB)—Oxygen(O2); part.pr. = ? NPU10265 Hb(Fe; tot.; vB)—Oxyhaemoglobin(Fe); kPa subst.fr. = ?

NPU09218 Hb(tot.; mixB)—Oxygen(O2); sat.fr. = ?

NPU09215 P(mixB)—Oxygen(O2); tension = ? kPa Plasma—

NPU03010 Hb(B)—Oxygen(O2); tension(halfsat.) = Acid phosphatase, prostatic type; ? kPa catalytic-activity concentration(37 °C;

NPU09216 P(mixB)—Oxygen(O2; free); subst.c. = ? procedure) mmol/l microkatal/liter

NPU09217 B(mixB)—Oxygen(O2; total); subst.c. = ? NPU01065 mmol/l P—Acid phosphatase, prostatic type; cat.c.(37 °C; NPU09219 Hb(Fe; deoxy+oxy; mixB)— proc.) = ? µkat/l Oxyhaemoglobin(Fe); subst.fr. = ? NPU09220 Hb(Fe; tot.; mixB)— Synovial fluid(specification)— Oxyhaemoglobin(Fe); subst.fr. = ? Acid phosphatase, prostatic type; catalytic-activity concentration(37 °C; Patient(venous Blood)— procedure) Acid base status; microkatal/liter property(list; procedure) NPU10609 NPU10755 Synf(spec.)—Acid phosphatase, prostatic type; Pt(vB)—Acid base status; prop.(list; proc.) cat.c.(37 °C; proc.) = ? µkat/l NPU12521 P(vB)—Base excess(H+binding group); subst.c.(actual-norm) = ? mmol/l Plasma— NPU08970 P(vB)—Base excess(H+binding group); Acid phosphatase, prostatic type;

subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? substance concentration mmol/l micromole/liter NPU04034 Pt(spec.)—Blood; temp. = ? °C NPU01066 NPU08676 Pt—Body; temp. = ? °C P—Acid phosphatase, prostatic type; subst.c. = ? NPU12484 P(vB)—Carbon dioxide(free); subst.c. = µmol/l ? mmol/l NPU10029 P(vB)—Carbon dioxide(free); tension(37 Plasma— °C) = ? kPa Acid phosphatase; NPU12529 P(vB)—Carbon dioxide(free); catalytic-activity concentration(37 °C; tension(body temp.) = ? kPa procedure) NPU01472 P(vB)—Carbon dioxide(tot.); subst.c. = ? microkatal/liter mmol/l NPU01064 NPU01473 Hb(Fe; B)—Carbon monoxide P—Acid phosphatase; cat.c.(37 °C; proc.) = ? µkat/l

Synovial fluid(specification)— (adrenalinium) = 183,20 g/mol Acid phosphatase; NPU10541 catalytic-activity concentration(37 °C; Pt—Adrenalinium secretion; subst.rate(clonidine procedure) p.o.; list; proc.) microkatal/liter NPU10536 Pt—Clonidine(administered); am.s.(p.o.) NPU10617 = ? µmol Synf(spec.)—Acid phosphatase; cat.c.(37 °C; proc.) NPU10666 P—Adrenalinium; subst.c.(-15 min)= ? = ? µkat/l µmol/l NPU10667 P—Adrenalinium; subst.c.(-5 min)= ? Urine— µmol/l Adenosyl-L-homocysteine/Creatininium; NPU10537 P—Adrenalinium; subst.c.(0 min)= ? substance ratio µmol/l 10-3 NPU10538 P—Adrenalinium; subst.c.(60 min)= ? NPU14184 µmol/l U—Adenosyl-L-homocysteine/Creatininium; NPU10539 P—Adrenalinium; subst.c.(120 min)= ? subst.ratio = ? × 10-3 µmol/l NPU10540 P—Adrenalinium; subst.c.(180 min)= ? Urine— µmol/l Adenosyl-L-homocysteine; substance concentration Urine— micromole/liter Adrenalinium; M = 384,4 g/mol amount-of-substance(procedure) NPU01084 micromole U—Adenosyl-L-homocysteine; subst.c. = ? µmol/l NPU17545 U—Adrenalinium; am.s.(proc.) = ? µmol Urine— Adenosyl-L-methionine/Creatininium; Plasma— substance ratio Adrenalinium; 10-3 substance concentration(15 minutes before NPU14185 challenge) U—Adenosyl-L-methionine/Creatininium; subst.ratio micromole/liter = ? × 10-3 M = 183,20 g/mol NPU10666 Plasma— P—Adrenalinium; subst.c.(-15 min)= ? µmol/l Adenosyl-L-methionine; substance concentration Plasma— micromole/liter Adrenalinium; M = 399,4 g/mol substance concentration(5 minutes before NPU01085 challenge) P—Adenosyl-L-methionine; subst.c. = ? µmol/l micromole/liter M = 183,20 g/mol Urine— NPU10667 Adenosyl-L-methionine; P—Adrenalinium; subst.c.(-5 min)= ? µmol/l substance concentration micromole/liter Plasma— M = 399,4 g/mol Adrenalinium; NPU01086 substance concentration(0 minutes after U—Adenosyl-L-methionine; subst.c. = ? µmol/l challenge) micromole/liter Urine— M = 183,20 g/mol Adipate; NPU10537 substance concentration P—Adrenalinium; subst.c.(0 min)= ? µmol/l micromole/liter M = 146,14 g/mol Plasma— NPU01104 Adrenalinium; U—Adipate; subst.c. = ? µmol/l substance concentration(60 minutes after challenge) Patient— micromole/liter Adrenalinium secretion; M = 183,20 g/mol substance rate(clonidine, oral administration; NPU10538 list; procedure) P—Adrenalinium; subst.c.(60 min)= ? µmol/l Other term(s): Epinephrine secretion Note: M (clonidine) = 230,10 g/mol; M

Plasma— NPU10543 P—Adrenalinium+Noradrenalinium; Adrenalinium; subst.c.(60 min)= ? µmol/l substance concentration(120 minutes after NPU10544 P—Adrenalinium+Noradrenalinium; challenge) subst.c.(120 min)= ? µmol/l micromole/liter NPU10545 P—Adrenalinium+Noradrenalinium; M = 183,20 g/mol subst.c.(180 min)= ? µmol/l NPU10539 P—Adrenalinium; subst.c.(120 min)= ? µmol/l Urine— Adrenalinium+Noradrenalinium; Plasma— amount-of-substance(procedure) Adrenalinium; micromole substance concentration(180 minutes after NPU17624 challenge) U—Adrenalinium+Noradrenalinium; am.s.(proc.) = ? micromole/liter µmol M = 183,20 g/mol NPU10540 Plasma— P—Adrenalinium; subst.c.(180 min)= ? µmol/l Adrenalinium+Noradrenalinium; substance concentration(15 minutes before Plasma— challenge) Adrenalinium; micromole/liter substance concentration NPU10620 micromole/liter P—Adrenalinium+Noradrenalinium; subst.c.(-15 M = 183,20 g/mol min)= ? µmol/l NPU14042 P—Adrenalinium; subst.c.= ? µmol/l Plasma— Adrenalinium+Noradrenalinium; Urine— substance concentration(5 minutes before Adrenalinium; challenge) substance concentration micromole/liter micromole/liter NPU10621 M = 183,20 g/mol P—Adrenalinium+Noradrenalinium; subst.c.(-5 Other term(s): Epinephrine min)= ? µmol/l Authority: IUPAC-IUB 83 NPU14041 Plasma— U—Adrenalinium; subst.c. = ? µmol/l Adrenalinium+Noradrenalinium; substance concentration(0 minutes after Patient(Urine)— challenge) Adrenalinium; micromole/liter substance rate(procedure) NPU10542 micromole/day P—Adrenalinium+Noradrenalinium; subst.c.(0 min)= NPU14043 ? µmol/l Pt(U)—Adrenalinium; subst.rate(proc.) = ? µmol/d Plasma— Patient— Adrenalinium+Noradrenalinium; Adrenalinium+noradrenalinium secretion; substance concentration(60 minutes after substance rate(clonidine, oral administration; challenge) list; procedure) micromole/liter Other term(s): Epinephrine+norepinephrine NPU10543 secretion P—Adrenalinium+Noradrenalinium; subst.c.(60 Note: M (clonidine) = 230,10 g/mol; M min)= ? µmol/l (adrenalinium) = 183,20 g/mol; M (noradrenalinium) = 169,18 g/mol Plasma— NPU10546 Adrenalinium+Noradrenalinium; Pt—Adrenalinium+noradrenalinium secretion; substance concentration(120 minutes after subst.rate(clonidine p.o.; list; proc.) challenge) NPU10536 Pt—Clonidine(administered); am.s.(p.o.) micromole/liter = ? µmol NPU10544 NPU10620 P—Adrenalinium+Noradrenalinium; P—Adrenalinium+Noradrenalinium; subst.c.(120 subst.c.(-15 min)= ? µmol/l min)= ? µmol/l NPU10621 P—Adrenalinium+Noradrenalinium; subst.c.(-5 min)= ? µmol/l Plasma— NPU10542 P—Adrenalinium+Noradrenalinium; Adrenalinium+Noradrenalinium; subst.c.(0 min)= ? µmol/l substance concentration(180 minutes after

challenge) Lung(specification)— micromole/liter Air; NPU10545 volume P—Adrenalinium+Noradrenalinium; subst.c.(180 liter min)= ? µmol/l NPU03789 Lung(spec.)—Air; vol. = ? l Plasma— Adrenalinium+Noradrenalinium; Amniotic fluid— substance concentration Alanine transaminase; micromole/liter catalytic-activity concentration(37 °C; Other term(s): Epinephrine+norepinephrine procedure) Note: M (adrenalin) = 183,20 g/mol; M microkatal/liter (noradrenalin) = 169,18 g/mol Other term(s): Glutamic-pyruvic transaminase; NPU14044 Glutamic-alanine transaminase P—Adrenalinium+Noradrenalinium; subst.c. = ? NPU03911 µmol/l Amf—Alanine transaminase; cat.c.(37 °C; proc.) = ? µkat/l Urine— Adrenalinium+Noradrenalinium; Plasma— substance concentration Alanine transaminase; micromole/liter catalytic-activity concentration(37 °C; Other term(s): Epinephrine+norepinephrine procedure) Note: M (adrenalin) = 183,20 g/mol; M microkatal/liter (noradrenalin) = 169,18 g/mol Other term(s): Glutamic-pyruvic transaminase; NPU14120 Glutamic-alanine transaminase U—Adrenalinium+Noradrenalinium; subst.c. = ? NPU01121 µmol/l P—Alanine transaminase; cat.c.(37 °C; proc.) = ? µkat/l Patient(Urine)— Adrenalinium+Noradrenalinium; Urine— substance rate(procedure) b- micromole/day Alanine/Creatininium; Other term(s): Catecholamines; Levarterenol substance ratio NPU01105 10–3 Pt(U)—Adrenalinium+Noradrenalinium; NPU14187 subst.rate(proc.) = ? µmol/d U—b-Alanine/Creatininium; subst.ratio = ? × 10–3

Plasma— Urine— Adrenocortex antibody(Immunoglobulin G); Alanine/Creatininium; arbitrary concentration(procedure) substance ratio NPU12545 10–3 P—Adrenocortex antibody(IgG); arb.c.(proc.) = ? NPU14186 U—Alanine/Creatininium; subst.ratio = ? × 10–3 Plasma— Adrenocortex antibody; Cerebrospinal fluid— arbitrary substance concentration(procedure) b- arbitrary unit/liter Alanine; NPU01106 substance concentration P—Adrenocortex antibody; arb.subst.c.(proc.) = ? micromole/liter arb.unit/l M = 89,09 g/mol Authority: IUPAC-IUB 84 Room— NPU09017 Air; Csf—b-Alanine; subst.c. = ? µmol/l pressure kilopascal Plasma— NPU04078 b- Room—Air; pr. = ? kPa Alanine; substance concentration Room— micromole/liter Air; M = 89,09 g/mol Celsius temperature Authority: IUPAC-IUB 84 degree Celsius NPU01119 NPU04082 P—b-Alanine; subst.c. = ? µmol/l Room—Air; temp. = ? °C

Urine— Urine— b- Albumin; Alanine; amount-of-substance(procedure) substance concentration micromole micromole/liter M = 66 000 g/mol M = 89,09 g/mol NPU10270 Authority: IUPAC-IUB 84 U—Albumin; am.s.(proc.) = ? µmol NPU01120 U—b-Alanine; subst.c. = ? µmol/l System(specification)— Albumin; Cerebrospinal fluid— mass concentration Alanine; gram/liter substance concentration NPU14338 micromole/liter Syst(spec.)—Albumin; mass c. = ? g/l M = 89,09 g/mol Authority: IUPAC-IUB 84 Protein(Cerebrospinal fluid)— NPU01116 Albumin; Csf—Alanine; subst.c. = ? µmol/l mass fraction NPU04949 Plasma— Prot.(Csf)—Albumin; mass fr. = ? Alanine; substance concentration Protein(Plasma)— micromole/liter Albumin; M = 89,09 g/mol mass fraction Authority: IUPAC-IUB 84 NPU04939 NPU01117 Prot.(P)—Albumin; mass fr. = ? P—Alanine; subst.c. = ? µmol/l Protein(Urine)— Urine— Albumin; Alanine; mass fraction substance concentration NPU04944 micromole/liter Prot.(U)—Albumin; mass fr. = ? M = 89,09 g/mol Authority: IUPAC-IUB 84 Cerebrospinal fluid— NPU01118 Albumin; U—Alanine; subst.c. = ? µmol/l relative substance concentration(Cerebrospinal fluid/Plasma) Kidney— M = 66 000 g/mol Albumin clearance/Creatininium clearance; NPU04980 volume rate ratio Csf—Albumin; rel.subst.c.(Csf/P) = ? 10-3 NPU04125 Urine— Kidn.—Albumin clearance/Creatininium clearance; Albumin; vol.rate ratio = ? × 10-3 substance concentration(procedure) micromole/liter Intestine, small— M = 66 000 g/mol Albumin loss; NPU01134 substance rate(procedure) U—Albumin; subst.c.(proc.) = ? µmol/l micromole/day M = 66 000 g/mol Amniotic fluid— NPU04041 Albumin; Intest., small—Albumin loss; subst.rate(proc.) = ? substance concentration µmol/d micromole/liter M = 66 000 g/mol Urine— NPU08600 Albumin/Creatininium; Amf—Albumin; subst.c. = ? µmol/l substance ratio 10-3 Ascites— Note: M (albumin) = 60 000 g/mol; M (creatininium) Albumin; = 113,12 substance concentration NPU03918 micromole/liter U—Albumin/Creatininium; subst.ratio = ? × 10-3 M = 66 000 g/mol NPU03920 Asc—Albumin; subst.c. = ? µmol/l

Cerebrospinal fluid— Synovial fluid(specification)— Albumin; Albumin; substance concentration substance concentration micromole/liter micromole/liter M = 66 000 g/mol M = 66 000 g/mol NPU01130 NPU03921 Csf—Albumin; subst.c. = ? µmol/l Synf(spec.)—Albumin; subst.c. = ? µmol/l

Dialysis solution— Urine— Albumin; Albumin; substance concentration substance concentration micromole/liter micromole/liter M = 66 000 g/mol M = 66 000 g/mol NPU10018 NPU03903 Dialysis solution—Albumin; subst.c. = ? µmol/l U—Albumin; subst.c. = ? µmol/l

Drain fluid(specification)— Patient(Urine)— Albumin; Albumin; substance concentration substance rate(procedure) micromole/liter micromole/day NPU17046 NPU01131 Drain fluid(spec.)—Albumin; subst.c. = ? µmol/l Pt(U)—Albumin; subst.rate(proc.) = ? µmol/d

Expectorate— Plasma— Albumin; Aldolase; substance concentration catalytic-activity concentration(37 °C; micromole/liter procedure) M = 66 000 g/mol microkatal/liter NPU10272 Other term(s): 1,6-Diphosphate aldolase; Aldolase Ex—Albumin; subst.c. = ? µmol/l A; Fructose-1,6-bisphosphate triosephosphate- lyase Plasma— Authority: IUB 84 Albumin; NPU02116 substance concentration P—Aldolase; cat.c.(37 °C; proc.) = ? µkat/l micromole/liter M = 66 000 g/mol Leukocytes(Blood)— NPU01132 Aldosterone receptor; P—Albumin; subst.c. = ? µmol/l arbitrary entitic number(procedure) NPU04063 Pleural fluid(specification)— Lkcs(B)—Aldosterone receptor; arb.entitic Albumin; num.(proc.) = ? substance concentration micromole/liter Leukocytes(Blood)— M = 66 000 g/mol Aldosterone receptor; NPU03919 entitic number(procedure) Plf(spec.)—Albumin; subst.c. = ? µmol/l NPU01137 Lkcs(B)—Aldosterone receptor; entitic num.(proc.) Saliva— = ? Albumin; substance concentration Adrenal cortex— micromole/liter Aldosterone secretion; M = 66 000 g/mol substance rate(furosemide, oral administration; NPU10019 list; procedure) Saliva—Albumin; subst.c. = ? µmol/l Note: M (furosemide) = 330,75 g/mol; M (aldosterone) = 360,44 g/mol Secretion(specification)— NPU10686 Albumin; Adrenal cortex—Aldosterone secretion; substance concentration subst.rate(furosemide p.o.; list; proc.) micromole/liter NPU10419 Pt—Furosemide(administered); M = 66 000 g/mol am.s.(p.o.) = ? µmol NPU10271 NPU10684 P—Aldosterone; subst.c.(0 min) = ? Secr(spec.)—Albumin; subst.c. = ? µmol/l pmol/l NPU10685 P—Aldosterone; subst.c.(300 min) = ? pmol/l

Plasma— Plasma—

Aldosterone; Aliphatic carboxylate(C10-C26); substance concentration(0 minutes after substance concentration challenge) millimole/liter picomole/liter Other term(s): Non esterified fatty acids; NEFA M = 360,44 g/mol NPU01139

Authority: IUPAC-IUB 89 P—Aliphatic carboxylate(C10-C26); subst.c. = ? NPU10684 mmol/l P—Aldosterone; subst.c.(0 min) = ? pmol/l Intestine, small—

Plasma— Aliphatic carboxylate(C14-C26) absorption; Aldosterone; substance rate(procedure) substance concentration(300 minutes after millimole/day challenge) NPU01138

picomole/liter Intest., small—Aliphatic carboxylate(C14-C26) M = 360,44 g/mol absorption; subst.rate(proc.) = ? mmol/d NPU10685 P—Aldosterone; subst.c.(300 min) = ? pmol/l Faeces—

Aliphatic carboxylate(C14-C26); Plasma— substance content Aldosterone; millimole/kilogram substance concentration NPU03926

nanomole/liter F—Aliphatic carboxylate(C14-C26); subst.cont. = ? M = 360,44 g/mol mmol/kg Authority: IUPAC-IUB 89 NPU14040 Patient(Faeces)—

P—Aldosterone; subst.c. = ? nmol/l Aliphatic carboxylate(C14-C26)+esters; substance rate(procedure) Urine— millimole/day Aldosterone; NPU01140

substance concentration Pt(F)—Aliphatic carboxylate(C14-C26)+esters; nanomole/liter subst.rate(proc.) = ? mmol/d M = 360,44 g/mol Authority: IUPAC-IUB 89 Plasma—

NPU14039 Aliphatic carboxylate(C22:0)/Aliphatic

U—Aldosterone; subst.c. = ? nmol/l carboxylate(C26:0); substance ratio Plasma— NPU01142

Aldosterone; P—Aliphatic carboxylate(C22:0)/Aliphatic

substance concentration carboxylate(C26:0); subst.ratio = ? picomole/liter M = 360,44 g/mol Plasma—

Authority: IUPAC-IUB 89 Aliphatic carboxylate(C24:0)/Aliphatic

NPU01135 carboxylate(C22:0); P—Aldosterone; subst.c. = ? pmol/l substance ratio NPU01141

Urine— P—Aliphatic carboxylate(C24:0)/Aliphatic

Aldosterone; carboxylate(C22:0); subst.ratio = ? substance concentration picomole/liter Plasma— M = 360,44 g/mol Alkaline phosphatase type; Authority: IUPAC-IUB 89 catalytic-activity concentration(list; 37 °C; NPU03853 procedure) U—Aldosterone; subst.c. = ? pmol/l NPU04589 P—Alkaline phosphatase type; cat.c.(list; 37 °C; Patient(Urine)— proc.) Aldosterone; NPU01145 P—Alkaline phosphatase, bone type; substance rate(procedure) cat.c.(37 °C; proc.) = ? µkat/l nanomole/day NPU10601 P—Alkaline phosphatase, liver Authority: IUPAC-IUB89 canaliculus type; cat.c.(37 °C; proc.) = ? µkat/l NPU01136 NPU10600 P—Alkaline phosphatase, liver Pt(U)—Aldosterone; subst.rate(proc.) = ? nmol/d endothelial type; cat.c.(37 °C; proc.) = ? µkat/l NPU01013 P—Alkaline phosphatase, liver type;

cat.c.(37 °C; proc.) = ? µkat/l Plasma— NPU01483 P—Alkaline phosphatase, placental Alkaline phosphatase, placental type; type; cat.c.(37 °C; proc.) = ? µkat/l catalytic-activity concentration(37 °C; NPU01530 P—Alkaline phosphatase, intestinal procedure) type; cat.c.(37 °C; proc.) = ? µkat/l microkatal/liter NPU10602 P—Alkaline phosphatase, ‚other‘ NPU01483 type(spec.); cat.c.(37 °C; proc.) = ? µkat/l P—Alkaline phosphatase, placental type; cat.c. (37 °C; proc.) = ? µkat/l Plasma— Alkaline phosphatase, bone type; Leukocytes(Blood)— catalytic-activity concentration(37 °C; Alkaline phosphatase; procedure) arbitrary catalytic activity(procedure) microkatal/liter NPU01143 NPU01145 Lkcs(B)—Alkaline phosphatase; arb.cat.act.(proc.) P—Alkaline phosphatase, bone type; cat.c.(37 °C; = ? proc.) = ? µkat/l Plasma— Plasma— Alkaline phosphatase; Alkaline phosphatase, intestinal type; catalytic-activity concentration(37 °C; catalytic-activity concentration(37 °C; procedure) procedure) microkatal/liter microkatal/liter NPU01144 NPU01530 P—Alkaline phosphatase; cat.c.(37 °C; proc.) = ? P—Alkaline phosphatase, intestinal type; cat.c. µkat/l (37 °C; proc.) = ? µkat/l Urine— Plasma— Alkaline phosphatase; Alkaline phosphatase, liver canaliculus type; catalytic-activity concentration(37 °C; catalytic-activity concentration(37 °C; procedure) procedure) microkatal/liter microkatal/liter NPU10020 NPU10601 U—Alkaline phosphatase; cat.c.(37 °C; proc.) = ? P—Alkaline phosphatase, liver canaliculus type; µkat/l cat.c.(37 °C; proc.) = ? µkat/l Plasma— Plasma— Alpha-1-globulin; Alkaline phosphatase, liver endothelial type; mass concentration catalytic-activity concentration(37 °C; gram/liter procedure) NPU04650 microkatal/liter P—Alpha-1-globulin; mass c. = ? g/l NPU10600 P—Alkaline phosphatase, liver endothelial type; Cerebrospinal fluid— cat.c.(37 °C; proc.) = ? µkat/l Alpha-1-globulin; mass concentration Plasma— milligram/liter Alkaline phosphatase, liver type; NPU04658 catalytic-activity concentration(37 °C; Csf—Alpha-1-globulin; mass c. = ? mg/l procedure) microkatal/liter Urine— NPU01013 Alpha-1-globulin; P—Alkaline phosphatase, liver type; cat.c.(37 °C; mass concentration proc.) = ? µkat/l milligram/liter NPU04654 Plasma— U—Alpha-1-globulin; mass c. = ? mg/l Alkaline phosphatase, ‘other’ type(specification); catalytic-activity concentration(37 °C; Protein(Cerebrospinal fluid)— procedure) Alpha-1-globulin; microkatal/liter mass fraction NPU10602 NPU04950 P—Alkaline phosphatase, ‘other’ type(spec.); Prot.(Csf)—Alpha-1-globulin; mass fr. = ? cat.c.(37 °C; proc.) = ? µkat/l

Protein(Plasma)— Urine— Alpha-1-globulin; Alpha-globulin; mass fraction mass concentration NPU04940 milligram/liter Prot.(P)—Alpha-1-globulin; mass fr. = ? NPU14037 U—Alpha-globulin; mass c. = ? mg/l Protein(Urine)— Alpha-1-globulin; Protein(Cerebrospinal fluid)— mass fraction Alpha-globulin; NPU04945 mass fraction Prot.(U)—Alpha-1-globulin; mass fr. = ? NPU14038 Prot.(Csf)—Alpha-globulin; mass fr. = ? Plasma— Alpha-2-globulin; Protein(Plasma)— mass concentration Alpha-globulin; gram/liter mass fraction NPU04651 NPU09264 P—Alpha-2-globulin; mass c. = ? g/l Prot.(P)—Alpha-globulin; mass fr. = ?

Cerebrospinal fluid— Protein(Urine)— Alpha-2-globulin; Alpha-globulin; mass concentration mass fraction milligram/liter NPU14036 NPU04659 Prot.(U)—Alpha-globulin; mass fr. = ? Csf—Alpha-2-globulin; mass c. = ? mg/l Plasma— Urine— Aluminium; Alpha-2-globulin; substance concentration mass concentration micromole/liter milligram/liter M = 26,98 g/mol NPU04655 Authority: IUPAC/VII-C-TOX U—Alpha-2-globulin; mass c. = ? mg/l NPU01157 P—Aluminium; subst.c. = ? µmol/l Protein(Cerebrospinal fluid)— Alpha-2-globulin; Urine— mass fraction Aluminium; NPU04951 substance concentration Prot.(Csf)—Alpha-2-globulin; mass fr. = ? micromole/liter M = 26,98 g/mol Protein(Plasma)— Authority: IUPAC/VII-C-TOX Alpha-2-globulin; NPU01158 mass fraction U—Aluminium; subst.c. = ? µmol/l NPU04941 Prot.(P)—Alpha-2-globulin; mass fr. = ? Cells(Blood)— Aluminium; Protein(Urine)— substance content Alpha-2-globulin; micromole/kilogram mass fraction M = 26,98 g/mol NPU04946 Authority: IUPAC/VII-C-TOX Prot.(U)—Alpha-2-globulin; mass fr. = ? NPU01155 Cells(B)—Aluminium; subst.cont. = ? µmol/kg Plasma— Alpha-globulin; Hair— mass concentration Aluminium; gram/liter substance content NPU09261 micromole/kilogram P—Alpha-globulin; mass c. = ? g/l M = 26,98 g/mol Authority: IUPAC/VII-C-TOX Cerebrospinal fluid— NPU01156 Alpha-globulin; Hair—Aluminium; subst.cont. = ? µmol/kg mass concentration milligram/liter NPU14035 Csf—Alpha-globulin; mass c. = ? mg/l

Urine— NPU14220 U—3-Hydroxy-3-carboxy-n-propylthio- Amino acid/Creatininium; cystine/Creatininium; subst.ratio = ? × 10-3 substance ratio(list; procedure) NPU14221 U—a-Hydroxy-b-chito-g-aminobutyrate/ NPU14178 Creatininium; subst.ratio = ? × 10-3 U—Amino acid/Creatininium; subst.ratio(list; proc.) NPU14222 U—3-Hydroxyasparagine/Creatininium; NPU14186 U—Alanine/Creatininium; subst.ratio = ? subst.ratio = ? × 10-3 × 10-3 NPU14223 U—3-Hydroxyisovalerate/Creatininium; NPU14187 U—b-Alanine/Creatininium; subst.ratio = subst.ratio = ? × 10-3 ? × 10-3 NPU14224 U—3-Hydroxykynurenine/Creatininium; NPU14188 U—Amino-2-piperidone/Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU14225 U—5-Hydroxylysine/Creatininium; NPU14189 U—a-Amino-n-butyrate/Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU14226 U—4-Hydroxyproline/Creatininium; NPU14190 U—a-Aminoadipate/Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU04210 U—Hydroxyproline/Creatininium; NPU14191 U—a-Aminobutyrate/Creatininium; subst.ratio= ? × 10-3 subst.ratio = ? × 10-3 NPU14228 U—3-Hydroxyproline/Creatininium; NPU14192 U—g-Aminobutyrate/Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU14229 U—Isoleucine/Creatininium; subst.ratio NPU14193 U—b-Aminoisobutyrate/Creatininium; = ? × 10-3 subst.ratio = ? × 10-3 NPU14230 U—Kynurenine/Creatininium; subst.ratio NPU14194 U—g-Aminoisobutyrate/Creatininium; = ? × 10-3 subst.ratio = ? × 10-3 NPU14231 U—Leucine/Creatininium; subst.ratio = ? NPU14200 U—g-Carboxyglutamate/Creatininium; × 10-3 subst.ratio = ? × 10-3 NPU14232 U—Levodopa/Creatininium; subst.ratio = NPU14201 U—N-e-Carboxymethyl lysine/ ? × 10-3 Creatininium; subst.ratio = ? × 10-3 NPU14233 U—Lysine/Creatininium; subst.ratio = ? NPU14202 U—Carnitine/Creatininium; subst.ratio = × 10-3 ? × 10-3 NPU14234 U—Malate/Creatininium; subst.ratio = ? NPU14203 U—Carnosine/Creatininium; subst.ratio × 10-3 = ? × 10-3 NPU14235 U—Methionine/Creatininium; subst.ratio NPU14204 U—Citrulline/Creatininium; subst.ratio = = ? × 10-3 ? × 10-3 NPU14236 U—Methionine sulfoxide/Creatininium; NPU14205 U—Cystathionine/Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU14237 U—Methylcitrate/Creatininium; NPU14206 U—Cysteine-L-homocysteine disulfide/ subst.ratio = ? × 10-3 Creatininium; subst.ratio = ? × 10-3 NPU14238 U—1-Methylhistidine/Creatininium; NPU14207 U—Cystine/Creatininium; subst.ratio = ? subst.ratio = ? × 10-3 × 10-3 NPU14239 U—3-Methylhistidine/Creatininium; NPU14208 U—Ethanolamine/Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU14240 U—Ornithine/Creatininium; subst.ratio = NPU14209 U—Glutamate/Creatininium; subst.ratio ? × 10-3 = ? × 10-3 NPU14241 U—Phenylalanine/Creatininium; NPU14210 U—Glutamine/Creatininium; subst.ratio subst.ratio = ? × 10-3 = ? × 10-3 NPU14242 U—Phosphoethanolamine/Creatininium; NPU14211 U—Glycine/Creatininium; subst.ratio = ? subst.ratio = ? × 10-3 × 10-3 NPU14243 U—Phosphoserine/Creatininium; NPU14212 U—Glycolate/Creatininium; subst.ratio = subst.ratio = ? × 10-3 ? × 10-3 NPU14244 U—Pipecolate/Creatininium; subst.ratio NPU14213 U—Histidine/Creatininium; subst.ratio = = ? × 10-3 ? × 10-3 NPU14245 U—Proline/Creatininium; subst.ratio = ? NPU14214 U—Homoarginine/Creatininium; × 10-3 subst.ratio = ? × 10-3 NPU14246 U—d-1-Pyrroline-5-carboxylate/ NPU14215 U—Homocarnosine/Creatininium; Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU14247 U—Saccharopine/Creatininium; NPU14216 U—Homocitrulline/Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU14248 U—Sarcosine/Creatininium; subst.ratio NPU14217 U—Homocystine/Creatininium; = ? × 10-3 subst.ratio = ? × 10-3 NPU14249 U—Serine/Creatininium; subst.ratio = ? NPU14218 U—Homoserine/Creatininium; × 10-3 subst.ratio = ? × 10-3 NPU14250 U—Sulfo-L-cysteine/Creatininium; NPU10164 U—Homovanillate/Creatininium; subst.ratio = ? × 10-3 subst.ratio = ? × 10-3 NPU14251 U—Taurine/Creatininium; subst.ratio = ?

× 10-3 NPU01207 P—b-Aminoisobutyrate; subst.c. = ? NPU14252 U—Threonine/Creatininium; subst.ratio µmol/l = ? × 10-3 NPU10401 P—g-Aminoisobutyrate; subst.c. = ? NPU14253 U—Tryptophan/Creatininium; subst.ratio µmol/l = ? × 10-3 NPU01267 P—Anserine; subst.c. = ? µmol/l NPU14254 U—Tyramine-O-sulphate/Creatininium; NPU01298 P—Arginine; subst.c. = ? µmol/l subst.ratio = ? × 10-3 NPU01319 P—Asparagine; subst.c. = ? µmol/l NPU14255 U—Tyramine/Creatininium; subst.ratio = NPU01322 P—Aspartate; subst.c. = ? µmol/l ? × 10-3 NPU01503 P—Carnosine; subst.c. = ? µmol/l NPU14256 U—Tyrosine/Creatininium; subst.ratio = NPU01611 P—Citrulline; subst.c. = ? µmol/l ? × 10-3 NPU01820 P—Cystathionine; subst.c. = ? µmol/l NPU14257 U—Valine/Creatininium; subst.ratio = ? NPU01826 P—Cystine; subst.c. = ? µmol/l × 10-3 NPU02229 P—Glutamate; subst.c. = ? µmol/l NPU14258 U—Xylosylserine/Creatininium; NPU02249 P—Glutamine; subst.c. = ? µmol/l subst.ratio = ? × 10-3 NPU02289 P—Glycine; subst.c. = ? µmol/l NPU02373 P—Histidine; subst.c. = ? µmol/l Cerebrospinal fluid— NPU02397 P—Homocystine; subst.c. = ? µmol/l Amino acid; NPU02433 P—5-Hydroxylysine; subst.c. = ? µmol/l substance concentration(list; procedure) NPU02463 P—3-Hydroxyproline; subst.c. = ? µmol/l NPU09013 NPU02464 P—4-Hydroxyproline; subst.c. = ? µmol/l Csf—Amino acid; subst.c.(list; proc.) NPU02510 P—Isoleucine; subst.c. = ? µmol/l NPU01116 Csf—Alanine; subst.c. = ? µmol/l NPU02589 P—Leucine; subst.c. = ? µmol/l NPU09017 Csf—b-Alanine; subst.c. = ? µmol/l NPU02639 P—Lysine; subst.c. = ? µmol/l NPU09018 Csf—a-Aminobutyrate; subst.c. = ? NPU02726 P—Methionine; subst.c. = ? µmol/l µmol/l NPU02776 P—1-Methylhistidine; subst.c. = ? µmol/l NPU09019 Csf—b-Aminoisobutyrate; subst.c. = ? NPU02778 P—3-Methylhistidine; subst.c. = ? µmol/l µmol/l NPU02936 P—Ornithine; subst.c. = ? µmol/l NPU01297 Csf—Arginine; subst.c. = ? µmol/l NPU03070 P—Phenylalanine; subst.c. = ? µmol/l NPU01318 Csf—Asparagine; subst.c. = ? µmol/l NPU03114 P—Phosphoethanolamine; subst.c. = ? NPU01321 Csf—Aspartate; subst.c. = ? µmol/l µmol/l NPU09020 Csf—Citrulline; subst.c. = ? µmol/l NPU10399 P—Phosphoserine; subst.c. = ? µmol/l NPU09021 Csf—Cystine; subst.c. = ? µmol/l NPU03256 P—Proline; subst.c. = ? µmol/l NPU02228 Csf—Glutamate; subst.c. = ? µmol/l NPU03396 P—Sarcosine; subst.c. = ? µmol/l NPU09022 Csf—Glutamine; subst.c. = ? µmol/l NPU03415 P—Serine; subst.c. = ? µmol/l NPU02288 Csf—Glycine; subst.c. = ? µmol/l NPU03541 P—Taurine; subst.c. = ? µmol/l NPU09023 Csf—Histidine; subst.c. = ? µmol/l NPU03558 P—Threonine; subst.c. = ? µmol/l NPU09025 Csf—3-Hydroxyproline; subst.c. = ? NPU03655 P—Tryptophan(free); subst.c. = ? µmol/l µmol/l NPU03659 P—Tyrosine; subst.c. = ? µmol/l NPU09026 Csf—4-Hydroxyproline; subst.c. = ? NPU03733 P—Valine; subst.c. = ? µmol/l µmol/l NPU09027 Csf—Isoleucine; subst.c. = ? µmol/l Urine— NPU09028 Csf—Leucine; subst.c. = ? µmol/l Amino acid; NPU09029 Csf—Lysine; subst.c. = ? µmol/l substance concentration(list; procedure) NPU09030 Csf—Methionine; subst.c. = ? µmol/l NPU09012 NPU09031 Csf—Ornithine; subst.c. = ? µmol/l U—Amino acid; subst.c.(list; proc.) NPU03069 Csf—Phenylalanine; subst.c. = ? µmol/l NPU01118 U—Alanine; subst.c. = ? µmol/l NPU03255 Csf—Proline; subst.c. = ? µmol/l NPU01120 U—b-Alanine; subst.c. = ? µmol/l NPU03414 Csf—Serine; subst.c. = ? µmol/l NPU09015 U—a-Aminobutyrate; subst.c. = ? µmol/l NPU03540 Csf—Taurine; subst.c. = ? µmol/l NPU01208 U—b-Aminoisobutyrate; subst.c. = ? NPU03557 Csf—Threonine; subst.c. = ? µmol/l µmol/l NPU03653 Csf—Tryptophan; subst.c. = ? µmol/l NPU01299 U—Arginine; subst.c. = ? µmol/l NPU09033 Csf—Tyrosine; subst.c. = ? µmol/l NPU01320 U—Asparagine; subst.c. = ? µmol/l NPU03732 Csf—Valine; subst.c. = ? µmol/l NPU01323 U—Aspartate; subst.c. = ? µmol/l NPU01612 U—Citrulline; subst.c. = ? µmol/l Plasma— NPU01828 U—Cystine; subst.c. = ? µmol/l Amino acid; NPU02230 U—Glutamate; subst.c. = ? µmol/l substance concentration(list; procedure) NPU02250 U—Glutamine; subst.c. = ? µmol/l NPU09011 NPU02290 U—Glycine; subst.c. = ? µmol/l P—Amino acid; subst.c.(list; proc.) NPU02374 U—Histidine; subst.c. = ? µmol/l NPU01117 P—Alanine; subst.c. = ? µmol/l NPU09024 U—3-Hydroxyproline; subst.c. = ? µmol/l NPU01119 P—b-Alanine; subst.c. = ? µmol/l NPU02465 U—4-Hydroxyproline; subst.c. = ? µmol/l NPU01203 P—a-Aminoadipate; subst.c. = ? µmol/l NPU02511 U—Isoleucine; subst.c. = ? µmol/l NPU09014 P—a-Aminobutyrate; subst.c. = ? µmol/l NPU02590 U—Leucine; subst.c. = ? µmol/l

NPU02640 U—Lysine; subst.c. = ? µmol/l Urine— NPU02727 U—Methionine; subst.c. = ? µmol/l g- NPU02937 U—Ornithine; subst.c. = ? µmol/l Aminobutyrate/Creatininium; NPU03071 U—Phenylalanine; subst.c. = ? µmol/l substance ratio NPU03257 U—Proline; subst.c. = ? µmol/l 10-3 NPU03416 U—Serine; subst.c. = ? µmol/l NPU14192 NPU03542 U—Taurine; subst.c. = ? µmol/l U—g-Aminobutyrate/Creatininium; subst.ratio = ? × NPU03559 U—Threonine; subst.c. = ? µmol/l 10-3 NPU03654 U—Tryptophan; subst.c. = ? µmol/l NPU03660 U—Tyrosine; subst.c. = ? µmol/l Cerebrospinal fluid— NPU03734 U—Valine; subst.c. = ? µmol/l a- Aminobutyrate; Urine— substance concentration Amino-2-piperidone/Creatininium; micromole/liter substance ratio NPU09018 10-3 Csf—a-Aminobutyrate; subst.c. = ? µmol/l NPU14188 U—Amino-2-piperidone/Creatininium; subst.ratio = Plasma— ? × 10-3 a- Aminobutyrate; Urine— substance concentration Amino-2-piperidone; micromole/liter substance concentration NPU09014 micromole/liter P—a-Aminobutyrate; subst.c. = ? µmol/l NPU01173 U—Amino-2-piperidone; subst.c. = ? µmol/l Urine— a- Urine— Aminobutyrate; a- substance concentration Aminoadipate/Creatininium; micromole/liter substance ratio NPU09015 10-3 U—a-Aminobutyrate; subst.c. = ? µmol/l NPU14190 U—a-Aminoadipate/Creatininium; subst.ratio = ? × Plasma— 10-3 g- Aminobutyrate; Plasma— substance concentration a- micromole/liter Aminoadipate; Other term(s): GABA substance concentration NPU01205 micromole/liter P—g-Aminobutyrate; subst.c. = ? µmol/l NPU01203 P—a-Aminoadipate; subst.c. = ? µmol/l Urine— g- Urine— Aminobutyrate; a- substance concentration Aminoadipate; micromole/liter substance concentration Other term(s): GABA micromole/liter NPU01206 NPU01204 U—g-Aminobutyrate; subst.c. = ? µmol/l U—a-Aminoadipate; subst.c. = ? µmol/l Urine— Urine— b- a- Aminoisobutyrate/Creatininium; Aminobutyrate/Creatininium; substance ratio substance ratio 10-3 10-3 NPU14193 NPU14191 U—b-Aminoisobutyrate/Creatininium; subst.ratio = ? U—a-Aminobutyrate/Creatininium; subst.ratio = ? × × 10-3 10-3

Urine— micromole/liter g- NPU04159 Aminoisobutyrate/Creatininium; U—5-Aminolevulinate; subst.c. = ? µmol/l substance ratio 10-3 Patient(Urine)— NPU14194 5- U—g-Aminoisobutyrate/Creatininium; subst.ratio = ? Aminolevulinate; × 10-3 substance rate(procedure) micromole/day Cerebrospinal fluid— NPU01209 b- Pt(U)—5-Aminolevulinate; subst.rate(proc.) = ? Aminoisobutyrate; µmol/d substance concentration micromole/liter Urine— NPU09019 a- Csf—b-Aminoisobutyrate; subst.c. = ? µmol/l Amino-n-butyrate/Creatininium; substance ratio Plasma— 10-3 b- NPU14189 Aminoisobutyrate; U—a-Amino-n-butyrate/Creatininium; subst.ratio = ? substance concentration × 10-3 micromole/liter NPU01207 Cerebrospinal fluid— P—b-Aminoisobutyrate; subst.c. = ? µmol/l a- Amino-n-butyrate; Urine— substance concentration b- micromole/liter Aminoisobutyrate; M = 103,1 g/mol substance concentration Note: D-form of acid:CAS2623-91-8; DL-form of micromole/liter acid:CAS2835-81-6; L-form of acid:CAS1492-24-6 NPU01208 NPU01184 U—b-Aminoisobutyrate; subst.c. = ? µmol/l Csf—a-Amino-n-butyrate; subst.c. = ? µmol/l

Plasma— Plasma— g- a- Aminoisobutyrate; Amino-n-butyrate; substance concentration substance concentration micromole/liter micromole/liter Authority: IUPAC-IUB84 NPU01185 NPU10401 P—a-Amino-n-butyrate; subst.c. = ? µmol/l P—g-Aminoisobutyrate; subst.c. = ? µmol/l Urine— Urine— a- 5- Amino-n-butyrate; Aminolevulinate/Creatininium; substance concentration substance ratio micromole/liter 10-3 NPU01186 NPU09006 U—a-Amino-n-butyrate; subst.c. = ? µmol/l U—5-Aminolevulinate/Creatininium; subst.ratio = ? × 10-3 Calculus(Urine)— Ammonium; Plasma— arbitrary content(procedure) 5- Note: M(ammonia) = 17,04 g/mol Aminolevulinate; NPU09232 substance concentration Calculus(U)—Ammonium; arb.cont.(proc.) = ? micromole/liter Other term(s): d-Aminolevulinate Plasma— NPU01210 Ammonium; P—5-Aminolevulinate; subst.c. = ? µmol/l substance concentration micromole/liter Urine— Authority: IFCC/C-BGE 5- Note: M (ammonia) = 17,04 g/mol Aminolevulinate; NPU03928 substance concentration P—Ammonium; subst.c. = ? µmol/l

Plasma(arterial Blood)— NPU03923 P—Amylase, saliva type; cat.c.(37 °C; Ammonium; proc.) = ? µkat/l substance concentration micromole/liter Amylase(Plasma)— Authority: IFCC/C-BGE Amylase type; Note: M (ammonia) = 17,04 g/mol catalytic-activity fraction(list; 37 °C; procedure) NPU01226 NPU04162 P(aB)—Ammonium; subst.c. = ? µmol/l Amylase(P)—Amylase type; cat.fr.(list; 37 °C; proc.) NPU04163 Amylase(P)—Amylase, pancreatic type Urine— 3; cat.fr.(37 °C; proc.) = ? Ammonium; NPU04165 Amylase(P)—Amylase, pancreatic type substance concentration 4+5; cat.fr.(37 °C; proc.) = ? micromole/liter NPU04164 Amylase(P)—Amylase, saliva type; Authority: IFCC/C-BGE cat.fr.(37 °C; proc.) = ? Note: M (ammonia) = 17,04 g/mol NPU01227 Plasma— U—Ammonium; subst.c. = ? µmol/l Amylase, pancreatic type 3; catalytic-activity concentration(37 °C; Calculus(Urine)— procedure) Ammonium; microkatal/liter substance content NPU03922 mole/kilogram P—Amylase, pancreatic type 3; cat.c.(37 °C; proc.) Note: M(ammonia) = 17,04 g/mol = ? µkat/l NPU09238 Calculus(U)—Ammonium; subst.cont. = ? mol/kg Amylase(Plasma)— Amylase, pancreatic type 3; Patient(Urine)— catalytic-activity fraction(37 °C; procedure) Ammonium; NPU04163 substance rate(procedure) Amylase(P)—Amylase, pancreatic type 3; cat.fr.(37 micromole/day °C; proc.) = ? Authority: IFCC/C-BGE Note: M (ammonia) = 17,04 g/mol Ascites— NPU01225 Amylase, pancreatic type 3+4+5; Pt(U)—Ammonium; subst.rate(proc.) = ? µmol/d catalytic-activity concentration(37 °C; procedure) Patient— microkatal/liter Amniotic fluid; NPU08589 relative volumic mass(20 °C/water, 20 °C; Asc—Amylase, pancreatic type 3+4+5; cat.c.(37 °C; procedure) proc.) = ? µkat/l NPU10184 Pt—Amniotic fluid; rel.volumic mass(20 °C/water, Drain fluid(specification)— 20 °C; proc.) = ? Amylase, pancreatic type 3+4+5; catalytic-activity concentration(37 °C; Pancreas— procedure) Amylase production; microkatal/liter catalytic-activity rate(37 °C; procedure) NPU08590 microkatal/second Drain fluid(spec.)—Amylase, pancreatic type 3+4+5; NPU01241 cat.c.(37 °C; proc.) = ? µkat/l Pancreas—Amylase production; cat.rate(37 °C; proc.) = ? µkat/s Plasma— Amylase, pancreatic type 3+4+5; Plasma— catalytic-activity concentration(37 °C; Amylase type; procedure) catalytic-activity concentration(list; 37 °C; microkatal/liter procedure) NPU08591 NPU01242 P—Amylase, pancreatic type 3+4+5; cat.c.(37 °C; P—Amylase type; cat.c.(list; 37 °C; proc.) proc.) = ? µkat/l NPU03922 P—Amylase, pancreatic type 3; cat.c.(37 °C; proc.) = ? µkat/l Urine— NPU08591 P—Amylase, pancreatic type 3+4+5; Amylase, pancreatic type 3+4+5; cat.c.(37 °C; proc.) = ? µkat/l catalytic-activity concentration(37 °C; NPU03964 P—Amylase, pancreatic type 4+5; procedure) cat.c.(37 °C; proc.) = ? µkat/l microkatal/liter NPU08969 U—Amylase, pancreatic type 3+4+5; cat.c.(37 °C; proc.) = ? µkat/l © 2000 IUPAC, Pure and Applied Chemistry 72, 747–972 770 H. OLESEN et al.

Plasma— Drain fluid(specification)— Amylase, pancreatic type 4+5; Amylase; catalytic-activity concentration(37 °C; catalytic-activity concentration(37 °C; procedure) procedure) microkatal/liter microkatal/liter NPU03964 NPU17195 P—Amylase, pancreatic type 4+5; cat.c.(37 °C; Drain fluid(spec.)—Amylase; cat.c.(37 °C; proc.) = ? proc.) = ? µkat/l µkat/l

Amylase(Plasma)— Duodenal fluid— Amylase, pancreatic type 4+5; Amylase; catalytic-activity fraction(37 °C; procedure) catalytic-activity concentration(37 °C; NPU04165 procedure) Amylase(P)—Amylase, pancreatic type 4+5; microkatal/liter cat.fr.(37 °C; proc.) = ? NPU10603 Duodf—Amylase; cat.c.(37 °C; proc.) = ? µkat/l Plasma— Amylase, saliva type; Plasma— catalytic-activity concentration(37 °C; Amylase; procedure) catalytic-activity concentration(37 °C; microkatal/liter procedure) NPU03923 microkatal/liter P—Amylase, saliva type; cat.c.(37 °C; proc.) = ? Other term(s): Glycogenase µkat/l NPU01238 P—Amylase; cat.c.(37 °C; proc.) = ? µkat/l Amylase(Plasma)— Amylase, saliva type; Pleural fluid(specification)— catalytic-activity fraction(37 °C; procedure) Amylase; NPU04164 catalytic-activity concentration(37 °C; Amylase(P)—Amylase, saliva type; cat.fr.(37 °C; procedure) proc.) = ? microkatal/liter Other term(s): Glycogenase Duodenal fluid— NPU14072 Amylase; Plf(spec.)—Amylase; cat.c.(37 °C; proc.) = ? µkat/l catalytic-activity concentration(0-20 minutes postprandial; 37 °C) Secretion(specification)— microkatal/liter Amylase; NPU09245 catalytic-activity concentration(37 °C; Duodf—Amylase; cat.c.(0-20 min; 37 °C) = ? µkat/l procedure) microkatal/liter Duodenal fluid— NPU08601 Amylase; Secr(spec.)—Amylase; cat.c.(37 °C; proc.) = ? catalytic-activity concentration(20-40 minutes µkat/l postprandial; 37 °C) microkatal/liter System(specification)— NPU09246 Amylase; Duodf—Amylase; cat.c.(20-40 min; 37 °C) = ? µkat/l catalytic-activity concentration(37 °C; procedure) Duodenal fluid— microkatal/liter Amylase; NPU10123 catalytic-activity concentration(30-150 minutes Syst(spec.)—Amylase; cat.c.(37 °C; proc.) = ? postprandial; 37 °C) µkat/l microkatal/liter NPU01240 Urine— Duodf—Amylase; cat.c.(30-150 min; 37 °C) = ? Amylase; µkat/l catalytic-activity concentration(37 °C; procedure) Ascites— microkatal/liter Amylase; Other term(s): Glycogenase catalytic-activity concentration(37 °C; NPU01239 procedure) U—Amylase; cat.c.(37 °C; proc.) = ? µkat/l microkatal/liter NPU10276 Asc—Amylase; cat.c.(37 °C; proc.) = ? µkat/l

Duodenal fluid— NPU03543 P—Testosterone(tot.); subst.c. = ? Amylase; nmol/l catalytic-activity concentration(40-60 minutes NPU03549 P—Testosterone(free); subst.c. = ? postprandial; 37 °C) nmol/l microkatal/liter NPU09247 Urine— Duodf—Amylase; cat.c.(40-60 min; 37 °C) = ? µkat/l Androstandione; substance concentration Duodenal fluid— nanomole/liter Amylase; M = 288,43 g/mol catalytic-activity concentration(60-80 minutes NPU01251 postprandial; 37 °C) U—Androstandione; subst.c. = ? nmol/l microkatal/liter NPU09248 Urine— Duodf—Amylase; cat.c.(60-80 min; 37 °C) = ? µkat/l Androstanolone; arbitrary concentration(procedure) Pancreas— M = 290,4 g/mol Amylase+triacylglycerollipase secretion; Other term(s): Stanolone catalytic-activity rate(postprandial; list; NPU04906 procedure) U—Androstanolone; arb.c.(proc.) = ? NPU09254 Pancreas—Amylase+triacylglycerollipase secretion; Plasma— cat.rate(postprandial; list; proc.) Androstanolone; NPU09245 Duodf—Amylase; cat.c.(0-20 min; 37 substance concentration °C) = ? µkat/l nanomole/liter NPU09246 Duodf—Amylase; cat.c.(20-40 min; 37 M = 290,4 g/mol °C) = ? µkat/l Other term(s): Dihydrotestosterone; Stanolone NPU09247 Duodf—Amylase; cat.c.(40-60 min; 37 Authority: INN °C) = ? µkat/l NPU01252 NPU09248 Duodf—Amylase; cat.c.(60-80 min; 37 P—Androstanolone; subst.c. = ? nmol/l °C) = ? µkat/l NPU01240 Duodf—Amylase; cat.c.(30-150 min; 37 Urine— °C) = ? µkat/l Androstanolone; NPU09249 Duodf—Triacylglycerol lipase; cat.c.(0- substance concentration 20 min; 37 °C) = ? µkat/l nanomole/liter NPU09250 Duodf—Triacylglycerol lipase; cat.c.(20- M = 290,4 g/mol 40 min; 37 °C) = ? µkat/l Other term(s): Stanolone NPU09251 Duodf—Triacylglycerol lipase; cat.c.(40- NPU04907 60 min; 37 °C) = ? µkat/l U—Androstanolone; subst.c. = ? nmol/l NPU09252 Duodf—Triacylglycerol lipase; cat.c.(60- 80 min; 37 °C) = ? µkat/l Plasma— NPU09253 Duodf—Triacylglycerol lipase; cat.c.(30- Androstenedione; 150 min; 37 °C) = ? µkat/l substance concentration nanomole/liter Urine— M = 286,42 g/mol Anabolic steroid; NPU01253 taxon(procedure) P—Androstenedione; subst.c. = ? nmol/l NPU12014 U—Anabolic steroid; taxon(proc.) = ? Plasma— Androsterone; Plasma— substance concentration Androgen; nanomole/liter substance concentration(list; procedure) M = 290,43 g/mol NPU12019 Authority: IUPAC-IUB 84 P—Androgen; subst.c.(list; proc.) NPU01255 NPU01253 P—Androstenedione; subst.c. = ? nmol/l P—Androsterone; subst.c. = ? nmol/l NPU04121 P—Dehydroepiandrosterone sulfate; subst.c. = ? µmol/l Urine— NPU14568 P—Dehydroepiandrosterone sulfate; Androsterone; subst.c. = ? nmol/l substance concentration NPU01852 P—Prasterone; subst.c. = ? nmol/l nanomole/liter NPU03419 P—Sexual-hormone-binding-globulin; M = 290,43 g/mol subst.c. = ? nmol/l Authority: IUPAC-IUB 84 NPU09097 U—Androsterone; subst.c. = ? nmol/l

Patient(Urine)— Plasma— Androsterone; Anserine; substance rate substance concentration nanomole/day micromole/liter NPU10133 M = 240,26 g/mol Pt(U)—Androsterone; subst.rate = ? nmol/d NPU01267 P—Anserine; subst.c. = ? µmol/l Plasma— Angiotensin; Urine— arbitrary substance concentration(procedure) Anserine; arbitrary unit/liter substance concentration M = 1 045 g/mol micromole/liter Other term(s): Angiotensin II M = 240,26 g/mol Authority: IUPAC-IUB 74 NPU01268 NPU01256 U—Anserine; subst.c. = ? µmol/l P—Angiotensin; arb.subst.c.(proc.) = ? arb.unit/l Plasma— Plasma— Antichymotrypsin; Angiotensin; substance concentration substance concentration micromole/liter picomole/liter M = 69 000 g/mol M = 1 045 g/mol NPU01270 Other term(s): Angiotensin II P—Antichymotrypsin; subst.c. = ? µmol/l Authority: IUPAC-IUB 74 NPU01257 Kidney— P—Angiotensin; subst.c. = ? pmol/l Antidiuretic effect; property(desmopressin, intranasal Plasma— administration; list; procedure) Angiotensinogen; Note: M(desmopressin) = 1 069,23 g/mol substance concentration NPU12874 micromole/liter Kidn.—Antidiuretic effect; prop.(desmopressin i.n.; M = 60 000 g/mol list; proc.) NPU01258 NPU09117 Pt—Desmopressin(administered); P—Angiotensinogen; subst.c. = ? µmol/l am.s.(i.n.) = ? nmol NPU09118 Pt—Desmopressin(administered); Blood— subst.cont.(i.n.; am.s./body mass) = ? nmol/kg Annulocytes; NPU03434 U—Solute; molal.(proc.) = ? mmol/kg arbitrary concentration(procedure) NPU17078 Blood— B—Annulocytes; arb.c.(proc.) = ? Antimony; substance concentration Urine— nanomole/liter Anorectic agent; M = 121,75 g/mol taxon(procedure) Authority: IUPAC/VII-C-TOX NPU14339 NPU01271 U—Anorectic agent; taxon(proc.) = ? B—Antimony; subst.c. = ? nmol/l

Urine— Plasma— Anserine/Creatininium; Antimony; substance ratio substance concentration 10-3 nanomole/liter NPU14195 M = 121,75 g/mol U—Anserine/Creatininium; subst.ratio = ? × 10-3 Authority: IUPAC/VII-C-TOX NPU01273 Cerebrospinal fluid— P—Antimony; subst.c. = ? nmol/l Anserine; substance concentration Urine— micromole/liter Antimony; M = 240,26 g/mol substance concentration NPU01266 nanomole/liter Csf—Anserine; subst.c. = ? µmol/l M = 121,75 g/mol Authority: IUPAC/VII-C-TOX NPU01274 U—Antimony; subst.c. = ? nmol/l

Hair— Plasma— Antimony; Antitrypsin; substance content substance concentration micromole/kilogram micromole/liter M = 121,75 g/mol M = 54 300 g/mol Authority: IUPAC/VII-C-TOX Other term(s): Proteinase inhibitor; alpha 1-Pi NPU01272 NPU03303 Hair—Antimony; subst.cont. = ? µmol/kg P—Antitrypsin; subst.c. = ? µmol/l

Antitrypsin(Plasma)— Plasma— Antitrypsin Pi type; Apolipoprotein A; substance fraction(list; procedure) arbitrary substance concentration(procedure) NPU10388 arbitrary unit/liter Atrp(P)—Antitrypsin Pi type; subst.fr.(list; proc.) NPU04042 NPU10383 Atrp(P)—Antitrypsin Pi–;subst.fr. = ? P—Apolipoprotein A; arb.subst.c.(proc.) = ? NPU10385 Atrp(P)—Antitrypsin PiM; subst.fr. = ? arb.unit/l NPU10386 Atrp(P)—Antitrypsin PiP; subst.fr. = ? NPU10387 Atrp(P)—Antitrypsin PiS; subst.fr. = ? Plasma(fasting Patient)— NPU10384 Atrp(P)—Antitrypsin PiZ; subst.fr. = ? Apolipoprotein A; arbitrary substance concentration(procedure) Antitrypsin(Plasma)— arbitrary unit/liter Antitrypsin Pi–; NPU14148 substance fraction P(fPt)—Apolipoprotein A; arb.subst.c.(proc.) = ? NPU10383 arb.unit/l Atrp(P)—Antitrypsin Pi–;subst.fr. = ? Plasma— Antitrypsin(Plasma)— Apolipoprotein A; Antitrypsin PiM; substance concentration substance fraction mole/liter NPU10385 NPU01278 Atrp(P)—Antitrypsin PiM; subst.fr. = ? P—Apolipoprotein A; subst.c.= ? prefix ? mol/l

Antitrypsin(Plasma)— Plasma— Antitrypsin PiP; Apolipoprotein A1; substance fraction arbitrary substance concentration(procedure) NPU10386 arbitrary unit/liter Atrp(P)—Antitrypsin PiP; subst.fr. = ? NPU04043 P—Apolipoprotein A1; arb.subst.c.(proc.) = ? Antitrypsin(Plasma)— arb.unit/l Antitrypsin PiS; substance fraction Plasma(fasting Patient)— NPU10387 Apolipoprotein A1; Atrp(P)—Antitrypsin PiS; subst.fr. = ? arbitrary substance concentration(procedure) arbitrary unit/liter Antitrypsin(Plasma)— NPU14149 Antitrypsin PiZ; P(fPt)—Apolipoprotein A1; arb.subst.c.(proc.) = ? substance fraction arb.unit/l NPU10384 Atrp(P)—Antitrypsin PiZ; subst.fr. = ? Plasma— Apolipoprotein A1; Plasma— substance concentration Antitrypsin type; mole/liter taxon(procedure) NPU01279 NPU10618 P—Apolipoprotein A1; subst.c.= ? prefix ? mol/l P—Antitrypsin type; taxon(proc.) = ? Plasma— Expectorate— Apolipoprotein A2; Antitrypsin; arbitrary substance concentration(procedure) substance concentration arbitrary unit/liter micromole/liter NPU04044 M = 54 300 g/mol P—Apolipoprotein A2; arb.subst.c.(proc.) = ? NPU10273 arb.unit/l Ex—Antitrypsin; subst.c. = ? µmol/l

Plasma(fasting Patient)— Plasma— Apolipoprotein A2; Apolipoprotein B100; arbitrary substance concentration(procedure) substance concentration arbitrary unit/liter mole/liter NPU14150 NPU01282 P(fPt)—Apolipoprotein A2; arb.subst.c.(proc.) = ? P—Apolipoprotein B100; subst.c.= ? prefix ? mol/l arb.unit/l Plasma— Plasma— Apolipoprotein B150; Apolipoprotein A2; arbitrary substance concentration(procedure) substance concentration arbitrary unit/liter mole/liter NPU04047 NPU01280 P—Apolipoprotein B150; arb.subst.c.(proc.) = ? P—Apolipoprotein A2; subst.c.= ? prefix ? mol/l arb.unit/l

Plasma— Plasma(fasting Patient)— Apolipoprotein B/Apolipoprotein A1; Apolipoprotein B150; substance ratio arbitrary substance concentration(procedure) NPU10238 arbitrary unit/liter P—Apolipoprotein B/Apolipoprotein A1; subst.ratio NPU14153 = ? P(fPt)—Apolipoprotein B150; arb.subst.c.(proc.) = ? arb.unit/l Plasma— Apolipoprotein B; Plasma— arbitrary substance concentration(procedure) Apolipoprotein B150; arbitrary unit/liter substance concentration NPU04045 mole/liter P—Apolipoprotein B; arb.subst.c.(proc.) = ? NPU01283 arb.unit/l P—Apolipoprotein B150; subst.c.= ? prefix ? mol/l

Plasma(fasting Patient)— Plasma— Apolipoprotein B; Apolipoprotein B48; arbitrary substance concentration(procedure) arbitrary substance concentration(procedure) arbitrary unit/liter arbitrary unit/liter NPU14151 NPU04048 P(fPt)—Apolipoprotein B; arb.subst.c.(proc.) = ? P—Apolipoprotein B48; arb.subst.c.(proc.) = ? arb.unit/l arb.unit/l

Plasma— Plasma(fasting Patient)— Apolipoprotein B; Apolipoprotein B48; substance concentration arbitrary substance concentration(procedure) mole/liter arbitrary unit/liter NPU01281 NPU14154 P—Apolipoprotein B; subst.c.= ? prefix ? mol/l P(fPt)—Apolipoprotein B48; arb.subst.c.(proc.) = ? arb.unit/l Plasma— Apolipoprotein B100; Plasma— arbitrary substance concentration(procedure) Apolipoprotein B48; arbitrary unit/liter substance concentration NPU04046 mole/liter P—Apolipoprotein B100; arb.subst.c.(proc.) = ? NPU01284 arb.unit/l P—Apolipoprotein B48; subst.c.= ? prefix ? mol/l

Plasma(fasting Patient)— Plasma— Apolipoprotein B100; Apolipoprotein C; arbitrary substance concentration(procedure) arbitrary substance concentration(procedure) arbitrary unit/liter arbitrary unit/liter NPU14152 NPU04049 P(fPt)—Apolipoprotein B100; arb.subst.c.(proc.) = ? P—Apolipoprotein C; arb.subst.c.(proc.) = ? arb.unit/l arb.unit/l

Plasma(fasting Patient)— Plasma— Apolipoprotein C; Apolipoprotein C3; arbitrary substance concentration(procedure) arbitrary substance concentration(procedure) arbitrary unit/liter arbitrary unit/liter NPU14155 NPU04052 P(fPt)—Apolipoprotein C; arb.subst.c.(proc.) = ? P—Apolipoprotein C3; arb.subst.c.(proc.) = ? arb.unit/l arb.unit/l

Plasma— Plasma(fasting Patient)— Apolipoprotein C; Apolipoprotein C3; substance concentration arbitrary substance concentration(procedure) mole/liter arbitrary unit/liter NPU01285 NPU14158 P—Apolipoprotein C; subst.c.= ? prefix ? mol/l P(fPt)—Apolipoprotein C3; arb.subst.c.(proc.) = ? arb.unit/l Plasma— Apolipoprotein C1; Plasma— arbitrary substance concentration(procedure) Apolipoprotein C3; arbitrary unit/liter substance concentration NPU04050 mole/liter P—Apolipoprotein C1; arb.subst.c.(proc.) = ? NPU01288 arb.unit/l P—Apolipoprotein C3; subst.c.= ? prefix ? mol/l

Plasma(fasting Patient)— Plasma— Apolipoprotein C1; Apolipoprotein D; arbitrary substance concentration(procedure) arbitrary substance concentration(procedure) arbitrary unit/liter arbitrary unit/liter NPU14156 NPU04053 P(fPt)—Apolipoprotein C1; arb.subst.c.(proc.) = ? P—Apolipoprotein D; arb.subst.c.(proc.) = ? arb.unit/l arb.unit/l

Plasma— Plasma(fasting Patient)— Apolipoprotein C1; Apolipoprotein D; substance concentration arbitrary substance concentration(procedure) mole/liter arbitrary unit/liter NPU01286 NPU14159 P—Apolipoprotein C1; subst.c.= ? prefix ? mol/l P(fPt)—Apolipoprotein D; arb.subst.c.(proc.) = ? arb.unit/l Plasma— Apolipoprotein C2; Plasma— arbitrary substance concentration(procedure) Apolipoprotein D; arbitrary unit/liter substance concentration NPU04051 mole/liter P—Apolipoprotein C2; arb.subst.c.(proc.) = ? NPU01289 arb.unit/l P—Apolipoprotein D; subst.c.= ? prefix ? mol/l

Plasma(fasting Patient)— Plasma— Apolipoprotein C2; Apolipoprotein E; arbitrary substance concentration(procedure) arbitrary substance concentration(procedure) arbitrary unit/liter arbitrary unit/liter NPU14157 NPU04054 P(fPt)—Apolipoprotein C2; arb.subst.c.(proc.) = ? P—Apolipoprotein E; arb.subst.c.(proc.) = ? arb.unit/l arb.unit/l

Plasma— Plasma(fasting Patient)— Apolipoprotein C2; Apolipoprotein E; substance concentration arbitrary substance concentration(procedure) mole/liter arbitrary unit/liter NPU01287 NPU14160 P—Apolipoprotein C2; subst.c.= ? prefix ? mol/l P(fPt)—Apolipoprotein E; arb.subst.c.(proc.) = ? arb.unit/l

Plasma— Plasma(fasting Patient)— Apolipoprotein E; Apolipoprotein Lp(a); substance concentration arbitrary substance concentration(procedure) mole/liter arbitrary unit/liter NPU01290 NPU14163 P—Apolipoprotein E; subst.c.= ? prefix ? mol/l P(fPt)—Apolipoprotein Lp(a); arb.subst.c.(proc.) = ? arb.unit/l Plasma— Apolipoprotein E2; Plasma— arbitrary substance concentration(procedure) Apolipoprotein Lp(a); arbitrary unit/liter substance concentration NPU04055 mole/liter P—Apolipoprotein E2; arb.subst.c.(proc.) = ? NPU01293 arb.unit/l P—Apolipoprotein Lp(a); subst.c.= ? prefix ? mol/l

Plasma(fasting Patient)— Plasma— Apolipoprotein E2; Apolipoprotein Lp(q); arbitrary substance concentration(procedure) arbitrary substance concentration(procedure) arbitrary unit/liter arbitrary unit/liter NPU14161 NPU04058 P(fPt)—Apolipoprotein E2; arb.subst.c.(proc.) = ? P—Apolipoprotein Lp(q); arb.subst.c.(proc.) = ? arb.unit/l arb.unit/l

Plasma— Plasma(fasting Patient)— Apolipoprotein E2; Apolipoprotein Lp(q); substance concentration arbitrary substance concentration(procedure) mole/liter arbitrary unit/liter NPU01291 NPU14164 P—Apolipoprotein E2; subst.c.= ? prefix ? mol/l P(fPt)—Apolipoprotein Lp(q); arb.subst.c.(proc.) = ? arb.unit/l Plasma— Apolipoprotein H; Plasma— arbitrary substance concentration(procedure) Apolipoprotein Lp(q); arbitrary unit/liter substance concentration Other term(s): b-2-glycoprotein 1 mole/liter NPU04056 NPU01294 P—Apolipoprotein H; arb.subst.c.(proc.) = ? P—Apolipoprotein Lp(q); subst.c.= ? prefix ? mol/l arb.unit/l Plasma(fasting Patient)— Plasma(fasting Patient)— Apolipoprotein; Apolipoprotein H; arbitrary substance concentration(list; arbitrary substance concentration(procedure) procedure) arbitrary unit/liter Authority: MSH94 NPU14162 NPU13817 P(fPt)—Apolipoprotein H; arb.subst.c.(proc.) = ? P(fPt)—Apolipoprotein; arb.subst.c.(list; proc.) arb.unit/l NPU14148 P(fPt)—Apolipoprotein A; arb.subst.c.(proc.) = ? arb.unit/l Plasma— NPU14149 P(fPt)—Apolipoprotein A1; Apolipoprotein H; arb.subst.c.(proc.) = ? arb.unit/l substance concentration NPU14150 P(fPt)—Apolipoprotein A2; mole/liter arb.subst.c.(proc.) = ? arb.unit/l Other term(s): b-2-glycoprotein 1 NPU14151 P(fPt)—Apolipoprotein B; NPU01292 arb.subst.c.(proc.) = ? arb.unit/l P—Apolipoprotein H; subst.c.= ? prefix ? mol/l NPU14152 P(fPt)—Apolipoprotein B100; arb.subst.c.(proc.) = ? arb.unit/l Plasma— NPU14153 P(fPt)—Apolipoprotein B150; Apolipoprotein Lp(a); arb.subst.c.(proc.) = ? arb.unit/l arbitrary substance concentration(procedure) NPU14154 P(fPt)—Apolipoprotein B48; arbitrary unit/liter arb.subst.c.(proc.) = ? arb.unit/l NPU04057 NPU14155 P(fPt)—Apolipoprotein C; P—Apolipoprotein Lp(a); arb.subst.c.(proc.) = ? arb.subst.c.(proc.) = ? arb.unit/l arb.unit/l NPU14156 P(fPt)—Apolipoprotein C1; arb.subst.c.(proc.) = ? arb.unit/l

NPU14157 P(fPt)—Apolipoprotein C2; Urine— arb.subst.c.(proc.) = ? arb.unit/l Argininosuccinate/Creatininium; NPU14158 P(fPt)—Apolipoprotein C3; substance ratio arb.subst.c.(proc.) = ? arb.unit/l 10-3 NPU14159 P(fPt)—Apolipoprotein D; NPU14197 arb.subst.c.(proc.) = ? arb.unit/l U—Argininosuccinate/Creatininium; subst.ratio = ? NPU14160 P(fPt)—Apolipoprotein E; × 10-3 arb.subst.c.(proc.) = ? arb.unit/l NPU14161 P(fPt)—Apolipoprotein E2; Plasma— arb.subst.c.(proc.) = ? arb.unit/l Argininosuccinate; NPU14162 P(fPt)—Apolipoprotein H; substance concentration arb.subst.c.(proc.) = ? arb.unit/l micromole/liter NPU14163 P(fPt)—Apolipoprotein Lp(a); NPU01300 arb.subst.c.(proc.) = ? arb.unit/l P—Argininosuccinate; subst.c. = ? µmol/l NPU14164 P(fPt)—Apolipoprotein Lp(q); arb.subst.c.(proc.) = ? arb.unit/l Urine— Argininosuccinate; Cobalamin(Plasma)— substance concentration Aquocobalamin; micromole/liter substance fraction NPU01301 NPU04956 U—Argininosuccinate; subst.c. = ? µmol/l Cobalamin(P)—Aquocobalamin; subst.fr. = ? Blood— Patient— Arsenic; Arginine(administered); substance concentration substance content(intravenous administration; nanomole/liter amount-of-substance/body mass) M = 74,92 g/mol mole/kilogram Authority: IUPAC/VII-C-TOX M = 174,20 g/mol NPU01306 NPU09354 B—Arsenic; subst.c. = ? nmol/l Pt—Arginine(administered); subst.cont.(i.v.; am.s./ body mass) = ? mol/kg Plasma— Arsenic; Urine— substance concentration Arginine/Creatininium; nanomole/liter substance ratio M = 74,92 g/mol 10-3 Authority: IUPAC/VII-C-TOX NPU14196 NPU04903 U—Arginine/Creatininium; subst.ratio = ? × 10-3 P—Arsenic; subst.c. = ? nmol/l

Cerebrospinal fluid— Urine— Arginine; Arsenic; substance concentration substance concentration micromole/liter nanomole/liter M = 174,20 g/mol M = 74,92 g/mol NPU01297 Authority: IUPAC/VII-C-TOX Csf—Arginine; subst.c. = ? µmol/l NPU01308 U—Arsenic; subst.c. = ? nmol/l Plasma— Arginine; Hair— substance concentration Arsenic; micromole/liter substance content M = 174,20 g/mol micromole/kilogram NPU01298 M = 74,92 g/mol P—Arginine; subst.c. = ? µmol/l Authority: IUPAC/VII-C-TOX NPU01307 Urine— Hair—Arsenic; subst.cont. = ? µmol/kg Arginine; substance concentration Cells(Blood)— micromole/liter Arsenic; M = 174,20 g/mol substance content NPU01299 nanomole/kilogram U—Arginine; subst.c. = ? µmol/l M = 74,92 g/mol Authority: IUPAC/VII-C-TOX NPU04807 Cells(B)—Arsenic; subst.cont. = ? nmol/kg © 2000 IUPAC, Pure and Applied Chemistry 72, 747–972 778 H. OLESEN et al.

Plasma— Plasma— Ascorbate; Aspartate transaminase; substance concentration catalytic-activity concentration(37 °C; micromole/liter procedure) Other term(s): Vitamin C microkatal/liter NPU01317 Other term(s): Glutamic-aspartic transaminase; P—Ascorbate; subst.c. = ? µmol/l Glutamic-oxaloacetictransaminase; Transaminase A; Plasma(fasting Patient)— NPU01324 Ascorbate; P—Aspartate transaminase; cat.c.(37 °C; proc.) = ? substance concentration µkat/l micromole/liter NPU04143 Urine— P(fPt)—Ascorbate; subst.c. = ? µmol/l Aspartate/Creatininium; substance ratio Urine— 10-3 Ascorbate; NPU14199 substance concentration U—Aspartate/Creatininium; subst.ratio = ? × 10-3 micromole/liter NPU10017 Cerebrospinal fluid— U—Ascorbate; subst.c. = ? µmol/l Aspartate; substance concentration Urine— micromole/liter Asparagine/Creatininium; NPU01321 substance ratio Csf—Aspartate; subst.c. = ? µmol/l 10-3 NPU14198 Plasma— U—Asparagine/Creatininium; subst.ratio = ? × 10-3 Aspartate; substance concentration Cerebrospinal fluid— micromole/liter Asparagine; NPU01322 substance concentration P—Aspartate; subst.c. = ? µmol/l micromole/liter M = 132,12 g/mol Urine— NPU01318 Aspartate; Csf—Asparagine; subst.c. = ? µmol/l substance concentration micromole/liter Plasma— NPU01323 Asparagine; U—Aspartate; subst.c. = ? µmol/l substance concentration micromole/liter Plasma— M = 132,12 g/mol Atrial natriuretic peptide; NPU01319 arbitrary substance concentration(IS 85/669; P—Asparagine; subst.c. = ? µmol/l procedure) international unit/liter Urine— M = 3 081 g/mol Asparagine; Recommended calibrator: Synthetic human atrial substance concentration natriuretic factor; WHO 1st IS 85/669 micromole/liter Other term(s): Atrial natriuretic factor M = 132,12 g/mol NPU01337 NPU01320 P—Atrial natriuretic peptide; arb.subst.c.(IS 85/669; U—Asparagine; subst.c. = ? µmol/l proc.) = ? int. unit/l

Amniotic fluid— Plasma— Aspartate transaminase; Atrial natriuretic peptide; catalytic-activity concentration(37 °C; substance concentration procedure) picomole/liter microkatal/liter M = 3 081 g/mol Other term(s): Glutamic-aspartic transaminase; Other term(s): Atrial natriuretic factor Glutamic-oxaloacetic transaminase; Transaminase NPU17180 A; P—Atrial natriuretic peptide; subst.c. = ? pmol/l NPU03908 Amf—Aspartate transaminase; cat.c.(37 °C; proc.) = ? µkat/l

Plasma(arterial Blood)— Plasma— Atrial natriuretic peptide; Bactericidal permeability increasing protein substance concentration antibody(Immunoglobulin G); picomole/liter arbitrary substance concentration(ANCA; M = 3 081 g/mol procedure) Recommended calibrator: Synthetic human atrial 10³ arbitrary unit/liter natriuretic factor; WHO 1st IS 85/669 NPU17705 Other term(s): Atrial natriuretic factor P—Bactericidal permeability increasing protein NPU01338 antibody(IgG); arb.subst.c.(ANCA; proc.) = ? × 10³ P(aB)—Atrial natriuretic peptide; subst.c. = ? pmol/l arb.unit/l

Urine— Vaginal fluid— Atrial natriuretic peptide; Bacterium(specification); substance concentration arbitrary concentration(procedure) picomole/liter NPU06687 M = 3 081 g/mol Vagf—Bacterium(spec.); arb.c.(proc.) = ? Recommended calibrator: Synthetic human atrial natriuretic factor; WHO 1st IS 85/669 Urine— Other term(s): Atrial natriuretic factor Bacterium, nitrite producing; NPU14005 arbitrary concentration(procedure) U—Atrial natriuretic peptide; subst.c. = ? pmol/l NPU10506 U—Bacterium, nitrite producing; arb.c.(proc.) = ? Patient(Urine)— Atrial natriuretic peptide; Urine— substance rate Bacterium, nitrite producing; picomole/day number concentration(procedure) M = 3 081 g/mol 109/liter Other term(s): Atrial natriuretic factor NPU01341 NPU14006 U—Bacterium, nitrite producing; num.c.(proc.) = ? × Pt(U)—Atrial natriuretic peptide; subst.rate = ? 109/l pmol/d Urine— Blood— Bacterium; Atypical cells; arbitrary concentration(procedure) number concentration NPU08592 109/liter U—Bacterium; arb.c.(proc.) = ? NPU10762 B—Atypical cells; num.c. = ? × 109/l Plasma— Barium; Urine— substance concentration Azithromycin; nanomole/liter arbitrary concentration(procedure) M = 137,34 g/mol M = 748,99 g/mol Authority: IUPAC/VII-C-TOX Authority: INN NPU01346 NPU08775 P—Barium; subst.c. = ? nmol/l U—Azithromycin; arb.c.(proc.) = ? Urine— Urine— Barium; Azithromycin; substance concentration substance concentration nanomole/liter mole/liter M = 137,34 g/mol M = 748,99 g/mol Authority: IUPAC/VII-C-TOX Authority: INN NPU01347 NPU08774 U—Barium; subst.c. = ? nmol/l U—Azithromycin; subst.c.= ? prefix ? mol/l Extracellular fluid— Plasma— Base excess(H+binding group); Bactericidal permeability increasing protein substance concentration(actual-norm) antibody(Immunoglobulin G); millimole/liter arbitrary concentration(procedure) Authority: IFCC/C-BGE NPU17670 NPU03815 P—Bactericidal permeability increasing protein Ecf—Base excess(H+binding group); antibody(IgG); arb.c.(proc.) = ? subst.c.(actual-norm) = ? mmol/l

Plasma(arterial Blood)— NPU01348 Base excess(H+binding group); P(aB)—Base excess(H+binding group);

substance concentration(actual-norm) subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? millimole/liter mmol/l NPU12518 P(aB)—Base excess(H+binding group); Plasma(capillary Blood)— subst.c.(actual-norm) = ? mmol/l Base excess(H+binding group);

substance concentration(pCO2 = 5,3 kPa; 37 °C; Plasma(capillary Blood)— actual-norm) Base excess(H+binding group); millimole/liter

substance concentration(actual-norm) Note: standard: blood; pCO2 = 5,3 kPa; 37 °C millimole/liter NPU12480 NPU12520 P(cB)—Base excess(H+binding group); + P(cB)—Base excess(H binding group); subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? subst.c.(actual-norm) = ? mmol/l mmol/l

Plasma(cord Blood)— Plasma(cord Blood)— Base excess(H+binding group); Base excess(H+binding group);

substance concentration(actual-norm) substance concentration(pCO2 = 5,3 kPa; 37 °C; millimole/liter actual-norm) NPU12519 millimole/liter P(cordB)—Base excess(H+binding group); Authority: IFCC/C-BGE

subst.c.(actual-norm) = ? mmol/l Note: standard: blood; pCO2 = 5,3 kPa; 37 °C NPU10219 Plasma(cord Blood; arterial Blood)— P(cordB)—Base excess(H+binding group); + Base excess(H binding group); subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? substance concentration(actual-norm) mmol/l millimole/liter NPU17133 Plasma(cord Blood; arterial Blood)— P(cordB; aB)—Base excess(H+binding group); Base excess(H+binding group);

subst.c.(actual-norm) = ? mmol/l substance concentration(pCO2 = 5,3 kPa; 37 °C; actual-norm) Plasma(cord Blood; venous Blood)— millimole/liter Base excess(H+binding group); Authority: IFCC/C-BGE

substance concentration(actual-norm) Note: standard: blood; pCO2 = 5,3 kPa; 37 °C millimole/liter NPU17135 NPU17134 P(cordB; aB)—Base excess(H+binding group); + P(cordB; vB)—Base excess(H binding group); subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? subst.c.(actual-norm) = ? mmol/l mmol/l

Plasma(mixed Blood)— Plasma(cord Blood; venous Blood)— Base excess(H+binding group); Base excess(H+binding group);

substance concentration(actual-norm) substance concentration(pCO2 = 5,3 kPa; 37 °C; millimole/liter actual-norm) NPU09200 millimole/liter P(mixB)—Base excess(H+binding group); Authority: IFCC/C-BGE

subst.c.(actual-norm) = ? mmol/l Note: standard: blood; pCO2 = 5,3 kPa; 37 °C NPU17136 Plasma(venous Blood)— P(cordB; vB)—Base excess(H+binding group); + Base excess(H binding group); subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? substance concentration(actual-norm) mmol/l millimole/liter NPU12521 Plasma(mixed Blood)— P(vB)—Base excess(H+binding group); Base excess(H+binding group);

subst.c.(actual-norm) = ? mmol/l substance concentration(pCO2 = 5,3 kPa; 37 °C; actual-norm) Plasma(arterial Blood)— millimole/liter Base excess(H+binding group); Authority: IFCC/C-BGE

substance concentration(pCO2 = 5,3 kPa; 37 °C; Note: standard: blood; pCO2 = 5,3 kPa; 37 °C actual-norm) NPU09201 millimole/liter P(mixB)—Base excess(H+binding group);

Authority: IFCC/C-BGE subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ?

Note: standard: blood; pCO2 = 5,3 kPa; 37 °C mmol/l

Plasma(venous Blood)— Urine— Base excess(H+binding group); Beryllium;

substance concentration(pCO2 = 5,3 kPa; 37 °C; substance concentration(Toxicology) actual-norm) nanomole/liter millimole/liter M = 9,01 g/mol Authority: IFCC/C-BGE NPU13480

Note: standard: blood; pCO2 = 5,3 kPa; 37 °C U—Beryllium; subst.c.(Toxicology) = ? nmol/l NPU08970 P(vB)—Base excess(H+binding group); Plasma—

subst.c.(pCO2 = 5,3 kPa; 37 °C; actual-norm) = ? Beryllium; mmol/l substance concentration nanomole/liter Blood— M = 9,01 g/mol Basophilocytes; Authority: IUPAC/VII-C-TOX number concentration NPU01364 109/liter P—Beryllium; subst.c. = ? nmol/l NPU01349 B—Basophilocytes; num.c. = ? × 109/l Urine— Beryllium; Blood fraction(specification)— substance concentration Basophilocytes; nanomole/liter number concentration M = 9,01 g/mol 109/liter Authority: IUPAC/VII-C-TOX NPU17547 NPU01365 B fract.(spec.)—Basophilocytes; num.c. = ? × 109/l U—Beryllium; subst.c. = ? nmol/l

Bone marrow— Plasma— Basophilocytes; Beta-1-globulin; number concentration mass concentration 109/liter gram/liter NPU04664 NPU09262 Marrow—Basophilocytes; num.c. = ? × 109/l P—Beta-1-globulin; mass c. = ? g/l

Leukocytes(Blood)— Protein(Plasma)— Basophilocytes; Beta-1-globulin; number fraction mass fraction NPU03968 NPU09265 Lkcs(B)—Basophilocytes; num.fr. = ? Prot.(P)—Beta-1-globulin; mass fr. = ?

Leukocytes(Bone marrow)— Plasma— Basophilocytes; Beta-2-globulin; number fraction mass concentration NPU04666 gram/liter Lkcs(Marrow)—Basophilocytes; num.fr. = ? NPU09263 P—Beta-2-globulin; mass c. = ? g/l Urine— Bence Jones’ protein; Protein(Plasma)— arbitrary concentration(procedure) Beta-2-globulin; NPU01351 mass fraction U—Bence Jones’ protein; arb.c.(proc.) = ? NPU09266 Prot.(P)—Beta-2-globulin; mass fr. = ? Urine— Bence Jones’ protein; Plasma— taxon(procedure) Beta-globulin; NPU09106 mass concentration U—Bence Jones’ protein; taxon(proc.) = ? gram/liter NPU04652 Plasma— P—Beta-globulin; mass c. = ? g/l Benzodiazepines; arbitrary concentration(procedure) NPU17591 P—Benzodiazepines; arb.c.(proc.) = ?

Cerebrospinal fluid— Plasma(neonatal)— Beta-globulin; Bilirubin glucuronide; mass concentration substance concentration milligram/liter micromole/liter NPU04660 NPU12532 Csf—Beta-globulin; mass c. = ? mg/l P(neonatal)—Bilirubin glucuronide; subst.c. = ? µmol/l Urine— Beta-globulin; Plasma— mass concentration Bilirubin type; milligram/liter substance concentration(list; procedure) NPU04656 NPU10022 U—Beta-globulin; mass c. = ? mg/l P—Bilirubin type; subst.c.(list; proc.) NPU01370 P—Bilirubins(tot.); subst.c. = ? µmol/l Protein(Cerebrospinal fluid)— NPU01367 P—Bilirubin albumin; subst.c. = ? µmol/l Beta-globulin; NPU01368 P—Bilirubin glucuronide; subst.c. = ? mass fraction µmol/l NPU04952 NPU17194 P—Bilirubin(conjugated); subst.c. = ? Prot.(Csf)—Beta-globulin; mass fr. = ? µmol/l NPU01366 P—Bilirubin(non-complexed); subst.c. = Protein(Plasma)— ? µmol/l Beta-globulin; mass fraction Plasma(neonatal)— NPU04942 Bilirubin type; Prot.(P)—Beta-globulin; mass fr. = ? substance concentration(list; procedure) NPU10023 Protein(Urine)— P(neonatal)—Bilirubin type; subst.c.(list; proc.) Beta-globulin; NPU04145 P(neonatal)—Bilirubins(tot.); subst.c. = ? mass fraction µmol/l NPU04947 NPU12531 P(neonatal)—Bilirubin albumin; subst.c. Prot.(U)—Beta-globulin; mass fr. = ? = ? µmol/l NPU12532 P(neonatal)—Bilirubin glucuronide; Plasma(fasting Patient)— subst.c. = ? µmol/l Bile salts; NPU17196 P(neonatal)—Bilirubin(conjugated); substance concentration subst.c. = ? µmol/l micromole/liter NPU12530 P(neonatal)—Bilirubin(non-complexed); NPU10607 subst.c. = ? µmol/l P(fPt)—Bile salts; subst.c. = ? µmol/l Plasma— Plasma— Bilirubin(conjugated); Bilirubin albumin; substance concentration substance concentration micromole/liter micromole/liter NPU17194 Other term(s): d-Bilirubin P—Bilirubin(conjugated); subst.c. = ? µmol/l NPU01367 P—Bilirubin albumin; subst.c. = ? µmol/l Plasma(neonatal)— Bilirubin(conjugated); Plasma(neonatal)— substance concentration Bilirubin albumin; micromole/liter substance concentration NPU17196 micromole/liter P(neonatal)—Bilirubin(conjugated); subst.c. = ? NPU12531 µmol/l P(neonatal)—Bilirubin albumin; subst.c. = ? µmol/l Plasma— Plasma— Bilirubin(non-complexed); Bilirubin glucuronide; substance concentration substance concentration micromole/liter micromole/liter M = 584,65 g/mol Other term(s): Bilirubin, conjugated Other term(s): Unconjugated bilirubin Note: M (bilirubin) = 584,65 g/mol NPU01366 NPU01368 P—Bilirubin(non-complexed); subst.c. = ? µmol/l P—Bilirubin glucuronide; subst.c. = ? µmol/l

Plasma(neonatal)— micromole/liter Bilirubin(non-complexed); NPU17034 substance concentration Plf—Bilirubins(tot.); subst.c. = ? µmol/l micromole/liter NPU12530 Plasma(neonatal)— P(neonatal)—Bilirubin(non-complexed); subst.c. = ? Bilirubins(total); µmol/l substance concentration micromole/liter Urine— Note: M (bilirubin) = 584,65 g/mol Bilirubins(total); NPU04145 arbitrary concentration(procedure) P(neonatal)—Bilirubins(tot.); subst.c. = ? µmol/l NPU01372 U—Bilirubins(tot.); arb.c.(proc.) = ? Secretion(specification)— Bilirubins(total); Urine— substance concentration Bilirubins(total); micromole/liter substance concentration(procedure) Note: M (bilirubin) = 584,65 g/mol micromole/liter NPU01371 Note: M (bilirubin) = 584,65 g/mol Secr(spec.)—Bilirubins(tot.); subst.c. = ? µmol/l NPU17162 U—Bilirubins(tot.); subst.c.(proc.) = ? µmol/l System(specification)— Bilirubins(total); Amniotic fluid— substance concentration Bilirubins(total); micromole/liter substance concentration Note: M (bilirubin) = 584,65 g/mol micromole/liter NPU10128 Note: M (bilirubin) = 584,65 g/mol Syst(spec.)—Bilirubins(tot.); subst.c. = ? µmol/l NPU01369 Amf—Bilirubins(tot.); subst.c. = ? µmol/l Skin(specification)— Bilirubins; Ascites— arbitrary concentration(procedure) Bilirubins(total); NPU17020 substance concentration Skin(spec.)—Bilirubins; arb.c.(proc.) = ? micromole/liter Note: M (bilirubin) = 584,65 g/mol Plasma— NPU17031 Bismuth; Asc—Bilirubins(tot.); subst.c. = ? µmol/l substance concentration nanomole/liter Cerebrospinal fluid(cell free)— M = 208,98 g/mol Bilirubins(total); Authority: IUPAC/VII-C-TOX substance concentration NPU01383 micromole/liter P—Bismuth; subst.c. = ? nmol/l NPU08602 Csf(cell free)—Bilirubins(tot.); subst.c. = ? µmol/l Urine— Bismuth; Drain fluid(specification)— substance concentration Bilirubins(total); nanomole/liter substance concentration M = 208,98 g/mol micromole/liter Authority: IUPAC/VII-C-TOX NPU17043 NPU01384 Drain fluid(spec.)—Bilirubins(tot.); subst.c. = ? U—Bismuth; subst.c. = ? nmol/l µmol/l Blood— Plasma— Blast cells; Bilirubins(total); number concentration substance concentration 109/liter micromole/liter NPU03972 Note: M (bilirubin) = 584,65 g/mol B—Blast cells; num.c. = ? × 109/l NPU01370 P—Bilirubins(tot.); subst.c. = ? µmol/l Blood fraction(specification)— Blast cells; Pleural fluid— number concentration Bilirubins(total); 109/liter substance concentration NPU17616 B fract.(spec.)—Blast cells; num.c. = ? × 109/l

Bone marrow— Patient— Blast cells; Blood; number concentration volume content 109/liter milliliter/kilogram NPU04667 NPU03808 Marrow—Blast cells; num.c. = ? × 109/l Pt—Blood; vol.cont. = ? ml/kg

Leukocytes(Blood)— Lavage fluid(specification)— Blast cells; Blood; number fraction volume NPU03971 milliliter Lkcs(B)—Blast cells; num.fr. = ? NPU14045 Lavagef(spec.)—Blood; vol. = ? ml Leukocytes(Bone marrow)— Blast cells; Patient(Sampling)— number fraction Blood; NPU04668 volume Lkcs(Marrow)—Blast cells; num.fr. = ? milliliter NPU14379 Liver— Pt(Sampling)—Blood; vol. = ? ml Blood flow; volume rate(procedure) Patient— milliliter/second Body; NPU03838 height Liver—Blood flow; vol.rate(proc.) = ? ml/s meter NPU03794 Patient— Pt—Body; height = ? m Blood fraction; property(list; procedure) Patient— NPU17593 Body; Pt—Blood fraction; prop.(list; proc.) mass increment(procedure) NPU17563 B fract.(spec.)—Erythrocytes; num.c. = kilogram ? × 1012/l NPU03805 NPU17565 B fract.(spec.)—Erythrocytes; vol.fr. = ? Pt—Body; mass incr.(proc.) = ? kg NPU17569 B fract.(spec.)—Haemoglobin(Fe); subst.c. = ? µmol/l Patient— NPU17570 B fract.(spec.)—Haemoglobin(Fe); Body; subst.c. = ? mmol/l mass NPU17571 B fract.(spec.)—Potassium ion; subst.c. kilogram = ? mmol/l NPU03804 NPU17578 B fract.(spec.)—Leukocytes; num.c. = ? Pt—Body; mass = ? kg × 109/l NPU17583 B fract.(spec.)—Sodium ion; subst.c. = ? Patient— mmol/l Body; NPU17586 B fract.(spec.)—Thrombocytes; num.c. = Celsius temperature ? × 109/l degree Celsius NPU08676 Patient(specification)— Pt—Body; temp. = ? °C Blood; Celsius temperature Cerebrospinal fluid— degree Celsius Bombesin; NPU04034 substance concentration Pt(spec.)—Blood; temp. = ? °C picomole/liter M = 2 805 g/mol Patient— Other term(s): Mammalian bombesin; Gastrin Blood; releasing polypeptide volume(procedure) NPU02162 liter Csf—Bombesin; subst.c. = ? pmol/l NPU03795 Pt—Blood; vol.(proc.) = ? l Plasma— Bombesin; substance concentration picomole/liter

M = 2 805 g/mol Patient(Urine)— Other term(s): Mammalian bombesin; Gastrin Brain natriuretic peptide; releasing polypeptide substance rate NPU02163 picomole/day P—Bombesin; subst.c. = ? pmol/l NPU17175 Pt(U)—Brain natriuretic peptide; subst.rate = ? Plasma— pmol/d Boron; substance concentration Blood— micromole/liter Bromide; M = 10,81 g/mol substance concentration Authority: IUPAC/VII-C-TOX micromole/liter NPU01400 M = 79,90 g/mol P—Boron; subst.c. = ? µmol/l Authority: IUPAC/VII-C-TOX NPU04834 Urine— B—Bromide; subst.c. = ? µmol/l Boron; substance concentration Plasma— micromole/liter Bromide; M = 10,81 g/mol substance concentration Authority: IUPAC/VII-C-TOX micromole/liter NPU04809 M = 79,90 g/mol U—Boron; subst.c. = ? µmol/l Authority: IUPAC/VII-C-TOX NPU01403 Hair— P—Bromide; subst.c. = ? µmol/l Boron; substance content Urine— micromole/kilogram Bromide; M = 10,81 g/mol substance concentration Authority: IUPAC/VII-C-TOX micromole/liter NPU04808 M = 79,90 g/mol Hair—Boron; subst.cont. = ? µmol/kg Authority: IUPAC/VII-C-TOX NPU04870 Plasma— U—Bromide; subst.c. = ? µmol/l Brainnatriuretic peptide; arbitrary substance concentration(procedure) Urine— arbitrary unit/liter Bufotenine; NPU17174 amount-of-substance(procedure) P—Brain natriuretic peptide; arb.subst.c.(proc.) = ? micromole arb.unit/l M = 204,3 g/mol Other term(s): Mappine Plasma— NPU01406 Brainnatriuretic peptide; U—Bufotenine; am.s.(proc.) = ? µmol substance concentration picomole/liter Urine— NPU17181 Cadmium/Creatininium; P—Brain natriuretic peptide; subst.c. = ? pmol/l substance ratio 10-6 Plasma(arterial Blood)— Note: M (cadmium) = 112,41 g/mol; M (creatininium) Brainnatriuretic peptide; = 113,12 g/mol substance concentration NPU09005 picomole/liter U—Cadmium/Creatininium; subst.ratio = ? × 10-6 NPU17176 P(aB)—Brain natriuretic peptide; subst.c. = ? pmol/l Blood— Cadmium; Urine— substance concentration Brainnatriuretic peptide; nanomole/liter substance concentration M = 112,41 g/mol picomole/liter Authority: IUPAC/VII-C-TOX NPU17177 NPU04874 U—Brain natriuretic peptide; subst.c. = ? pmol/l B—Cadmium; subst.c. = ? nmol/l

Plasma— Urine— Cadmium; Caesium; substance concentration substance concentration nanomole/liter nanomole/liter M = 112,41 g/mol M = 132,90 g/mol Authority: IUPAC/VII-C-TOX Authority: IUPAC/VII-C-TOX NPU01425 NPU01431 P—Cadmium; subst.c. = ? nmol/l U—Caesium; subst.c. = ? nmol/l

Urine— Hair— Cadmium; Caesium; substance concentration substance content nanomole/liter micromole/kilogram M = 112,41 g/mol M = 132,90 g/mol Authority: IUPAC/VII-C-TOX Authority: IUPAC/VII-C-TOX NPU01426 NPU01429 U—Cadmium; subst.c. = ? nmol/l Hair—Caesium; subst.cont. = ? µmol/kg

Hair— Cells(Blood)— Cadmium; Caesium; substance content substance content micromole/kilogram nanomole/kilogram M = 112,41 g/mol M = 132,90 g/mol Authority: IUPAC/VII-C-TOX Authority: IUPAC/VII-C-TOX NPU01424 NPU01428 Hair—Cadmium; subst.cont. = ? µmol/kg Cells(B)—Caesium; subst.cont. = ? nmol/kg

Cells(Blood)— Plasma— Cadmium; Calcifediol; substance content substance concentration nanomole/kilogram nanomole/liter M = 112,41 g/mol M = 400,65 g/mol Authority: IUPAC/VII-C-TOX Other term(s): Calcifediol; 25-Hydroxy-Vitamin D3 NPU04881 Authority: IUPAC-IUB 81 Cells(B)—Cadmium; subst.cont. = ? nmol/kg NPU01435 P—Calcifediol; subst.c. = ? nmol/l Patient(Urine)— Cadmium; Plasma— substance rate Calcifediol+25-Hydroxyergocalciferol; nanomole/day substance concentration M = 112,41 g/mol nanomole/liter Authority: IUPAC/VII-C-TOX NPU10267 NPU10024 P—Calcifediol+25-Hydroxyergocalciferol; subst.c. = Pt(U)—Cadmium; subst.rate = ? nmol/d ? nmol/l

Blood— Plasma— Caesium; Calcifediol+Ergocalciferol; substance concentration substance concentration nanomole/liter nanomole/liter M = 132,90 g/mol M = 400,65 g/mol Authority: IUPAC/VII-C-TOX Authority: IUPAC-IUB 81 NPU01427 NPU09105 B—Caesium; subst.c. = ? nmol/l P—Calcifediol+Ergocalciferol; subst.c. = ? nmol/l

Plasma— Plasma— Caesium; Calciferol binding protein; substance concentration substance concentration nanomole/liter micromole/liter M = 132,90 g/mol M = 58 000 g/mol Authority: IUPAC/VII-C-TOX Other term(s): Gc-globulin; Vitamin D-binding NPU01430 protein P—Caesium; subst.c. = ? nmol/l NPU01436 P—Calciferol binding protein; subst.c. = ? µmol/l

Plasma— subst.cont.(i.v.; am.s./body mass) = ? nmol/kg Calciol; NPU10378 P—Calcitonin; subst.c.(-20 min) = ? substance concentration pmol/l nanomole/liter NPU10377 P—Calcitonin; subst.c.(-10 min) = ? M = 384,62 g/mol pmol/l Other term(s): Colecalciferol; Vitamin D3 NPU10478 P—Calcitonin; subst.c.(0 min) = ? pmol/l Authority: IUPAC-IUB 81 NPU10479 P—Calcitonin; subst.c.(1,5 min) = ? NPU01437 pmol/l P—Calciol; subst.c. = ? nmol/l NPU10376 P—Calcitonin; subst.c.(2 min) = ? pmol/l NPU10480 P—Calcitonin; subst.c.(5 min) = ? pmol/l Plasma— Calcitonin gene related peptide; Plasma— substance concentration Calcitonin; picomole/liter arbitrary substance concentration(IRP 70/234; NPU10605 procedure) P—Calcitonin gene related peptide; subst.c. = ? international unit/liter pmol/l M = 3 425 g/mol Recommended calibrator: WHO 2nd IS 89/620 Urine— Calibrator(s): WHO 1st IRP 70/234 Calcitonin gene related peptide; Other term(s): Thyrocalcitonin substance concentration Authority: IUPAC-IUB 74 picomole/liter NPU04002 NPU14007 P—Calcitonin; arb.subst.c.(IRP 70/234; proc.) = ? U—Calcitonin gene related peptide; subst.c. = ? int. unit/l pmol/l Plasma— Patient(Urine)— Calcitonin; Calcitonin gene related peptide; arbitrary substance concentration(IS 89/620; substance rate procedure) picomole/day international unit/liter NPU14008 M = 3 425 g/mol Pt(U)—Calcitonin gene related peptide; subst.rate = Recommended calibrator: WHO 2nd IS 89/620 ? pmol/d Calibrator(s): WHO 1st IRP 70/234 Other term(s): Thyrocalcitonin Thyroid gland— Authority: IUPAC-IUB 74 Calcitonin secretion; NPU01438 substance rate(calcium compound, intravenous P—Calcitonin; arb.subst.c.(IS 89/620; proc.) = ? int. administration; list; procedure) unit/l Note: M (calcitonin) = 3 425 g/mol NPU10476 Plasma— Thyroid gland—Calcitonin secretion; Calcitonin; subst.rate(calcium compound i.v.; list; proc.) substance concentration(20 minutes before NPU10472 Pt—Calcium compound(administered); challenge) subst.cont.(i.v.; am.s./body mass) = ? mmol/kg picomole/liter NPU10478 P—Calcitonin; subst.c.(0 min) = ? pmol/l M = 3 425 g/mol NPU10480 P—Calcitonin; subst.c.(5 min) = ? pmol/l NPU10378 NPU10473 P—Calcitonin; subst.c.(10 min) = ? P—Calcitonin; subst.c.(-20 min) = ? pmol/l pmol/l NPU10474 P—Calcitonin; subst.c.(180 min) = ? Plasma— pmol/l Calcitonin; NPU10475 P—Calcitonin; subst.c.(240 min) = ? substance concentration(10 minutes before pmol/l challenge) picomole/liter Thyroid gland— M = 3 425 g/mol Calcitonin secretion; NPU10377 substance rate(pentagastrin, intravenous P—Calcitonin; subst.c.(-10 min) = ? pmol/l administration; list; procedure) Note: M (pentagastrin) = 770 g/mol; M (calcitonin) = Plasma— 3 425 g/mol Calcitonin; NPU10481 substance concentration(0 minutes after Thyroid gland—Calcitonin secretion; challenge) subst.rate(pentagastrin i.v.; list; proc.) picomole/liter NPU10477 Pt—Pentagastrin(administered); M = 3 425 g/mol NPU10478 P—Calcitonin; subst.c.(0 min) = ? pmol/l

Plasma— Plasma— Calcitonin; 1,25- substance concentration(1,5 minutes after Calcitriol; challenge) substance concentration picomole/liter picomole/liter M = 3 425 g/mol M = 416,3 g/mol NPU10479 Other term(s): 1,25-Dihydroxy-cholecalciferol; 1,25- P—Calcitonin; subst.c.(1,5 min) = ? pmol/l Dihydroxy-vitamin D3 Authority: IUPAC-IUB 81; INN Plasma— NPU01440 Calcitonin; P—1,25-Calcitriol; subst.c. = ? pmol/l substance concentration(2 minutes after challenge) Plasma— picomole/liter 1,25- M = 3 425 g/mol Calcitriol+1,25-Dihydroxyergocalciferol; NPU10376 substance concentration P—Calcitonin; subst.c.(2 min) = ? pmol/l picomole/liter NPU10266 Plasma— P—1,25-Calcitriol+1,25-Dihydroxyergocalciferol; Calcitonin; subst.c. = ? pmol/l substance concentration(5 minutes after challenge) Calculus(Urine)— picomole/liter Calcium carbonate; M = 3 425 g/mol arbitrary content(procedure) NPU10480 M = 100,09 g/mol P—Calcitonin; subst.c.(5 min) = ? pmol/l NPU10364 Calculus(U)—Calcium carbonate; arb.cont.(proc.) = Plasma— ? Calcitonin; substance concentration(10 minutes after Calculus(Urine)— challenge) Calcium carbonate; picomole/liter substance content M = 3 425 g/mol mole/kilogram NPU10473 M = 100,09 g/mol P—Calcitonin; subst.c.(10 min) = ? pmol/l NPU01445 Calculus(U)—Calcium carbonate; subst.cont. = ? Plasma— mol/kg Calcitonin; substance concentration(180 minutes after Kidney— challenge) Calcium clearance; picomole/liter volume rate(procedure) M = 3 425 g/mol milliliter/second NPU10474 NPU08595 P—Calcitonin; subst.c.(180 min) = ? pmol/l Kidn.—Calcium clearance; vol.rate(proc.) = ? ml/s

Plasma— Patient— Calcitonin; Calcium compound(administered); substance concentration(240 minutes after substance content(intravenous administration; challenge) amount-of-substance/body mass) picomole/liter millimole/kilogram M = 3 425 g/mol NPU10472 NPU10475 Pt—Calcium compound(administered); P—Calcitonin; subst.c.(240 min) = ? pmol/l subst.cont.(i.v.; am.s./body mass) = ? mmol/kg

Plasma— Plasma— Calcitonin; Calcium ion(free); substance concentration substance concentration(pH = 7,40; procedure) picomole/liter millimole/liter M = 3 425 g/mol Authority: IFCC/C-BGE Other term(s): Thyrocalcitonin NPU04144 Authority: IUPAC-IUB 74 P—Calcium ion(free); subst.c.(pH = 7,40; proc.) = ? NPU01439 mmol/l P—Calcitonin; subst.c. = ? pmol/l

Plasma— Calculus(Urine)— Calcium ion(free); Calcium(II; total); substance concentration arbitrary content(procedure) millimole/liter M = 40,080 g/mol Other term(s): Coagulation factor IV NPU09230 Authority: IFCC/C-BGE Calculus(U)—Calcium(II; total); arb.cont.(proc.) = ? NPU01446 P—Calcium ion(free); subst.c. = ? mmol/l Plasma— Calcium(II; total); Calculus(Urine)— substance concentration(corrected; procedure) Calcium oxalate; millimole/liter arbitrary content(procedure) M = 40,08 g/mol M = 128,10 g/mol NPU04169 NPU10365 P—Calcium(II; total); subst.c.(corr.; proc.) = ? mmol/ Calculus(U)—Calcium oxalate; arb.cont.(proc.) = ? l

Calculus(Urine)— Plasma— Calcium oxalate; Calcium(II; total); substance content substance concentration(list; corrected; mole/kilogram procedure) M = 128,10 g/mol Authority: IFCC/C-BGE NPU01447 NPU17123 Calculus(U)—Calcium oxalate; subst.cont. = ? mol/ P—Calcium(II; total); subst.c.(list; corr.; proc.) kg NPU01132 P—Albumin; subst.c. = ? µmol/l NPU01443 P—Calcium(II; total); subst.c. = ? mmol/l Calculus(Urine)— NPU04169 P—Calcium(II; total); subst.c.(corr.; Calcium phosphate; proc.) = ? mmol/l arbitrary content(procedure) M = 310,20 g/mol Amniotic fluid— NPU10366 Calcium(II; total); Calculus(U)—Calcium phosphate; arb.cont.(proc.) = substance concentration ? millimole/liter NPU08605 Calculus(Urine)— Amf—Calcium(II; total); subst.c. = ? mmol/l Calcium phosphate; substance content Ascites— mole/kilogram Calcium(II; total); M = 310,20 g/mol substance concentration NPU08608 millimole/liter Calculus(U)—Calcium phosphate; subst.cont. = ? M = 40,080 g/mol mol/kg Authority: IFCC/C-BGE NPU08603 Calculus(Synovial fluid; specification)— Asc—Calcium(II; total); subst.c. = ? mmol/l Calcium pyrophosphate; arbitrary content(procedure) Dialysis solution— M = 310,20 g/mol Calcium(II; total); NPU14141 substance concentration Calculus(Synf; spec.)—Calcium pyrophosphate; millimole/liter arb.cont.(proc.) = ? M = 40,080 g/mol Authority: IFCC/C-BGE Urine— NPU17172 Calcium(II; total)/Creatininium; Dialysis solution—Calcium(II; total); subst.c. = ? substance ratio mmol/l NPU03929 U—Calcium(II; total)/Creatininium; subst.ratio = ? Plasma— Calcium(II; total); Urine— substance concentration Calcium(II; total); millimole/liter amount-of-substance(procedure) M = 40,080 g/mol millimole Authority: IFCC/C-BGE NPU17550 NPU01443 U—Calcium(II; total); am.s.(proc.) = ? mmol P—Calcium(II; total); subst.c. = ? mmol/l

System(specification)— NPU01442 Calcium(II; total); Pt(U)—Calcium(II; total); subst.rate(proc.) = ? substance concentration mmol/d millimole/liter M = 40,08 g/mol Kidney— NPU10289 Calcium/Creatininium; Syst(spec.)—Calcium(II; total); subst.c. = ? mmol/l volume rate ratio(procedure) NPU08596 Urine— Kidn.—Calcium/Creatininium; vol.rate ratio(proc.) = Calcium(II; total); ? substance concentration millimole/liter Faeces— M = 40,08 g/mol Calcium; NPU04160 amount-of-substance(procedure) U—Calcium(II; total); subst.c. = ? mmol/l millimole NPU17549 Faeces— F—Calcium; am.s.(proc.) = ? mmol Calcium(II; total); substance content Secretion(Ileum)— millimole/kilogram Calcium; M = 40,08 g/mol amount-of-substance(procedure) NPU04212 millimole F—Calcium(II; total); subst.cont. = ? mmol/kg NPU17623 Secr(Ileum)—Calcium; am.s.(proc.) = ? mmol Faeces(specification)— Calcium(II; total); Secretion(Ileum)— substance content Calcium; millimole/kilogram substance concentration NPU08606 millimole/liter F(spec.)—Calcium(II; total); subst.cont. = ? mmol/kg NPU17548 Secr(Ileum)—Calcium; subst.c. = ? mmol/l Calculus(Urine)— Calcium(II; total); Synovial fluid(specification)— substance content Calculus composition; mole/kilogram arbitrary content(list; procedure) M = 40,080 g/mol NPU14278 NPU09236 Synf(spec.)—Calculus composition; arb.cont.(list; Calculus(U)—Calcium(II; total); subst.cont. = ? proc.) mol/kg NPU14141 Calculus(Synf; spec.)—Calcium pyrophosphate; arb.cont.(proc.) = ? Patient(Faeces)— NPU14109 Calculus(Synf; spec.)—Urate; Calcium(II; total); arb.cont.(proc.) = ? substance rate(procedure) millimole/day Urine— Authority: IFCC/C-BGE Calculus composition; NPU01441 arbitrary content(list; procedure) Pt(F)—Calcium(II; total); subst.rate(proc.) = ? NPU08868 mmol/d U—Calculus composition; arb.cont.(list; proc.) NPU09232 Calculus(U)—Ammonium; Patient(Ileum)— arb.cont.(proc.) = ? Calcium(II; total); NPU10364 Calculus(U)—Calcium carbonate; substance rate(procedure) arb.cont.(proc.) = ? millimole/day NPU10365 Calculus(U)—Calcium oxalate; NPU08607 arb.cont.(proc.) = ? Pt(Ileum)—Calcium(II; total); subst.rate(proc.) = ? NPU10366 Calculus(U)—Calcium phosphate; mmol/d arb.cont.(proc.) = ? NPU09230 Calculus(U)—Calcium(II; total); Patient(Urine)— arb.cont.(proc.) = ? Calcium(II; total); NPU09229 Calculus(U)—Carbonate; substance rate(procedure) arb.cont.(proc.) = ? millimole/day NPU10367 Calculus(U)—Cystine; arb.cont.(proc.) = M = 40,080 g/mol ? Authority: IFCC/C-BGE NPU10368 Calculus(U)—Magnesium ammonium

phosphate; arb.cont.(proc.) = ? Plasma— NPU09234 Calculus(U)—Magnesium(II; total); Cancer antigen 15-3; arb.cont.(proc.) = ? arbitrary substance concentration(procedure) NPU09231 Calculus(U)—Oxalate; arb.cont.(proc.) = 10³ arbitrary unit/liter ? NPU01449 NPU09233 Calculus(U)—Phosphate(P; inorganic); P—Cancer antigen 15-3; arb.subst.c.(proc.) = ? × arb.cont.(proc.) = ? 10³ arb.unit/l NPU10369 Calculus(U)—Urate; arb.cont.(proc.) = ? Plasma— Urine— Cancer antigen 19-9; Calculus composition; arbitrary substance concentration(procedure) substance content(list; procedure) 10³ arbitrary unit/liter NPU09359 NPU01450 U—Calculus composition; subst.cont.(list; proc.) P—Cancer antigen 19-9; arb.subst.c.(proc.) = ? × NPU09238 Calculus(U)—Ammonium; subst.cont. = 10³ arb.unit/l ? mol/kg NPU01445 Calculus(U)—Calcium carbonate; Plasma— subst.cont. = ? mol/kg Cancer antigen 50; NPU09236 Calculus(U)—Calcium(II; total); arbitrary substance concentration(procedure) subst.cont. = ? mol/kg 10³ arbitrary unit/liter NPU01447 Calculus(U)—Calcium oxalate; NPU01451 subst.cont. = ? mol/kg P—Cancer antigen 50; arb.subst.c.(proc.) = ? × 10³ NPU08608 Calculus(U)—Calcium phosphate; arb.unit/l subst.cont. = ? mol/kg NPU09235 Calculus(U)—Carbonate; subst.cont. = ? Kidney— mol/kg Carbamide clearance; NPU01827 Calculus(U)—Cystine; subst.cont. = ? volume rate(procedure) mol/kg milliliter/second NPU09240 Calculus(U)—Magnesium(II; total); NPU10028 subst.cont. = ? mol/kg Kidn.—Carbamide clearance; vol.rate(proc.) = ? NPU02649 Calculus(U)—Magnesium ammonium ml/s phosphate; subst.cont. = ? mol/kg NPU09237 Calculus(U)—Oxalate; subst.cont. = ? Ascites— mol/kg Carbamide; NPU09239 Calculus(U)—Phosphate(P; inorganic); amount-of-substance(procedure) subst.cont. = ? mol/kg millimole NPU03689 Calculus(U)—Urate; subst.cont. = ? M = 60,06 g/mol mol/kg NPU08611 Asc—Carbamide; am.s.(proc.) = ? mmol Faeces— Calprotectin; Urine— substance content Carbamide; millimole/kilogram amount-of-substance(procedure) NPU09255 millimole F—Calprotectin; subst.cont. = ? mmol/kg NPU17551 U—Carbamide; am.s.(proc.) = ? mmol Cerebrospinal fluid— Cancer antigen 125; Amniotic fluid— arbitrary substance concentration(procedure) Carbamide; 10³ arbitrary unit/liter substance concentration NPU10290 millimole/liter Csf—Cancer antigen 125; arb.subst.c.(proc.) = ? × M = 60,06 g/mol 10³ arb.unit/l NPU08610 Amf—Carbamide; subst.c. = ? mmol/l Plasma— Cancer antigen 125; Ascites— arbitrary substance concentration(procedure) Carbamide; 10³ arbitrary unit/liter substance concentration NPU01448 millimole/liter P—Cancer antigen 125; arb.subst.c.(proc.) = ? × M = 60,06 g/mol 10³ arb.unit/l NPU08609 Asc—Carbamide; subst.c. = ? mmol/l

Cerebrospinal fluid— Plasma— Carbamide; Carbohydrate-deficient transferrin; substance concentration arbitrary substance concentration(procedure) millimole/liter arbitrary unit/liter M = 60,06 g/mol NPU10005 NPU09349 P—Carbohydrate-deficient transferrin; Csf—Carbamide; subst.c. = ? mmol/l arb.subst.c.(proc.) = ? arb.unit/l

Dialysis solution— Plasma— Carbamide; Carbohydrate-deficient transferrin; substance concentration substance concentration millimole/liter micromole/liter M = 60,06 g/mol NPU17006 NPU10026 P—Carbohydrate-deficient transferrin; subst.c. = ? Dialysis solution—Carbamide; subst.c. = ? mmol/l µmol/l

Drain fluid(specification)— Transferrin(Plasma)— Carbamide; Carbohydrate-deficient transferrin; substance concentration substance fraction millimole/liter NPU10000 NPU17047 Transferrin(P)—Carbohydrate-deficient transferrin; Drain fluid(spec.)—Carbamide; subst.c. = ? mmol/l subst.fr. = ?

Plasma— Plasma(arterial Blood)— Carbamide; Carbon dioxide(free); substance concentration substance concentration millimole/liter millimole/liter M = 60,06 g/mol NPU12476 NPU01459 P(aB)—Carbon dioxide(free); subst.c. = ? mmol/l P—Carbamide; subst.c. = ? mmol/l Plasma(capillary Blood)— Secretion(Conjunctiva; specification)— Carbon dioxide(free); Carbamide; substance concentration substance concentration millimole/liter millimole/liter NPU12482 M = 60,06 g/mol P(cB)—Carbon dioxide(free); subst.c. = ? mmol/l NPU09353 Secr(Conj; spec.)—Carbamide; subst.c. = ? mmol/l Plasma(cord Blood)— Carbon dioxide(free); System(specification)— substance concentration Carbamide; millimole/liter substance concentration NPU12483 millimole/liter P(cordB)—Carbon dioxide(free); subst.c. = ? mmol/l M = 60,06 g/mol NPU10027 Plasma(cord Blood; arterial Blood)— Syst(spec.)—Carbamide; subst.c. = ? mmol/l Carbon dioxide(free); substance concentration Urine— millimole/liter Carbamide; NPU17137 substance concentration P(cordB; aB)—Carbon dioxide(free); subst.c. = ? millimole/liter mmol/l M = 60,06 g/mol NPU03930 Plasma(cord Blood; venous Blood)— U—Carbamide; subst.c. = ? mmol/l Carbon dioxide(free); substance concentration Patient(Urine)— millimole/liter Carbamide; NPU17138 substance rate(procedure) P(cordB; vB)—Carbon dioxide(free); subst.c. = ? millimole/day mmol/l NPU01458 Pt(U)—Carbamide; subst.rate(proc.) = ? mmol/d Plasma(mixed Blood)— Carbon dioxide(free); substance concentration

millimole/liter M = 44,01 g/mol NPU09204 Authority: IFCC/C-BGE P(mixB)—Carbon dioxide(free); subst.c. = ? mmol/l NPU09202 P(mixB)—Carbon dioxide(free); tension(37 °C) = ? Plasma(venous Blood)— kPa Carbon dioxide(free); substance concentration Plasma(venous Blood)— millimole/liter Carbon dioxide(free); NPU12484 gas tension(37 °C) P(vB)—Carbon dioxide(free); subst.c. = ? mmol/l kilopascal M = 44,01 g/mol Plasma(arterial Blood)— Authority: IFCC/C-BGE Carbon dioxide(free); NPU10029 gas tension(37 °C) P(vB)—Carbon dioxide(free); tension(37 °C) = ? kilopascal kPa M = 44,01 g/mol Authority: IFCC/C-BGE Plasma(arterial Blood)— NPU01470 Carbon dioxide(free); P(aB)—Carbon dioxide(free); tension(37 °C) = ? gas tension(patient body temperature) kPa kilopascal NPU12526 Plasma(capillary Blood)— P(aB)—Carbon dioxide(free); tension(body temp.) = Carbon dioxide(free); ? kPa gas tension(37 °C) kilopascal Plasma(capillary Blood)— NPU12481 Carbon dioxide(free); P(cB)—Carbon dioxide(free); tension(37 °C) = ? gas tension(patient body temperature) kPa kilopascal NPU12528 Plasma(cord Blood)— P(cB)—Carbon dioxide(free); tension(body temp.) = Carbon dioxide(free); ? kPa gas tension(37 °C) kilopascal Plasma(cord Blood)— M = 44,01 g/mol Carbon dioxide(free); Authority: IFCC/C-BGE gas tension(patient body temperature) NPU10030 kilopascal P(cordB)—Carbon dioxide(free); tension(37 °C) = ? NPU12527 kPa P(cordB)—Carbon dioxide(free); tension(body temp.) = ? kPa Plasma(cord Blood; arterial Blood)— Carbon dioxide(free); Plasma(cord Blood; arterial Blood)— gas tension(37 °C) Carbon dioxide(free); kilopascal gas tension(patient body temperature) M = 44,01 g/mol kilopascal Authority: IFCC/C-BGE NPU17141 NPU17139 P(cordB; aB)—Carbon dioxide(free); tension(body P(cordB; aB)—Carbon dioxide(free); tension(37 °C) temp.) = ? kPa = ? kPa Plasma(cord Blood; venous Blood)— Plasma(cord Blood; venous Blood)— Carbon dioxide(free); Carbon dioxide(free); gas tension(patient body temperature) gas tension(37 °C) kilopascal kilopascal NPU17142 M = 44,01 g/mol P(cordB; vB)—Carbon dioxide(free); tension(body Authority: IFCC/C-BGE temp.) = ? kPa NPU17140 P(cordB; vB)—Carbon dioxide(free); tension(37 °C) Plasma(mixed Blood)— = ? kPa Carbon dioxide(free); gas tension(patient body temperature) Plasma(mixed Blood)— kilopascal Carbon dioxide(free); NPU09203 gas tension(37 °C) P(mixB)—Carbon dioxide(free); tension(body temp.) kilopascal = ? kPa

Plasma(venous Blood)— Plasma(cord Blood; arterial Blood)— Carbon dioxide(free); Carbon dioxide(total); gas tension(patient body temperature) substance concentration kilopascal millimole/liter NPU12529 M = 44,01 g/mol P(vB)—Carbon dioxide(free); tension(body temp.) = Authority: IFCC/C-BGE ? kPa NPU17143 P(cordB; aB)—Carbon dioxide(tot.); subst.c. = ? Blood(arterial Blood)— mmol/l Carbon dioxide(total); substance concentration Plasma(cord Blood; venous Blood)— millimole/liter Carbon dioxide(total); NPU12522 substance concentration B(aB)—Carbon dioxide(tot.); subst.c. = ? mmol/l millimole/liter M = 44,01 g/mol Blood(capillary Blood)— Authority: IFCC/C-BGE Carbon dioxide(total); NPU17144 substance concentration P(cordB; vB)—Carbon dioxide(tot.); subst.c. = ? millimole/liter mmol/l NPU12524 B(cB)—Carbon dioxide(tot.); subst.c. = ? mmol/l Plasma(mixed Blood)— Carbon dioxide(total); Blood(cord Blood)— substance concentration Carbon dioxide(total); millimole/liter substance concentration M = 44,01 g/mol millimole/liter Authority: IFCC/C-BGE NPU12523 NPU09206 B(cordB)—Carbon dioxide(tot.); subst.c. = ? mmol/l P(mixB)—Carbon dioxide(tot.); subst.c. = ? mmol/l

Blood(mixed Blood)— Plasma(venous Blood)— Carbon dioxide(total); Carbon dioxide(total); substance concentration substance concentration millimole/liter millimole/liter NPU09205 M = 44,01 g/mol B(mixB)—Carbon dioxide(tot.); subst.c. = ? mmol/l Authority: IFCC/C-BGE NPU01472 Blood(venous Blood)— P(vB)—Carbon dioxide(tot.); subst.c. = ? mmol/l Carbon dioxide(total); substance concentration Alveolar gas— millimole/liter Carbon dioxide; NPU12525 partial pressure B(vB)—Carbon dioxide(tot.); subst.c. = ? mmol/l kilopascal NPU04079 Plasma(arterial Blood)— Alveolar gas—Carbon dioxide; part.pr. = ? kPa Carbon dioxide(total); substance concentration Haemoglobin(Fe; Blood)— millimole/liter Carbon monoxide haemoglobin(Fe); M = 44,01 g/mol substance fraction Authority: IFCC/C-BGE Authority: IFCC/C-BGE NPU01471 NPU01473 P(aB)—Carbon dioxide(tot.); subst.c. = ? mmol/l Hb(Fe; B)—Carbon monoxide haemoglobin(Fe); subst.fr. = ? Plasma(capillary Blood)— Carbon dioxide(total); Erythrocytes(Blood)— substance concentration Carbonate dehydratase; millimole/liter entitic amount-of-substance(procedure) NPU12485 attomole P(cB)—Carbon dioxide(tot.); subst.c. = ? mmol/l M = 30 000 g/mol Other term(s): Carbonic anhydrase; Carbonate Plasma(cord Blood)— dehydratase type I Carbon dioxide(total); NPU01474 substance concentration Ercs(B)—Carbonate dehydratase; entitic millimole/liter am.s.(proc.) = ? amol NPU12517 P(cordB)—Carbon dioxide(tot.); subst.c. = ? mmol/l

Erythrocytes(Blood)— NPU01478 Carbonate dehydratase; P—Carcinoembryonic antigen; arb.subst.c.(IRP 73/ entitic catalytic activity(37 °C; procedure) 601; proc.) = ? int. unit/l attokatal Other term(s): Carbonic anhydrase; Carbonate Plasma— dehydratase Carcinoembryonic antigen; NPU01475 substance concentration Ercs(B)—Carbonate dehydratase; entitic cat.act. mole/liter (37 °C; proc.) = ? akat Other term(s): CEA NPU03931 Calculus(Urine)— P—Carcinoembryonic antigen; subst.c.= ? prefix ? Carbonate; mol/l arbitrary content(procedure) NPU09229 Urine— Calculus(U)—Carbonate; arb.cont.(proc.) = ? Carnitine/Creatine; substance ratio Calculus(Urine)— NPU01502 Carbonate; U—Carnitine/Creatine; subst.ratio = ? substance content mole/kilogram Urine— NPU09235 Carnitine/Creatininium; Calculus(U)—Carbonate; subst.cont. = ? mol/kg substance ratio 10-3 Urine— NPU14202 g- U—Carnitine/Creatininium; subst.ratio = ? × 10-3 Carboxyglutamate/Creatininium; substance ratio Plasma— 10-3 Carnitine; NPU14200 substance concentration U—g-Carboxyglutamate/Creatininium; subst.ratio = micromole/liter ? × 10-3 M = 161,20 g/mol NPU01482 Urine— P—Carnitine; subst.c. = ? µmol/l g- Carboxyglutamate; Urine— substance concentration Carnitine; micromole/liter substance concentration M = 191,14 g/mol micromole/liter NPU01476 M = 161,20 g/mol U—g-Carboxyglutamate; subst.c. = ? µmol/l NPU01485 U—Carnitine; subst.c. = ? µmol/l Urine— N-e- Patient(Urine)— Carboxymethyl lysine/Creatininium; Carnitine; substance ratio substance rate 10-3 micromole/day NPU14201 M = 161,20 g/mol U—N-e-Carboxymethyl lysine/Creatininium; NPU10031 subst.ratio = ? × 10-3 Pt(U)—Carnitine; subst.rate = ? µmol/d

Urine— Urine— N-e- Carnosine/Creatininium; Carboxymethyl lysine; substance ratio substance concentration 10-3 micromole/liter NPU14203 NPU01477 U—Carnosine/Creatininium; subst.ratio = ? × 10-3 U—N-e-Carboxymethyl lysine; subst.c. = ? µmol/l Plasma— Plasma— Carnosine; Carcinoembryonic antigen; substance concentration arbitrary substance concentration(IRP 73/601; micromole/liter procedure) M = 226,23 g/mol international unit/liter NPU01503 Recommended calibrator: WHO 1st IRP 73/601 P—Carnosine; subst.c. = ? µmol/l Other term(s): CEA

Urine— NPU02402 U—Homovanillate; subst.c. = ? µmol/l Carnosine; substance concentration Plasma— micromole/liter Cefotaxime; M = 226,23 g/mol substance concentration NPU01504 mole/liter U—Carnosine; subst.c. = ? µmol/l NPU17025 P—Cefotaxime; subst.c.= ? prefix ? mol/l Plasma— Carotene; System(specification)— substance concentration Cells; micromole/liter arbitrary concentration(procedure) M = 536,85 g/mol NPU10292 NPU01505 Syst(spec.)—Cells; arb.c.(proc.) = ? P—Carotene; subst.c. = ? µmol/l Ascites— Faeces— Cells; Catalase; number concentration arbitrary content(procedure) 106/liter NPU04215 NPU08683 F—Catalase; arb.cont.(proc.)= ? Asc—Cells; num.c. = ? × 106/l

Urine— Cerebrospinal fluid— Catecholamine; Cells; amount-of-substance(list) number concentration NPU17625 106/liter U—Catecholamine; am.s.(list) NPU04775 NPU17545 U—Adrenalinium; am.s.(proc.) = ? µmol Csf—Cells; num.c.= ? × 106/l NPU17624 U—Adrenalinium+Noradrenalinium; am.s.(proc.) = ? µmol Pleural fluid(specification)— NPU08619 U—Dopamine; am.s.(proc.) = ? µmol Cells; NPU17626 U—3-Methoxyadrenalinium+3- number concentration Methoxynoradrenalinium; am.s.(proc.) = ? µmol 106/liter NPU17585 U—Noradrenalinium; am.s.(proc.) = ? NPU08682 µmol Plf(spec.)—Cells; num.c. = ? × 106/l

Urine— Synovial fluid(specification)— Catecholamine; Cells; substance concentration(list; procedure) number concentration NPU17594 106/liter U—Catecholamine; subst.c.(list; proc.) NPU04229 NPU14041 U—Adrenalinium; subst.c. = ? µmol/l Synf(spec.)—Cells; num.c. = ? × 106/l NPU14120 U—Adrenalinium+Noradrenalinium; subst.c. = ? µmol/l System(specification)— NPU01915 U—Dopamine; subst.c. = ? µmol/l Cells; NPU02740 U—3-Methoxyadrenalinium+3- number concentration Methoxynoradrenalinium; subst.c. = ? µmol/l 106/liter NPU17116 U—Noradrenalinium; subst.c. = ? µmol/l NPU10291 Syst(spec.)—Cells; num.c. = ? × 106/l Urine— Catecholmetabolite; Cerebrospinal fluid— amount-of-substance(list; procedure) Cells; NPU17628 number concentration U—Catecholmetabolite; am.s.(list; proc.) 109/liter NPU17568 U—Homovanillate; am.s. = ? µmol NPU08681 NPU17627 U—Vanillylmandelate; am.s.(proc.) = ? Csf—Cells; num.c. = ? × 109/l µmol Synovial fluid(specification)— Urine— Cells; Catecholmetabolite; number concentration substance concentration(list; procedure) 109/liter NPU17595 NPU08684 U—Catecholmetabolite; subst.c.(list; proc.) Synf(spec.)—Cells; num.c. = ? × 109/l NPU08685 U—Vanillylmandelate; subst.c. = ? µmol/l

Plasma— NPU17539 Centromer antibody(Immunoglobulin G); U—Chloride; am.s.(proc.) = ? mmol arbitrary concentration(procedure) NPU01518 Sweat(specification)— P—Centromer antibody(IgG); arb.c.(proc.) = ? Chloride; substance concentration(stimulated; procedure) Plasma— millimole/liter Centromer antibody(Immunoglobulin G); M = 35,45 g/mol arbitrary substance concentration(procedure) NPU04126 arbitrary unit/liter Sweat(spec.)—Chloride; subst.c.(stim.; proc.) = ? NPU12015 mmol/l P—Centromer antibody(IgG); arb.subst.c.(proc.) = ? arb.unit/l Amniotic fluid— Chloride; Leukocytes(Blood)— substance concentration Cerebroside-sulfatase; millimole/liter entitic catalytic activity(37 °C; procedure) M = 35,45 g/mol attokatal NPU08612 Other term(s): Arylsulfatase A Amf—Chloride; subst.c. = ? mmol/l NPU09104 Lkcs(B)—Cerebroside-sulfatase; entitic cat.act. Plasma— (37 °C; proc.) = ? akat Chloride; substance concentration Cerebrospinal fluid— millimole/liter Cerebrospinal fluid; M = 35,453 g/mol clarity(after spinning; procedure) Authority: IFCC/C-BGE NPU04225 NPU01536 Csf—Cerebrospinal fluid; clarity(after spinn.; proc.) P—Chloride; subst.c. = ? mmol/l = ? Sweat— Cerebrospinal fluid— Chloride; Cerebrospinal fluid; substance concentration clarity(before spinning; procedure) millimole/liter NPU04224 M = 35,453 g/mol Csf—Cerebrospinal fluid; clarity(before spinn.; Authority: IFCC/C-BGE proc.) = ? NPU01537 Sweat—Chloride; subst.c. = ? mmol/l Cerebrospinal fluid— Cerebrospinal fluid; System(specification)— colour(procedure) Chloride; NPU17026 substance concentration Csf—Cerebrospinal fluid; colour(proc.) = ? millimole/liter M = 35,453 g/mol Cerebrospinal fluid— NPU10122 Cerebrospinal fluid; Syst(spec.)—Chloride; subst.c. = ? mmol/l property(list; procedure) NPU14911 Urine— Csf—Cerebrospinal fluid; prop.(list; proc.) Chloride; NPU01130 Csf—Albumin; subst.c. = ? µmol/l substance concentration NPU04224 Csf—Cerebrospinal fluid; clarity(before millimole/liter spinn.; proc.)= ? M = 35,45 g/mol NPU04225 Csf—Cerebrospinal fluid; clarity(after NPU08613 spinn.; proc.)= ? U—Chloride; subst.c. = ? mmol/l NPU01962 Csf—Erythrocytes; num.c. = ? × 106/l NPU02190 Csf—Glucose; subst.c. = ? mmol/l Faeces— NPU01523 Csf—Glucose; rel.subst.c.(Csf/P) = ? Chloride; NPU02594 Csf—Leukocytes; num.c. = ? × 106/l substance content NPU03276 Csf—Protein; mass c. = ? g/l millimole/kilogram NPU03816 Urine— F—Chloride; subst.cont. = ? mmol/kg Chloride; amount-of-substance(procedure) millimole

Patient(Urine)— NPU10157 Chloride; P(fPt)—Cholesterol+ester, in HDL; subst.c. = ? substance rate(procedure) mmol/l millimole/day Authority: IFCC/C-BGE Pleural fluid— NPU01535 Cholesterol+ester, in HDL; Pt(U)—Chloride; subst.rate(proc.) = ? mmol/d substance concentration millimole/liter Plasma— Other term(s): High density lipoprotein cholesterol Cholecystokinin; Note: (H)igh (D)ensity substance concentration NPU17016 picomole/liter Plf—Cholesterol+ester, in HDL; subst.c. = ? mmol/l NPU17555 P—Cholecystokinin; subst.c. = ? pmol/l Plasma— Cholesterol+ester, in LDL/Cholesterol+ester, in Plasma— HDL; Cholesterol(non ester); substance ratio substance concentration NPU04146 millimole/liter P—Cholesterol+ester, in LDL/Cholesterol+ester, in M = 386,64 g/mol HDL; subst.ratio = ? NPU01549 P—Cholesterol(non ester); subst.c. = ? mmol/l Plasma(fasting Patient)— Cholesterol+ester, in LDL/Cholesterol+ester, in Plasma— HDL; Cholesterol; substance ratio property(list; procedure) NPU10172 M = 386,64 g/mol P(fPt)—Cholesterol+ester, in LDL/ NPU17029 Cholesterol+ester, in HDL; subst.ratio = ? P—Cholesterol; prop.(list; proc.) NPU01549 P—Cholesterol(non ester); subst.c. = ? Plasma— mmol/l Cholesterol+ester, in LDL; NPU01566 P—Cholesterol+ester; subst.c. = ? substance concentration mmol/l millimole/liter NPU01567 P—Cholesterol+ester, in HDL; subst.c. = Other term(s): Low density lipoprotein cholesterol ? mmol/l Note: (L)ow (D)ensity NPU01568 P—Cholesterol+ester, in LDL; subst.c. = NPU01568 ? mmol/l P—Cholesterol+ester, in LDL; subst.c. = ? mmol/l NPU01569 P—Cholesterol+ester, in VLDL; subst.c. = ? mmol/l Plasma(fasting Patient)— NPU04146 P—Cholesterol+ester, in LDL/ Cholesterol+ester, in LDL; Cholesterol+ester, in HDL; subst.ratio = ? substance concentration NPU10293 P(fPt)—Cholesterol+ester/ millimole/liter Cholesterol+ester, in HDL; subst.ratio = ? NPU10171 P(fPt)—Cholesterol+ester, in LDL; subst.c. = ? Ascites— mmol/l Cholesterol+ester, in HDL; substance concentration Pleural fluid— millimole/liter Cholesterol+ester, in LDL; Other term(s): High density lipoprotein cholesterol substance concentration Note: (H)igh (D)ensity millimole/liter NPU17014 Other term(s): Low density lipoprotein cholesterol Asc—Cholesterol+ester, in HDL; subst.c. = ? mmol/l Note: (L)ow (D)ensity NPU17017 Plasma— Plf—Cholesterol+ester, in LDL; subst.c. = ? mmol/l Cholesterol+ester, in HDL; substance concentration Plasma— millimole/liter Cholesterol+ester, in VLDL; Other term(s): High density lipoprotein cholesterol substance concentration Note: (H)igh (D)ensity millimole/liter NPU01567 Other term(s): Very low density lipoprotein P—Cholesterol+ester, in HDL; subst.c. = ? mmol/l cholesterol Note: (V)ery (L)ow (D)ensity Plasma(fasting Patient)— NPU01569 Cholesterol+ester, in HDL; P—Cholesterol+ester, in VLDL; subst.c. = ? mmol/l substance concentration millimole/liter © 2000 IUPAC, Pure and Applied Chemistry 72, 747–972 Properties and units in general clinical chemistry 799

Plasma(fasting Patient)— M = 386,64 g/mol Cholesterol+ester, in VLDL; NPU10033 substance concentration Syst(spec.)—Cholesterol+ester; subst.c. = ? mmol/l millimole/liter Other term(s): Very low density lipoprotein Plasma— cholesterol Cholinesterase antibody; Note: (V)ery (L)ow (D)ensity arbitrary substance concentration(procedure) NPU09256 arbitrary unit/liter P(fPt)—Cholesterol+ester, in VLDL; subst.c. = ? NPU12063 mmol/l P—Cholinesterase antibody; arb.subst.c.(proc.) = ? arb.unit/l Pleural fluid— Cholesterol+ester, in VLDL; Cholinesterase(Plasma)— substance concentration Cholinesterase type; millimole/liter catalytic-activity fraction(list; 25 °C; procedure) Other term(s): Very low density lipoprotein Note: obs the sum of fractions may be >1 cholesterol NPU03565 Note: (V)ery (L)ow (D)ensity ChE(P)—Cholinesterase type; cat.fr.(list; 25 °C; NPU17019 proc.) Plf—Cholesterol+ester, in VLDL; subst.c. = ? mmol/l NPU04603 ChE(P)—Cholinesterase, cinchocaine inhibited; cat.fr.(25 °C; proc.) = ? Plasma(fasting Patient)— NPU04595 ChE(P)—Cholinesterase, dibucain Cholesterol+ester/Cholesterol+ester, in HDL; inhibited; cat.fr.(25 °C; proc.) = ? substance ratio NPU04566 ChE(P)—Cholinesterase, fluoride NPU10293 inhibited; cat.fr.(25 °C; proc.)= ? P(fPt)—Cholesterol+ester/Cholesterol+ester, in NPU04494 ChE(P)—Cholinesterase, RO-20683 HDL; subst.ratio = ? inhibited; cat.fr.(25 °C; proc.)= ? NPU04594 ChE(P)—Cholinesterase, carbamide Amniotic fluid— inhibited; cat.fr.(25 °C; proc.)= ? Cholesterol+ester; substance concentration Cholinesterase(Plasma)— millimole/liter Cholinesterase type; NPU17784 catalytic-activity fraction(list; 37 °C; procedure) Amf—Cholesterol+ester; subst.c. = ? mmol/l Note: obs the sum of fractions may be >1 NPU03792 Ascites— ChE(P)—Cholinesterase type; cat.fr.(list; 37 °C; Cholesterol+ester; proc.) substance concentration NPU04170 ChE(P)—Cholinesterase, cinchocaine millimole/liter inhibited; cat.fr.(37 °C; proc.) = ? M = 386,64 g/mol NPU04601 ChE(P)—Cholinesterase, dibucain NPU10032 inhibited; cat.fr.(37 °C; proc.)= ? Asc—Cholesterol+ester; subst.c. = ? mmol/l NPU04600 ChE(P)—Cholinesterase, fluoride inhibited; cat.fr.(37 °C; proc.)= ? Plasma— NPU04604 ChE(P)—Cholinesterase, RO-20683 Cholesterol+ester; inhibited; cat.fr.(37 °C; proc.)= ? substance concentration NPU04602 ChE(P)—Cholinesterase, carbamide millimole/liter inhibited; cat.fr.(37 °C; proc.) = ? M = 386,64 g/mol Other term(s): Cholesterol; Cholesterol, total Cholinesterase(Plasma)— NPU01566 Cholinesterase, butan-1-ol inhibited; P—Cholesterol+ester; subst.c. = ? mmol/l catalytic-activity fraction(25 °C; procedure) Note: Fraction of total activity inhibited by butan-1-ol Pleural fluid— NPU08568 Cholesterol+ester; ChE(P)—Cholinesterase, butan-1-ol inhibited; substance concentration cat.fr.(25 °C; proc.) = ? millimole/liter M = 386,64 g/mol Cholinesterase(Plasma)— Other term(s): Cholesterol; Cholesterol, total Cholinesterase, carbamide inhibited; NPU17028 catalytic-activity fraction(25 °C; procedure) Plf—Cholesterol+ester; subst.c. = ? mmol/l Note: fraction of total activity inhibited by urea NPU04594 System(specification)— ChE(P)—Cholinesterase, carbamide inhibited; Cholesterol+ester; cat.fr.(25 °C; proc.)= ? substance concentration millimole/liter

Cholinesterase(Plasma)— Note: Fraction of total activity inhibited by RO-20683 Cholinesterase, carbamide inhibited; NPU04494 catalytic-activity fraction(37 °C; procedure) ChE(P)—Cholinesterase, RO-20683 inhibited; Note: fraction of total activity inhibited by urea cat.fr.(25 °C; proc.) = ? NPU04602 ChE(P)—Cholinesterase, carbamide inhibited; Cholinesterase(Plasma)— cat.fr.(37 °C; proc.) = ? Cholinesterase, RO-20683 inhibited; catalytic-activity fraction(37 °C; procedure) Cholinesterase(Plasma)— Note: Fraction of total activity inhibited by RO-20683 Cholinesterase, cinchocaine inhibited; NPU04604 catalytic-activity fraction(25 °C; procedure) ChE(P)—Cholinesterase, RO-20683 inhibited; Other term(s): Dibucaine; Cinchoine cat.fr.(37 °C; proc.) = ? Note: Fraction of total activity inhibited by cinchocaine Plasma— NPU04603 Cholinesterase; ChE(P)—Cholinesterase, cinchocaine inhibited; catalytic-activity concentration(25 °C; cat.fr.(25 °C; proc.) = ? procedure) microkatal/liter Cholinesterase(Plasma)— Other term(s): Benzoylcholinesterase; Choline Cholinesterase, cinchocaine inhibited; esterase II; Pseudocholinesterase catalytic-activity fraction(37 °C; procedure) NPU04593 Other term(s): Dibucaine; Cinchoine P—Cholinesterase; cat.c.(25 °C; proc.) = ? µkat/l Note: Fraction of total activity inhibited by cinchocaine Amniotic fluid— NPU04170 Cholinesterase; ChE(P)—Cholinesterase, cinchocaine inhibited; catalytic-activity concentration(37 °C; cat.fr.(37 °C; proc.) = ? procedure) microkatal/liter Cholinesterase(Plasma)— NPU03914 Cholinesterase, dibucain inhibited; Amf—Cholinesterase; cat.c.(37 °C; proc.) = ? µkat/l catalytic-activity fraction(25 °C; procedure) Note: Fraction of total activity inhibited by dibucain Plasma— NPU04595 Cholinesterase; ChE(P)—Cholinesterase, dibucain inhibited; catalytic-activity concentration(37 °C; cat.fr.(25 °C; proc.) = ? procedure) microkatal/liter Cholinesterase(Plasma)— Other term(s): Benzoylcholinesterase; Choline Cholinesterase, dibucain inhibited; esterase II; Pseudocholinesterase catalytic-activity fraction(37 °C; procedure) NPU01570 Note: Fraction of total activity inhibited by dibucain P—Cholinesterase; cat.c.(37 °C; proc.) = ? µkat/l NPU04601 ChE(P)—Cholinesterase, dibucain inhibited; Plasma— cat.fr.(37 °C; proc. )= ? Cholinesterase; substance concentration Cholinesterase(Plasma)— nanomole/liter Cholinesterase, fluoride inhibited; M = 300 000 g/mol catalytic-activity fraction(25 °C; procedure) Other term(s): Benzoylcholinesterase; Choline Note: Fraction of total activity inhibited by fluoride esterase II; Pseudocholinesterase NPU04566 NPU10294 ChE(P)—Cholinesterase, fluoride inhibited; P—Cholinesterase; subst.c. = ? nmol/l cat.fr.(25 °C; proc.) = ? Urine— Cholinesterase(Plasma)— Chondroitin sulfate; Cholinesterase, fluoride inhibited; substance concentration catalytic-activity fraction(37 °C; procedure) micromole/liter Note: Fraction of total activity inhibited by fluoride M = 50 000 g/mol NPU04600 Authority: IUPAC-IUB85 ChE(P)—Cholinesterase, fluoride inhibited; NPU01571 cat.fr.(37 °C; proc.) = ? U—Chondroitin sulfate; subst.c. = ? µmol/l

Cholinesterase(Plasma)— Plasma— Cholinesterase, RO-20683 inhibited; Choriogonadotropin a-chain; catalytic-activity fraction(25 °C; procedure) arbitrary substance concentration(IRP 75/569; procedure)

international unit/liter Urine— M = 14 000 g/mol Choriogonadotropin; Recommended calibrator: WHO 1st IRP 75/569 arbitrary concentration(procedure) Other term(s): hCG alpha M = 39 000 g/mol NPU01578 Authority: IUPAC-IUB 74 P—Choriogonadotropin a-chain; arb.subst.c.(IRP NPU10394 75/569; proc.) = ? int. unit/l U—Choriogonadotropin; arb.c.(proc.) = ?

Plasma— Plasma— Choriogonadotropin a-chain; Choriogonadotropin; substance concentration arbitrary substance concentration(IS 61/6; picomole/liter procedure) M = 14 000 g/mol international unit/liter Other term(s): hCG alpha M = 39 000 g/mol NPU01579 Recommended calibrator: WHO 2nd IS 61/6 P—Choriogonadotropin a-chain; subst.c. = ? pmol/l Other term(s): hCG Authority: IUPAC-IUB 74 Plasma— NPU04003 Choriogonadotropin b-chain core fragment; P—Choriogonadotropin; arb.subst.c.(IS 61/6; proc.) substance concentration = ? int. unit/l picomole/liter Other term(s): hCG b-cf Urine— NPU08936 Choriogonadotropin; P—Choriogonadotropin b-chain core fragment; arbitrary substance concentration(IS 61/6; subst.c. = ? pmol/l procedure) international unit/liter Plasma— M = 39 000 g/mol Choriogonadotropin b-chain nicked; Recommended calibrator: WHO 2nd IS 61/6 substance concentration Other term(s): hCG picomole/liter Authority: IUPAC-IUB 74 Other term(s): hCG b-n NPU01576 NPU08938 U—Choriogonadotropin; arb.subst.c.(IS 61/6; proc.) P—Choriogonadotropin b-chain nicked; subst.c. = ? = ? int. unit/l pmol/l Plasma— Plasma— Choriogonadotropin; Choriogonadotropin b-chain; arbitrary substance concentration(IS 75/537; arbitrary substance concentration(IRP 75/551; procedure) procedure) international unit/liter international unit/liter M = 39 000 g/mol M = 25 000 g/mol Recommended calibrator: WHO 3rd IS 75/537 Recommended calibrator: WHO 1st IRP 75/551 Calibrator(s): WHO 1st IRP 75/537 (for Other term(s): hCG beta immunoassay; identical to 3rd IS NPU01580 Other term(s): hCG P—Choriogonadotropin b-chain; arb.subst.c.(IRP Authority: IUPAC-IUB 74 75/551; proc.) = ? int. unit/l NPU01572 P—Choriogonadotropin; arb.subst.c.(IS 75/537; Plasma— proc.) = ? int. unit/l Choriogonadotropin b-chain; substance concentration Urine— picomole/liter Choriogonadotropin; M = 25 000 g/mol arbitrary substance concentration(IS 75/537; Other term(s): hCG beta procedure) NPU01581 international unit/liter P—Choriogonadotropin b-chain; subst.c. = ? pmol/l M = 39 000 g/mol Recommended calibrator: 3rd IS 75/537 Plasma— Calibrator(s): 1st IRP 75/537 (identical to 3rd IS) Choriogonadotropin nicked; Authority: IUPAC-IUB 74 substance concentration NPU10034 picomole/liter U—Choriogonadotropin; arb.subst.c.(IS 75/537; Other term(s): hCGn proc.) = ? int. unit/l NPU08937 P—Choriogonadotropin nicked; subst.c. = ? pmol/l

Patient— Plasma— Choriogonadotropin; Choriomammotropin; arbitrary substance content(intramuscular substance concentration administration; arbitrary amount-of-substance/ nanomole/liter body m; procedure; IS 75/537) M = 21 600 g/mol international unit/kilogram Other term(s): Chorionic somatomammotropin; NPU10423 Chorionsomatomammotropin; Human placenta Pt—Choriogonadotropin; arb.subst.cont.(i.m.; lactogen arb.am.s./body mass; proc.; IS 75/537)= ? int. unit/ Authority: IUPAC-IUB 74 kg NPU01585 P—Choriomammotropin; subst.c. = ? nmol/l Plasma— Choriogonadotropin; Plasma— substance concentration Chromium(III); picomole/liter substance concentration M = 39 000 g/mol nanomole/liter Other term(s): hCG M = 52,00 g/mol Authority: IUPAC-IUB 74 Authority: IUPAC/VII-C-TOX NPU01573 NPU01589 P—Choriogonadotropin; subst.c. = ? pmol/l P—Chromium(III); subst.c. = ? nmol/l

Urine— Urine— Choriogonadotropin; Chromium(III); substance concentration substance concentration picomole/liter nanomole/liter M = 39 000 g/mol M = 52,00 g/mol Other term(s): hCG Authority: IUPAC/VII-C-TOX Authority: IUPAC-IUB 74 NPU01590 NPU01577 U—Chromium(III); subst.c. = ? nmol/l U—Choriogonadotropin; subst.c. = ? pmol/l Hair— Plasma— Chromium(III); Choriogonadotropin+b-chain; substance content arbitrary substance concentration(IS 75/537; micromole/kilogram procedure) M = 52,00 g/mol international unit/liter Authority: IUPAC/VII-C-TOX Recommended calibrator: WHO 3rd IS 75/537 NPU01588 Calibrator(s): 1st IRP 75/537 (identical to 3rd IS) Hair—Chromium(III); subst.cont. = ? µmol/kg NPU01582 P—Choriogonadotropin+b-chain; arb.subst.c.(IS 75/ Cells(Blood)— 537; proc.) = ? int. unit/l Chromium(III); substance content Plasma— nanomole/kilogram Choriogonadotropin+b-chain; M = 52,00 g/mol substance concentration Authority: IUPAC/VII-C-TOX picomole/liter NPU01586 NPU01583 Cells(B)—Chromium(III); subst.cont. = ? nmol/kg P—Choriogonadotropin+b-chain; subst.c. = ? pmol/l Air(specification)— Plasma— Chromium(IV); Choriomammotropin; substance concentration arbitrary substance concentration(IRP 73/545; micromole/(meter)³ procedure) M = 52,00 g/mol international unit/liter Authority: IUPAC/VII-C-TOX M = 21 600 g/mol NPU01591 Recommended calibrator: WHO 1st IRP 73/545 Air(spec.)—Chromium(IV); subst.c. = ? µmol/m³ Other term(s): Chorionic somatomammotropin; Chorionsomatomammotropin; Human placenta Kidney— lactogen Chromium-EDTA-clearance; Authority: IUPAC-IUB 74 volume rate(procedure) NPU01584 milliliter/second P—Choriomammotropin; arb.subst.c.(IRP 73/545; NPU10295 proc.) = ? int. unit/l Kidn.—Chromium-EDTA-clearance; vol.rate(proc.) = ? ml/s

Plasma— Plasma— Chromogranin A; Citrulline; arbitrary substance concentration(procedure) substance concentration arbitrary unit/liter micromole/liter NPU10614 M = 175,19 g/mol P—Chromogranin A; arb.subst.c.(proc.) = ? NPU01611 arb.unit/l P—Citrulline; subst.c. = ? µmol/l

Plasma— Urine— Chromogranin A; Citrulline; substance concentration substance concentration picomole/liter micromole/liter NPU17556 M = 175,19 g/mol P—Chromogranin A; subst.c. = ? pmol/l NPU01612 U—Citrulline; subst.c. = ? µmol/l Plasma— Chromogranin B; Patient— substance concentration Clonidine(administered); picomole/liter amount-of-substance(oral administration) NPU17557 micromole P—Chromogranin B; subst.c. = ? pmol/l M = 230,10 g/mol NPU10536 Plasma— Pt—Clonidine(administered); am.s.(p.o.) = ? µmol Chylomicrons; arbitrary concentration(procedure) Vaginal fluid— NPU10035 Clue cells; P—Chylomicrons; arb.c.(proc.) = ? arbitrary concentration(procedure) NPU14316 Faeces— Vagf—Clue cells; arb.c.(proc.) = ? Chymotrypsin; arbitrary content(procedure) Plasma— NPU04850 Coagulation, tissue factor-induced; F—Chymotrypsin; arb.cont.(proc.)= ? arbitrary substance concentration(procedure; BCR/CRM148/149R) Urine— arbitrary unit/liter Citrate; NPU14567 substance concentration P—Coagulation, tissue factor-induced; millimole/liter arb.subst.c.(proc.; BCR/CRM148/149R) = ? NPU01594 arb.unit/l U—Citrate; subst.c. = ? mmol/l Synovial fluid— Patient(Urine)— Coagulum; Citrate; arbitrary concentration(procedure) substance rate(procedure) NPU17067 millimole/day Synf—Coagulum; arb.c.(proc.) = ? NPU14263 Pt(U)—Citrate; subst.rate(proc.) = ? mmol/d Intestine, small— Cobalamin absorption; Urine— substance rate(Intrinsic factor; oral Citrulline/Creatininium; administration; list; procedure) substance ratio NPU13813 10-3 Intest., small—Cobalamin absorption; NPU14204 subst.rate(Intrinsic factor; p.o.; list; proc.) U—Citrulline/Creatininium; subst.ratio = ? × 10-3 NPU13809 Pt—Cobalamin(administered); am.s.(i.m.) = ? µmol Cerebrospinal fluid— NPU13805 Pt—57Co-Cobalamin(administered); Citrulline; am.s.(p.o.) = ? pmol substance concentration NPU13812 Pt—58Co-Cobalamin(administered); micromole/liter am.s.(p.o.) = ? pmol M = 175,19 g/mol NPU13808 Pt—57Co-Cobalamin(administered); NPU09020 radioact.(p.o.) = ? kBq Csf—Citrulline; subst.c. = ? µmol/l NPU13810 Pt—58Co-Cobalamin(administered); radioact.(p.o.) = ? kBq

NPU13807 Pt(U)—57Co-Cobalamin; rel.radioact.(U Patient— 1 d/intake) = ? 58Co- NPU13811 Pt(U)—58Co-Cobalamin; rel.radioact.(U Cobalamin(administered); 1 d/intake) = ? amount-of-substance(oral administration) picomole Intestine, small— NPU13812 Cobalamin absorption; Pt—58Co-Cobalamin(administered); am.s.(p.o.) = ? substance rate(no intrinsic factor; list; pmol procedure) NPU13804 Patient— Intest., small—Cobalamin absorption; subst.rate(no 57Co- intrinsic factor; list; proc.) Cobalamin(administered); NPU13809 Pt—Cobalamin(administered); radioactivity(oral administration) am.s.(i.m.) = ? µmol kilobecquerel NPU13805 Pt—57Co-Cobalamin(administered); NPU13808 am.s.(p.o.) = ? pmol Pt—57Co-Cobalamin(administered); radioact.(p.o.) = NPU13812 Pt—58Co-Cobalamin(administered); ? kBq am.s.(p.o.) = ? pmol NPU13808 Pt—57Co-Cobalamin(administered); Patient— radioact.(p.o.) = ? kBq 58Co- NPU13810 Pt—58Co-Cobalamin(administered); Cobalamin(administered); radioact.(p.o.) = ? kBq radioactivity(oral administration) NPU13807 Pt(U)—57Co-Cobalamin; rel.radioact.(U kilobecquerel 1 d/intake) = ? NPU13810 NPU13811 Pt(U)—58Co-Cobalamin; rel.radioact.(U Pt—58Co-Cobalamin(administered); radioact.(p.o.) = 1 d/intake) = ? ? kBq

Cobalamin(Plasma)— Patient(Urine)— Cobalamin type; 57Co- substance fraction(list; procedure) Cobalamin; 57 NPU01701 relative amount-of-substance( Co-B12 and Cobalamin(P)—Cobalamin type; subst.fr.(list; proc.) intrinsic factor, oral administration; urine 1 d/ NPU04956 Cobalamin(P)—Aquocobalamin; intake; procedure) subst.fr. = ? M = 1 355 g/mol NPU04954 Cobalamin(P)—Cyanocobalamin; Other term(s): Schilling test II subst.fr. = ? NPU01698 57 57 NPU04959 Cobalamin(P)—Deoxycobalamin; Pt(U)— Co-Cobalamin; rel.ams.( Co-B12 and IF subst.fr.= ? p.o.; U 1 d/intake; proc.) = ? NPU04955 Cobalamin(P)—Hydroxocobalamin; subst.fr. = ? Patient(Urine)— NPU04958 Cobalamin(P)—Methylcobalamin; 57Co- subst.fr.= ? Cobalamin; 57 NPU04957 Cobalamin(P)—Sulfitocobalamin; relative amount-of-substance( Co-B12, oral subst.fr. = ? administration; urine 1 d/intake; procedure) M = 1 355 g/mol Patient— Other term(s): Schilling test I Cobalamin(administered); NPU01699 57 57 amount-of-substance(intramuscular Pt(U)— Co-Cobalamin; rel.ams.( Co-B12 p.o.; U 1 administration) d/intake; proc.) = ? micromole NPU13809 Patient(Faeces)— Pt—Cobalamin(administered); am.s.(i.m.) = ? µmol 58Co- Cobalamin; 58 Patient— relative amount-of-substance( Co-B12 and 57Co- intrinsic factor, oral administration; faeces/ Cobalamin(administered); intake; procedure) amount-of-substance(oral administration) M = 1 355 g/mol picomole Other term(s): ISA-test; Incomplete Stool NPU13805 Absorption test Pt—57Co-Cobalamin(administered); am.s.(p.o.) = ? NPU01696 58 58 pmol Pt(F)— Co-Cobalamin; rel.ams.( Co-B12 and IF p.o.; F/intake; proc.) = ?

Patient(Faeces)— Urine— 58Co- Cobalt; Cobalamin; substance concentration 58 relative amount-of-substance( Co-B12, oral nanomole/liter administration; faeces/intake; procedure) M = 58,93 g/mol M = 1 355 g/mol Authority: IUPAC/VII-C-TOX Other term(s): ISA-test; Incomplete Stool NPU01705 Absorption test U—Cobalt; subst.c. = ? nmol/l NPU01695 58 58 Pt(F)— Co-Cobalamin; rel.ams.( Co-B12 p.o.; F/ Hair— intake; proc.) = ? Cobalt; substance content Patient(Urine)— micromole/kilogram 57Co- M = 58,93 g/mol Cobalamin; Authority: IUPAC/VII-C-TOX relative radioactivity(urine 1 d/intake) NPU01704 NPU13807 Hair—Cobalt; subst.cont. = ? µmol/kg Pt(U)—57Co-Cobalamin; rel.radioact.(U 1 d/intake) = ? Plasma— Coeliac disease antibody; Patient(Urine)— property(list; procedure) 58Co- NPU14503 Cobalamin; P—Coeliac disease antibody; prop.(list; proc.) relative radioactivity(urine 1 d/intake) NPU12538 P—Endomysium antibody(IgA); NPU13811 arb.c.(proc.) = ? Pt(U)—58Co-Cobalamin; rel.radioact.(U 1 d/intake) = NPU08945 P—Gliadin antibody(IgA); ? arb.subst.c.(proc.) = ? × 10³ arb.unit/l NPU08944 P—Gliadin antibody(IgG); Plasma— arb.subst.c.(proc.) = ? × 10³ arb.unit/l Cobalamin; NPU12247 P—Reticulin antibody(IgA); arb.c.(proc.) substance concentration = ? picomole/liter NPU12248 P—Reticulin antibody(IgG); arb.c.(proc.) NPU01700 = ? P—Cobalamin; subst.c. = ? pmol/l NPU17704 P—Transglutaminase antibody(IgA); arb.c.(proc.) = ? Air(specification)— NPU14566 P—Transglutaminase antibody(IgA); Cobalt; arb.subst.c.(proc.) = ? × 10³ arb.unit/l substance concentration micromole/(meter)³ Plasma— M = 58,93 g/mol Colistin; Authority: IUPAC/VII-C-TOX substance concentration NPU01702 mole/liter Air(spec.)—Cobalt; subst.c. = ? µmol/m³ NPU10297 P—Colistin; subst.c.= ? prefix ? mol/l Blood— Cobalt; Plasma— substance concentration Complement activity, antibody-induced; nanomole/liter property(erythrolysis; procedure) M = 58,93 g/mol Other term(s): Hemolytic complement titer classical Authority: IUPAC/VII-C-TOX system; CH50; AP50 NPU01703 Authority: ICW91 B—Cobalt; subst.c. = ? nmol/l NPU01715 P—Complement activity, antibody-induced; Plasma— prop.(erythrol.; proc.) = ? Cobalt; substance concentration Plasma— nanomole/liter Complement activity, cell-surface-induced; M = 58,93 g/mol property(erythrolysis; procedure) Authority: IUPAC/VII-C-TOX Other term(s): Hemolytic complement titer NPU04904 alternative system P—Cobalt; subst.c. = ? nmol/l Authority: ICW91 NPU01716 P—Complement activity, cell-surface-induced; prop.(erythrol.; proc.) = ?

Plasma— M = 462 000 g/mol Complement C1 esterase inhibitor; Authority: ICW91 arbitrary concentration(enzymatic; procedure) NPU01722 M = 105 000 g/mol P—Complement C1q; subst.c.(proc.) = ? µmol/l Other term(s): C1 Inactivator; C1 INA; C1IA; C1 esterase inhibitor; C1 INH; C1 inhibitor Plasma— Authority: ICW91 Complement C1r2-C1s2; NPU01718 arbitrary concentration(erythrolysis; procedure) P—Complement C1 esterase inhibitor; arb.c.(enz.; M = 332 000 g/mol proc.) = ? Authority: ICW91 NPU01723 Plasma— P—Complement C1r2-C1s2; arb.c.(erythrol.; proc.) Complement C1 esterase inhibitor; = ? arbitrary concentration(immunological; procedure) Plasma— M = 105 000 g/mol Complement C1r2-C1s2; Other term(s): C1 Inactivator; C1 INA; C1IA; C1 arbitrary concentration(immunological; esterase inhibitor; C1 INH; C1 inhibitor procedure) Authority: ICW91 M = 332 000 g/mol NPU01719 Authority: ICW91 P—Complement C1 esterase inhibitor; arb.c.(imm.; NPU03858 proc.) = ? P—Complement C1r2-C1s2; arb.c.(imm.; proc.) = ?

Plasma— Plasma— Complement C1 esterase inhibitor; Complement C1r2-C1s2; arbitrary substance concentration(enzymatic; substance concentration(procedure) procedure) micromole/liter NPU14340 M = 332 000 g/mol P—Complement C1 esterase inhibitor; Authority: ICW91 arb.subst.c.(enz.; proc.) = ? NPU01724 P—Complement C1r2-C1s2; subst.c.(proc.) = ? Plasma— µmol/l Complement C1 esterase inhibitor; substance concentration(procedure) Plasma— micromole/liter Complement C1s; M = 105 000 g/mol arbitrary substance Other term(s): C1 Inactivator; C1 INA; C1IA; C1 concentration(immunological; procedure) esterase inhibitor; C1 INH; C1 inhibitor arbitrary unit/liter Authority: ICW91 NPU03900 NPU01720 P—Complement C1s; arb.subst.c.(imm.; proc.) = ? P—Complement C1 esterase inhibitor; arb.unit/l subst.c.(proc.) = ? µmol/l Plasma— Plasma— Complement C2; Complement C1q; arbitrary concentration(erythrolysis; procedure) arbitrary concentration(erythrolysis; procedure) M = 102 000 g/mol M = 462 000 g/mol Authority: ICW91 Authority: ICW91 NPU01725 NPU01721 P—Complement C2; arb.c.(erythrol.; proc.) = ? P—Complement C1q; arb.c.(erythrol.; proc.) = ? Plasma— Plasma— Complement C2; Complement C1q; arbitrary concentration(immunological; arbitrary concentration(immunological; procedure) procedure) M = 102 000 g/mol M = 462 000 g/mol Authority: ICW91 Authority: ICW91 NPU03859 NPU03857 P—Complement C2; arb.c.(imm.; proc.) = ? P—Complement C1q; arb.c.(imm.; proc.) = ? Plasma— Plasma— Complement C2; Complement C1q; substance concentration(procedure) substance concentration(procedure) micromole/liter micromole/liter

M = 102 000 g/mol Plasma— Authority: ICW91 Complement C3b; NPU01726 substance concentration P—Complement C2; subst.c.(proc.) = ? µmol/l micromole/liter M = 176 000 g/mol Erythrocytes(Blood)— Authority: ICW91 Complement C3 fragment; NPU01730 arbitrary entitic number(procedure) P—Complement C3b; subst.c. = ? µmol/l Authority: ICW91 NPU01728 Erythrocytes(Blood)— Ercs(B)—Complement C3 fragment; arb.entitic Complement C3b-C4b receptor; num.(proc.) = ? arbitrary entitic number(procedure) Other term(s): Complement receptor type 1; CR 1 Erythrocytes(Blood)— NPU03869 Complement C3 fragment; Ercs(B)—Complement C3b-C4b receptor; arb.entitic entitic number(procedure) num.(proc.) = ? Authority: ICW91 NPU03885 Erythrocytes(Blood)— Ercs(B)—Complement C3 fragment; entitic Complement C3b-C4b receptor; num.(proc.) = ? entitic number(procedure) Other term(s): Complement receptor type 1; CR 1 Plasma— Authority: ICW91 Complement C3; NPU01731 arbitrary concentration(procedure) Ercs(B)—Complement C3b-C4b receptor; entitic M = 185 000 g/mol num.(proc.) = ? Other term(s): b-1-C-globulin; Factor A Authority: ICW91 Plasma— NPU03861 Complement C3c; P—Complement C3; arb.c.(proc.) = ? arbitrary concentration(procedure) M = 134 000 g/mol Plasma— Authority: ICW91 Complement C3; NPU03864 substance concentration P—Complement C3c; arb.c.(proc.) = ? micromole/liter M = 185 000 g/mol Plasma— Other term(s): beta1-C-globulin; Factor A Complement C3c; Authority: ICW91 substance concentration NPU01727 micromole/liter P—Complement C3; subst.c. = ? µmol/l M = 134 000 g/mol Authority: ICW91 Plasma— NPU01732 Complement C3a; P—Complement C3c; subst.c. = ? µmol/l arbitrary concentration(procedure) M = 9 000 g/mol Plasma— Authority: ICW91 Complement C3d,g; NPU03862 arbitrary concentration(procedure) P—Complement C3a; arb.c.(proc.) = ? M = 40 000 g/mol Authority: ICW91 Plasma— NPU01735 Complement C3a; P—Complement C3d,g; arb.c.(proc.) = ? substance concentration micromole/liter Plasma— M = 9 000 g/mol Complement C3d,g; Authority: ICW91 substance concentration NPU01729 micromole/liter P—Complement C3a; subst.c. = ? µmol/l M = 40 000 g/mol Authority: ICW91 Plasma— NPU03865 Complement C3b; P—Complement C3d,g; subst.c. = ? µmol/l arbitrary concentration(procedure) M = 176 000 g/mol Authority: ICW91 NPU03863 P—Complement C3b; arb.c.(proc.) = ?

Erythrocytes(Blood)— Plasma— Complement C3d; Complement C4a; arbitrary entitic number(procedure) arbitrary concentration(immunological; Authority: ICW91 procedure) NPU01733 M = 7 000 g/mol Ercs(B)—Complement C3d; arb.entitic num.(proc.) Authority: ICW91 = ? NPU03866 P—Complement C4a; arb.c.(imm.; proc.) = ? Plasma— Complement C3d; Plasma— arbitrary substance concentration Complement C4a; arbitrary unit/liter substance concentration(procedure) Authority: ICW91 micromole/liter NPU10298 M = 7 000 g/mol P—Complement C3d; arb.subst.c. = ? arb.unit/l Authority: ICW91 NPU01738 Erythrocytes(Blood)— P—Complement C4a; subst.c.(proc.) = ? µmol/l Complement C3d; entitic number(procedure) Plasma— Authority: ICW91 Complement C4b binding protein; NPU03886 arbitrary concentration(immunological; Ercs(B)—Complement C3d; entitic num.(proc.) = ? procedure) M = 500 000 g/mol B-lymphocytes(Blood)— Authority: ICW91 Complement C3d-C3d,g-iC3b receptor; NPU03867 arbitrary entitic number(procedure) P—Complement C4b binding protein; arb.c.(imm.; Other term(s): Complement receptor type 2; CR 2 proc.) = ? Authority: ICW91 NPU01734 Plasma— B-lymphocs(B)—Complement C3d-C3d,g-iC3b Complement C4b binding protein; receptor; arb.entitic num.(proc.) = ? substance concentration(procedure) micromole/liter Plasma— M = 500 000 g/mol Complement C4; Authority: ICW91 arbitrary concentration(adhesion; procedure) NPU01739 M = 205 000 g/mol P—Complement C4b binding protein; Authority: ICW91 subst.c.(proc.) = ? µmol/l NPU01736 P—Complement C4; arb.c.(adhesion; proc.) = ? Erythrocytes(Blood)— Complement C4d; Plasma— arbitrary entitic number(procedure) Complement C4; Authority: ICW91 arbitrary substance NPU01740 concentration(immunological; procedure) Ercs(B)—Complement C4d; arb.entitic num.(proc.) arbitrary unit/liter = ? M = 205 000 g/mol Other term(s): beta1-E-globulin Erythrocytes(Blood)— Authority: ICW91 Complement C4d; NPU03860 entitic number(procedure) P—Complement C4; arb.subst.c.(imm.; proc.) = ? Authority: ICW91 arb.unit/l NPU03887 Ercs(B)—Complement C4d; entitic num.(proc.) = ? Plasma— Complement C4; Plasma— substance concentration(procedure) Complement C5; micromole/liter arbitrary concentration(adhesion; procedure) M = 205 000 g/mol M = 190 000 g/mol Other term(s): beta1-E-globulin Other term(s): ß1-F-globulin Authority: ICW91 Authority: ICW91 NPU01737 NPU01741 P—Complement C4; subst.c.(proc.) = ? µmol/l P—Complement C5; arb.c.(adhesion; proc.) = ?

Plasma— Plasma— Complement C5; Complement C7; arbitrary substance arbitrary concentration(adhesion; procedure) concentration(immunological; procedure) M = 110 000 g/mol arbitrary unit/liter Authority: ICW91 M = 190 000 g/mol NPU01746 Other term(s): ß1-F-globulin P—Complement C7; arb.c.(adhesion; proc.) = ? Authority: ICW91 NPU03873 Plasma— P—Complement C5; arb.subst.c.(imm.; proc.) = ? Complement C7; arb.unit/l arbitrary concentration(immunological; procedure) Plasma— M = 110 000 g/mol Complement C5; Authority: ICW91 substance concentration(procedure) NPU03876 micromole/liter P—Complement C7; arb.c.(imm.; proc.) = ? M = 190 000 g/mol Other term(s): ß1-F-globulin Plasma— Authority: ICW91 Complement C7; NPU01742 substance concentration(procedure) P—Complement C5; subst.c.(proc.) = ? µmol/l micromole/liter M = 110 000 g/mol Plasma— Authority: ICW91 Complement C5a; NPU01747 arbitrary concentration(procedure) P—Complement C7; subst.c.(proc.) = ? µmol/l M = 11 000 g/mol Authority: ICW91 Plasma— NPU03874 Complement C8; P—Complement C5a; arb.c.(proc.) = ? arbitrary concentration(adhesion; procedure) M = 150 000 g/mol Plasma— Authority: ICW91 Complement C5a; NPU01748 substance concentration(procedure) P—Complement C8; arb.c.(adhesion; proc.) = ? micromole/liter M = 11 000 g/mol Plasma— Authority: ICW91 Complement C8; NPU01743 arbitrary concentration(immunological; P—Complement C5a; subst.c.(proc.) = ? µmol/l procedure) M = 150 000 g/mol Plasma— Authority: ICW91 Complement C6; NPU03877 arbitrary concentration(adhesion; procedure) P—Complement C8; arb.c.(imm.; proc.) = ? M = 120 000 g/mol Authority: ICW91 Plasma— NPU01744 Complement C8; P—Complement C6; arb.c.(adhesion; proc.) = ? substance concentration(procedure) micromole/liter Plasma— M = 150 000 g/mol Complement C6; Authority: ICW91 arbitrary concentration(immunological; NPU01749 procedure) P—Complement C8; subst.c.(proc.) = ? µmol/l M = 120 000 g/mol Authority: ICW91 Plasma— NPU03875 Complement C9; P—Complement C6; arb.c.(imm.; proc.) = ? arbitrary concentration(immunological; procedure) Plasma— M = 71 000 g/mol Complement C6; Authority: ICW91 substance concentration(procedure) NPU03878 micromole/liter P—Complement C9; arb.c.(imm.; proc.) = ? M = 120 000 g/mol Authority: ICW91 NPU01745 P—Complement C6; subst.c.(proc.) = ? µmol/l

Erythrocytes(Blood)— Plasma— Complement C9; Complement factor B; arbitrary entitic number(adhesion; procedure) arbitrary substance M = 71 000 g/mol concentration(immunological; procedure) Authority: ICW91 arbitrary unit/liter NPU01750 NPU12891 Ercs(B)—Complement C9; arb.entitic P—Complement factor B; arb.subst.c.(imm.; proc.) num.(adhesion; proc.) = ? = ? arb.unit/l

Plasma— Plasma— Complement C9; Complement factor B; substance concentration(procedure) substance concentration(procedure) micromole/liter micromole/liter M = 71 000 g/mol M = 92 000 g/mol Authority: ICW91 Other term(s): C3 proactivator; Complement C3 NPU01751 proactivator+activator; Glycine-rich b-glycoprotein; P—Complement C9; subst.c.(proc.) = ? µmol/l Heat labile factor Authority: ICW91 Erythrocytes(Blood)— NPU01754 Complement decay accelerating factor; P—Complement factor B; subst.c.(proc.) = ? µmol/l arbitrary entitic number(immunological; procedure) Plasma— Other term(s): DAF; Cluster of differentiation 55; CD Complement factor Ba; 55 arbitrary concentration(immunological; Authority: ICW91 procedure) NPU03879 M = 33 000 g/mol Ercs(B)—Complement decay accelerating factor; Authority: ICW91 arb.entitic num.(imm.; proc.) = ? NPU03881 P—Complement factor Ba; arb.c.(imm.; proc.) = ? Erythrocytes(Blood)— Complement decay accelerating factor; Plasma— entitic number(immunological; procedure) Complement factor Ba; Other term(s): DAF substance concentration(procedure) Authority: ICW91 micromole/liter Note: Other name: Cluster of differentiation 55; CD M = 33 000 g/mol 55 Authority: ICW91 NPU01752 NPU01755 Ercs(B)—Complement decay accelerating factor; P—Complement factor Ba; subst.c.(proc.) = ? entitic num.(imm.; proc.) = ? µmol/l

Plasma— Plasma— Complement factor B; Complement factor Bb; arbitrary concentration(adhesion; procedure) arbitrary concentration(immunological; M = 92 000 g/mol procedure) Other term(s): C3 proactivator; Complement C3 M = 60 000 g/mol proactivator+activator; Glycine-rich b-glycoprotein; Authority: ICW91 Heat labile factor NPU03882 Authority: ICW91 P—Complement factor Bb; arb.c.(imm.; proc.) = ? NPU01753 P—Complement factor B; arb.c.(adhesion; proc.) = Plasma— ? Complement factor Bb; substance concentration(procedure) Plasma— micromole/liter Complement factor B; M = 60 000 g/mol arbitrary concentration(immunological; Authority: ICW91 procedure) NPU01756 M = 92 000 g/mol P—Complement factor Bb; subst.c.(proc.) = ? µmol/ Other term(s): C3 proactivator; Complement C3 proactivator+activator; Glycine-rich b-glycoprotein; Heat labile factor Authority: ICW91 NPU03880 P—Complement factor B; arb.c.(imm.; proc.) = ?